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ABSTRACT 
CHI-CHUAN WANG: The Effect of Adjunctive Psychotherapy on Health Related Outcomes 
among Patients with Schizophrenia  
(Under the direction of Dr. Joel F. Farley) 
 
Although antipsychotics have been recommended as the first-line treatment for 
schizophrenia, many patients are not adherent to their treatment regimens, which leads to 
worse treatment outcomes.  As a result, psychotherapy has been suggested as an adjunctive 
treatment to improve patients’ treatment outcomes.  However, the effectiveness of 
psychotherapy on treatment outcomes is unclear.  Therefore, the purpose of this study is to 
assess whether using psychotherapy in addition to pharmacotherapy improves medication 
persistency, reduces the risk of hospitalization, and lowers treatment costs among Medicaid 
populations.   
2001 to 2003 Medicaid Analytic eXtract (MAX) files were used as a data source to 
identify patients with schizophrenia who received antipsychotic treatments.  The use of 
psychotherapy was dichotomized as users versus non-users.  Medication persistency was 
measured as the number of days to discontinuation after the initiation of antipsychotic use.  
Number of hospitalizations and treatment costs were measured as continuous variables. 
Factors associated with psychotherapy use were evaluated by a logistic model, and 
medication persistency between psychotherapy users and non-users was compared by Cox 
proportional-hazard regressions.  Hospitalizations and treatment costs were analyzed by a 
hurdle model and generalized linear models respectively. 
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The prevalence of psychotherapy use was about 16% in this study.  Older and Black 
patients were less likely to receive psychotherapy, while patients with comorbid depression 
were more likely to receive psychotherapy.  We found psychotherapy only improved 
patients’ persistency within the first two months of follow-up.  The use of psychotherapy was 
not found to be associated with hospitalizations, but it was associated with higher treatment 
costs.   
In conclusion, our results suggest that the rate of psychotherapy use was low and that 
most patients only received psychotherapy for a short period of time.  These results may 
explain the short-term effect of psychotherapy on medication persistency as well as the null 
association between psychotherapy use and hospitalizations.  Since the effect of 
psychotherapy may not appear until a patient receives sufficient psychotherapy treatment, 
clinicians should better incorporate psychotherapy into treatment courses.  In addition, 
Medicaid policy makers should make sure that patients with schizophrenia have adequate 
access to psychotherapy in order to achieve the best treatment outcomes.  
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 CHAPTER 1: INTRODUCTION 
 
1.1 Overview 
With the introduction of antipsychotics, especially atypical antipsychotics, patients 
with schizophrenia are able to better control their symptoms and thus reduce the burden of 
the disease.  However, due to intolerable side effects and other environmental barriers, non-
adherence is a common phenomenon among patients receiving antipsychotic treatments, 
which often leads to worse outcomes.  Even for patients who are adherent to their regimen, 
they are likely to have some residual symptoms or experience a future relapse.
1
  In order to 
achieve the best treatment outcomes, it is now generally agreed that psychosocial 
interventions should be used in combination with pharmacological treatment.
2, 3
  Because 
there is limited information available about the effectiveness of adjunctive psychotherapy, 
the objective of this study is to assess whether using psychotherapy with the addition of 
pharmacotherapy improves patients adherence and outcomes.  
 
1.1.1 Epidemiology of Schizophrenia  
Schizophrenia affects about 24 million people in the world, and more than 50% of 
them do not receive appropriate treatments.
4
  In the United States, the 12-month prevalence 
of schizophrenia was estimated to be 0.51% in 2002, with the highest prevalence in the 
Medicaid population (1.66%).
5
  The estimated life-time incidence was 15.2 per 100,000
 2 
 
 
persons, with a wide range from 7.7 to 43 per 100,000 persons.
6
  The estimations of 
prevalence and incidence of schizophrenia can vary by the definition of schizophrenia, study 
settings, and study populations.
2, 6, 7
  Generally, males have a higher incidence rate than 
females (incidence rate ratio: 1.4).
6
  Most patients with schizophrenia experience the onset of 
schizophrenia between ages of 16 to 30 years, with an earlier onset age among males.
2, 6, 7
  In 
2006, approximately 32% of patients with schizophrenia were covered by Medicaid, 22% by 
Medicare, and 16% by private insurance.  About 30% of the patients do not have any 
insurance coverage.
5
  
 
1.1.1.1  Disease Burden of Schizophrenia 
Patients with schizophrenia usually have a shorter life expectancy.
2, 7, 8
  Life 
expectancy for patients with schizophrenia is 12 to 15 years less than the general population.
2
 
Although suicide causes some deaths, the increased risk of mortality is mainly due to 
physical causes.  Patients with schizophrenia often are more likely to engage in risky 
behaviors (e.g. poor diet, smoking, and substance abuse) and often suffer from comorbid 
conditions caused by medication side effects (ex. weight gain and metabolic syndrome).  In 
addition, most patients have limited access to health care,
2, 6
 which could also lead to worse 
health outcomes and higher risks of mortality.   
Patients with schizophrenia are mentally or functionally impaired.  In the U.S., 
schizophrenia accounts for about 20% of Social Security disability days and 20% to 30% of 
homelessness.
9
  Because of the impairment, even though most patients want to work, only 
10% to 20% of patients are employed.
1, 2
  Patients may lose their self-esteem or suffer from 
stigma because of their disability.
10
  Furthermore, schizophrenia not only affects patients 
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individually, it also has a significant effect on patients’ families and communities.  Caring for 
a patient with schizophrenia requires substantial time and money, and coping can be stressful.  
Family members may need to break their routine life, reduce their social activities, and 
confront stigma.  It has also been found that living with the mentally ill is associated with a 
negative health impact for family and caregivers.
10
  
 Besides functional impairment, patients with schizophrenia also face a high risk of 
relapse.  According to a review conducted by Hogarty and Ulrich in 1998, without adequate 
medication treatment, the relapse rate for patients with schizophrenia may be over 50%, and 
the risk of relapse increases with the number of subsequent relapses (up to 87% for patients 
with five or more previous relapse episodes).
11
  With antipsychotic treatment, the annual 
relapse rate can be reduced to around half of the original rate, but the relapse rate is still 
around 40% for outpatients.
11
  Wiersma et al. followed 82 patients with schizophrenia for 15 
years in the Netherlands.  They found that about 27% of patients experienced a complete 
remission over a period of 15 years, 50% of patients experienced a partial remission, and at 
least 10% of patients remained psychotic.
12
  About two-thirds of the participants had at least 
one relapse, and most relapses occurred within one to two years after a patient remitted from 
a previous relapse.
12, 13
  In addition, patients were more likely to become chronically 
psychotic after each subsequent relapse.
12
  
 Schizophrenia also creates large financial burdens on individuals and society.  
Despite its low prevalence, schizophrenia accounts for 2% to 3% of overall health care costs 
in the U.S.
9
  Weiden and Olfson estimated the inpatient costs of schizophrenia relapse using 
the 1986 Inventory of Mental Health Organizations and General Hospital Mental Health 
Services data.  According to their study, short-term inpatient services for multi-episode 
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schizophrenia patients costed approximately $2.3 billion, and average inpatient costs per 
patient was estimated as $9,252 (in 1993 dollars).
13
  The estimated cost for rehospitalization 
within two years after discharge was $2 billion, with 60% ($1.2 billion) caused by a lack of 
narcoleptic treatment efficacy and 40% ($705 million) by non-adherence.
13
  The total costs 
associated with schizophrenia was around $32.5 billion in 1990, with $17.3 billion in direct 
costs.
14
  Compared to the general population, the estimated costs in 2002 for schizophrenia 
were $62.7 billion higher, with $22.7 billion for direct medical care costs, $32.4 billion for 
indirect health care costs, and $7.6 billion for indirect societal costs.
15
  
   
1.1.1.2  The Non-adherence Problem 
Because antipsychotics have been shown as the most effective way to reduce 
symptoms of schizophrenia, it has been recommended as the first-line treatment.
16-21
  With 
slightly different pharmacological mechanisms (discussed in section 2.1.3), two types of 
antipsychotics, typical and atypical antipsychotics, have been introduced.  Typical 
antipsychotics are usually known for the unpleasant motion side effects such as 
extrapyramidal symptoms, while atypical antipsychotics are often associated with weight 
gain and metabolic syndrome.
7, 22, 23
  Because atypical antipsychotics produce fewer 
intolerable side effects, it is generally believed that atypical agents should be better tolerated 
than typical agents.  
However, non-adherence is still a common phenomenon in patients with 
schizophrenia.  The estimated adherence rate for antipsychotic treatment varies by study 
design and population.  Generally, around 40% of patients with schizophrenia do not adhere 
to treatment regimens, with estimates ranging from 20% to 89%.
13, 24-28
  After discharge or 
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therapy initiation, the adherence rate is around 50% within one year and may be as low as 
25% within two years.
29
  The Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) also found that the all-cause discontinuation rate rises to 74%  for atypical 
antipsychotics within 18 months.
30
   
One major cause of non-adherence is intolerable side effects, such as extrapyramidal 
symptoms, weight gain, and glucose or lipid abnormalities.
31, 32
  With the introduction of 
atypical antipsychotics, there is hope that patients’ adherence is going to be improved 
because of fewer extrapyramidal side effects.  Although there is evidence showing that 
atypical antipsychotics improve patients’ adherence than the typical antipsychotics,26 some 
studies do not find significant improvement on patients’ adherence comparing atypical to 
typical antipsychotics.
24, 30, 33
  Therefore, simply switching patients from typical to atypical 
antipsychotics may not solve the non-adherence problem. 
 
1.1.1.3  The Role of Psychotherapy 
Although the efficacy of antipsychotics is proven, it is usually not sufficient for 
patients to reach full remission or functional recovery with medication treatment only.  The 
relapse rate for patients continuing with medication treatment was found to be 30% to 40% 
during the first year of discharge.
11
  In addition, as discussed above, many patients do not 
follow their regimens.  As a result, psychotherapy has been recommended to be applied 
adjunctively with pharmacotherapy to maximize the treatment effect and improve patients’ 
functioning.
16, 18-21
 
Because patients with schizophrenia often have a variety of symptoms and functional 
impairments, managing the disease can be complicated for both patients and clinicians, and 
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non-pharmacological treatment is often required.  Many trials have evaluated the efficacy of 
different types of psychosocial interventions, but how these interventions can be applied as 
psychotherapy has not been standardized clinically.  Psychotherapy contains a broad range of 
patterns from emotional consultation to behavior modification and can be provided by a 
variety of types of providers, such as psychiatrists, psychologists, and social workers.  Even 
within a given type of psychotherapy, different treatment orientations and/or modalities can 
be applied.  For example, individual psychotherapy can simply contain medication tailoring, 
or it can incorporate some behavioral modification techniques.  Despite the heterogeneity of 
psychotherapy, it can be roughly categorized into three groups: individual, family, and group 
psychotherapy. 
Even though the designs and outcomes of psychosocial interventions vary across 
studies, overall, evidence has shown that psychotherapy can reduce clinical symptoms and 
relapses, improve patients’ social functioning, and reduce stress in families.  Psychosocial 
interventions have also been shown to improve medication adherence, enhance 
understanding about the disease and treatment, and help patients and their family members to 
develop better coping strategies.
1, 34-38
  In addition, psychotherapy has been suggested as a 
strategy to optimize treatment outcomes and reduce side effects either before or after 
antipsychotic switching.
39, 40
  It is generally agreed that patients can benefit from adjunctive 
psychotherapy in addition to the standard antipsychotic treatment.
41-45
 
   
1.1.2 Significance of the Study 
Many studies have evaluated the effects of different types of psychosocial 
interventions at trial levels (i.e. efficacy).  To the author’s knowledge, no studies have 
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examined the effects of psychotherapy on a population basis (i.e. effectiveness).  The present 
study fills this gap by providing real-world information regarding the utilization and the 
effectiveness of psychotherapy.     
Few studies document the utilization patterns and factors associated with the use of 
psychotherapy among patients with schizophrenia at a population level.
46-48
  Using 1991 
Medicare claims data, Dixon et al. evaluated the costs and use of outpatient visits among 
Medicare-eligible patients with schizophrenia and found that individual therapy was used 
more often than group or family therapy.
46
  The study also showed that African Americans 
were less likely to receive individual therapy than Caucasian patients.  Patients with dual 
eligibility (both Medicare and Medicaid) or aged 65 or older were less likely to receive 
individual therapy but more likely to receive group therapy compared to those enrolled in 
Medicare only.  When considering all psychosocial services together (individual therapy, 
group therapy, family therapy, and psychiatric somatotherapy), it was found that patients 
with a higher number of other comorbid mental conditions, drug abuse, or dually enrolled in 
Medicaid were more likely to receive ambulatory psychosocial services, while males, 
African Americans, and patients aged 65 or older were less likely to receive these services.
46
   
Although outpatient psychotherapy use has been documented using a claims data set, 
our study can be an improvement of the previous research.  Since the previous study was 
conducted using data in 1991, the results may be outdated.  In addition, the previous study 
focused on Medicare population.  Given that Medicare covers both the elderly and 
permanently disabled groups, patients in the study can have different characteristics than the 
general schizophrenia populations.  For example, patients with schizophrenia who were older 
than age 65 and became eligible for Medicare were more likely to be patients who had better 
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controlled disease and thus live longer, while the younger patients are more likely to be those 
with severe symptoms and became permanently disabled.  As a result, this study likely 
contained a highly selected group of patients with schizophrenia, which limits the 
generalizability.  By using 2001 to 2003 Medicaid claims data, the current study provides 
updated information about psychotherapy use, and by constructing this study on a younger 
cohort covered by Medicaid, our results can be better generalized to the general 
schizophrenia population.   
Another study evaluating guideline concordance of schizophrenia treatment found 
that around 37% of patients were not fully adherent to their treatments.  Almost all of the 
patients in the study received antipsychotic treatments, and 69% of them received 
psychosocial treatment.
48
  However, upon further examination of the different types of 
recommended psychotherapy, less than half of the patients received guideline recommended 
psychosocial treatments (e.g. percentage of patients receiving family education, individual or 
group therapy, or cognitive/behavioral treatment).  Around 40% of patients received both 
pharmacotherapy and psychotherapy.
48
  Given the study was conducted on 151 psychiatrist-
reported patients, the generalizability is limited.  In addition, the data was gathered from 
psychiatrists’ report of treatment in the past 30 days, which may not fully capture certain 
services use.  Our study will improve the generalizability by using a large data set and an 18-
month follow-up period, which allows us to better capture the use of psychotherapy.  
In addition, Olfson and colleagues conducted a study comparing the treatment 
patterns between schizoaffective disorder and schizophrenia among the Medicaid population.  
They found more than 85% of patients received antipsychotics, while only 23% of patients 
with schizoaffective disorder and 13% of patients with schizophrenia received psychotherapy.  
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The estimated medication adherence rate in this study was around 60% for both groups.
47
  
However, this study has a short follow-up period (6 months) and does not further distinguish 
the type of psychotherapy used.  Our study provides a more comprehensive picture of 
psychotherapy use by implementing a longer follow-up period (18 months) and document the 
type of psychotherapy use.  Instead of using a prevalent cohort as in Olfson et al.’s study, the 
new-user design is applied in our study, which allows us to better capture the patterns of 
psychotherapy use from the initiation of antipsychotic treatment to the end of 18-month 
follow-up.  In addition, the current study has a broader array of adherence measurement 
(including both persistency and switching) than the previous study (which measured 
adherence as a dichotomous outcome), and our study evaluates mental health related 
hospitalizations as well as treatment costs rather than outpatient visits.  Finally, the main 
focus of our study is to compare the health service utilization between psychotherapy users 
and non-users controlling for antipsychotic adherence, which is different from the purpose of 
Olfson et al.’s study. 
   As mentioned before, although the efficacy of psychosocial interventions have been 
evaluated, the effectiveness of these interventions remains unclear.
41
  Because most studies 
that have examined the influence of psychotherapy on medication adherence have been 
conducted as clinical trials with small sample sizes, the generalizability of these results is 
limited.  A large-scale study also allows us to generate population-level estimates of 
medication persistency, hospitalization rates, and mental-health related treatment costs (i.e. 
the effectiveness) among patients with schizophrenia.  To our knowledge, this is the first 
study that evaluates the effectiveness of psychotherapy on antipsychotic persistency, mental-
health related hospitalizations, and treatment costs.  Because we are unable to extract 
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remission rates or disease severity information from claims, adjunctive psychotherapy is 
considered effective if it improves persistency, reduces hospitalization rates, or reduces 
treatment costs.  Many studies were conducted before atypical antipsychotics were widely 
adopted, which entails a different practice environment than that of today.  Given the change 
in clinical practice, it is necessary to re-evaluate the effectiveness of adjunctive 
psychotherapy, especially in combination with the second-generation agents.  Finally, 
although psychotherapy is recommended as an adjunctive therapy for patients switch their 
medication treatments, to the authors’ knowledge, the effectiveness of psychotherapy on 
antipsychotic switching has not been evaluated.  It is therefore important to evaluate the 
effectiveness of psychotherapy for further evidence.     
This dissertation work investigated the role of psychotherapy on medication 
adherence on a larger scale using Medicaid claims data.  Because most studies evaluated the 
effectiveness of psychotherapy on clinical outcomes, little is known about the influence of 
psychotherapy on health care costs or service use.  This study expands the existing literature 
by investigating the influence of psychotherapy on schizophrenic health care costs and 
utilization.  Findings from this study can improve our understanding of the effectiveness of 
psychotherapy and can help to inform clinicians and policy makers about the most 
appropriate treatment options to use for schizophrenic patients.     
 
1.1.3 Aims and Hypotheses 
 Assessing the clinical use of adjunctive psychotherapy as well as its effect on 
medication adherence, inpatient service utilization, and costs provides more evidence about 
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the effectiveness of psychotherapy.  Specifically, this dissertation addresses these issues by 
accomplishing the following aims:  
 
Aim 1: To describe the patterns and factors associated with the use of adjunctive 
psychotherapy. 
Descriptive statistics was first applied to evaluate the prevalence of psychotherapy 
and types of psychotherapy being used.  Two groups were compared: patients who received 
both pharmacotherapy and psychotherapy versus those who received psychotherapy only.  
Because our samples were composed of incident antipsychotic users (who were newly on 
their medication treatment), these patients were less likely to have received psychotherapy 
before the initiation of their pharmacological treatment.  Since previous psychotherapy use 
may affect medication use behaviors, for the incident cohort, patients who had a record of 
psychotherapy use before the initiation of antipsychotic treatment were dropped.  In addition 
to frequency and types of psychotherapy use, time of psychotherapy initiation was also 
evaluated during the follow-up periods.  Types of psychotherapy were categorized as 
individual therapy, family therapy, and group therapy using the Current Procedural 
Terminology and Healthcare Common Procedure Coding System codes.   
Patient characteristics (age, gender, and ethnicity), types of initial antipsychotic 
treatment (atypical/typical), and other physical as well as mental comorbid conditions were 
also summarized in Aim 1.  Besides descriptive statistics, regression models were performed 
to assess factors associated with psychotherapy use, and the results were used to inform the 
following analyses (Aim 2 and Aim 3).  Due to limited samples of adjunctive psychotherapy 
users, patients with different types of psychotherapy were only compared descriptively.  All 
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psychotherapy users were combined as one group and compared with patients who did not 
receive psychotherapy in a logistic regression model.  
 
Aim 2: To assess whether the use of adjunctive psychotherapy in addition to 
pharmacotherapy improves patients’ adherence to antipsychotic treatments. 
 Aim 2 used medication persistency as a measure of adherence.  We compared time to 
medication discontinuation (i.e. medication persistency) between patients who received 
adjunctive psychotherapy and who did not.  It is hypothesized that patients who received 
adjunctive psychotherapy are better adherent to their treatment regimens than those who did 
not have any psychotherapy.   
For incident antipsychotic users, survival analysis technique was performed to evaluate 
time from the first prescription to all-cause discontinuation or the end of follow-up.  In order 
to best reflect a clinically meaningful discontinuation, two definitions were applied to assess 
medication discontinuation: a gap longer than 15 or 30 days. This study only evaluated 
adherence to oral antipsychotic agents but not injectable agents due to limited sample size 
(N=101).  Patients with injectable antipsychotic agents were excluded from the analysis.  
 In addition to the main analysis, a sub-analysis was performed to evaluate the 
association between the use of psychotherapy and antipsychotic switching.  It is hypothesized 
that patients receiving psychotherapy have a lower likelihood of medication switching.  
Patients were considered as switchers if they initiated a second antipsychotic agent within 30 
days after the end of supply from the first antipsychotic agent.  A sensitivity analysis was 
conducted using a 15-day window to define medication switching.  A logistic regression was 
used to assess the likelihood of antipsychotic switching between users and non-users. 
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Aim 3: To assess whether receiving adjunctive psychotherapy in addition to 
pharmacotherapy reduces hospitalization rates and health care costs.   
Aim 3 assessed the influence of using adjunctive psychotherapy on the use of 
inpatient services and health care costs.  It is hypothesized that patients who used adjunctive 
psychotherapy have fewer inpatient admissions and lower total health care costs compared to 
those who do not receive psychotherapy.  For hospitalizations, a hurdle model was applied to 
compare the rate of hospitalization between the two groups during the follow-up.  Because 
the distribution of health care costs was highly skewed, a generalized linear model was used 
to compare total health care costs between the treatment and control groups. 
 
In Aim 2 and Aim 3, patient characteristics can systematically differ between those 
who receive psychotherapy and those who do not due to observable and/or unobservable 
confounders.  The observable confounders were adjusted by using the multiple regression 
techniques as addressed above.  For the unobservable factors, instrumental variable (IV) 
technique was applied to reduce potential unobservable confounding, or the endogeneity 
issue, between treatment and control groups.  By applying IV with a two-stage regression 
model, we should be able to eliminate both observed and unobserved cofounding and 
estimate the local average treatment effect (i.e. the ―marginal patients‖: who can be treated 
with or without psychotherapy depending on their providers’ preference).   
 
1.1.4 Summary 
 Although not highly prevalent, schizophrenia has contributed substantial functional 
and financial burdens to patients and society.  Because pharmacotherapy alone often has a 
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limited effect on functional recovery, and many patients do not adhere to their regimens, 
psychotherapy has been recommended as an adjunctive treatment to improve health 
outcomes.  However, due to the lack of sufficient evidence for the effectiveness of 
psychotherapy, clinicians and policy makers may be reluctant to provide psychotherapy to 
patients, which could lead to lower quality of care.
9, 49
  In contrast to previous studies, which 
have examined the efficacy of psychotherapy, this study evaluated the effectiveness of 
psychotherapy at a population level using Medicaid claims data.  By contributing more 
evidence about the effectiveness of psychotherapy, findings from this study will help 
clinicians to better determine the clinical use of psychotherapy.  Additionally, this study 
assessed treatment costs associated with the implementation of adjunctive psychotherapy.  
With this study being conducted based on Medicaid populations, both the effectiveness and 
costs information will be valuable for policy makers to better determine the allocation of 
resources and guide Medicaid coverage decisions. 
 
 
 
 
 CHAPTER 2: LITERATURE REVIEW 
 
2.1 Schizophrenia: the Disease and the Treatments 
2.1.1 Symptoms and Diagnosis of Schizophrenia 
Due to the broad spectrum of symptoms and signs shared by other mental disorders, it 
is not easy to diagnose schizophrenia.  Common signs of schizophrenia include positive 
(psychotic) symptoms, negative symptoms, and cognitive and/or behavioral impairments 
(Table 2.1).
2, 7, 17, 50, 51
  Positive symptoms appear to reflect an extraction from reality, and the 
symptoms are usually presented in a form of false belief (delusions) or false perception 
(hallucinations).
7, 17, 50, 51
   Negative symptoms involve loss of emotional or behavioral 
expressions.  Three negative symptoms defining schizophrenia are immobile facial 
appearance (affective flattening), diminished quality and thoughts of speech (alogia), and 
lack of ability to initiate or follow through with plans (avolition).
7, 17, 50, 51
  
Cognitive/behavioral impairments include disorganized thinking, disorganized behavior, and 
catatonic motor behaviors.
7, 17, 50, 51
  Because cognitive/behavioral impairments also appear as 
deviations from normal functions, these symptoms are sometimes categorized as positive 
symptoms.
17
 
 16 
 
 
Table 2.1.Clinical Symptoms and Features of Schizophrenia 
 
               Source: Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia.                           
                  Lancet. Aug 19 1995;346(8973):477-81. 
 
 
 
 
Two major diagnostic systems for schizophrenia currently used are the International 
Classification of Disease, Tenth Edition (ICD-10)
51
 and the Diagnostic and Statistical 
Manual, Fourth Edition, Text Revision (DSM-IV-TR).
17
  Despite some differences, the ICD 
and DSM have similar diagnostic criteria.  Both the ICD and DSM identify similar symptoms 
and features for the diagnosis of schizophrenia, and both require the symptoms to be present 
for a long period of time to rule out temporary psychotic symptoms or conditions.  In 
addition, to make a diagnosis of schizophrenia, both the ICD and DSM require the 
schizophrenic symptoms are not induced by substance abuse or other medical conditions (e.g. 
frontal lobe trauma or other mood disorders).
17, 50, 51
  One difference between the two systems 
is that the ICD requires the symptoms to persist for at least one month, while the DSM 
requires the symptoms to be present for at least six months.  Another difference is that DSM 
also requires social/occupational dysfunction during the onset of disturbance, while ICD does 
not.
17, 50, 51
  Table 2.2 summarizes the diagnostic criteria from the two systems.  Differential 
diagnosis of psychotic disorders is provided in Appendix 1, and detailed diagnostic criteria 
for ICD and DSM are provided in Appendices 2 and 3. 
 17 
 
 
Table 2.2. ICD and DSM Diagnostic Criteria for Schizophrenia 
 
                                  Source: Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. 
                                  Lancet. Aug 19 1995;346(8973):477-81. 
 
 
 
 
2.1.2 Treatment Guidelines 
Numerous guidelines and recommendations for schizophrenia treatments have been 
published in the past decade.  Commonly cited practice guidelines and recommendations 
include the American Psychiatric Association (APA) Schizophrenia Treatment Guideline
18, 
20
, the Schizophrenia Patient Outcomes Research Team (PORT) Treatment 
Recommendations,
19, 21
 and the Expert Consensus Guideline Series: Treatment of 
Schizophrenia.
16
  Among these guidelines, the APA guideline and the PORT 
recommendations are synthesized based on scientific evidence, while the Expert Consensus 
Guideline is based on clinical experts’ opinions.52   
Both pharmacological and psychological treatments are recommended in these 
guidelines.  Antipsychotic monotherapy is recommended as the first line treatment for 
schizophrenia, especially for the acute phase.
16, 18-21, 52, 53
  Two common reasons for 
antipsychotic switching are lack of efficacy and intolerable side effects.
16, 18, 39
  Switching to 
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another antipsychotic is recommended if patients do not respond to the treatment after 
maximizing the dose or after a substantial treatment period (usually 4-6 weeks of 
treatment).
16, 39
  Long-acting injectable antipsychotics should be considered if patients do not 
respond will with oral antipsychotics or have poor adherence to oral agents.
16, 18-20
  
Combination therapy, or polypharmacy, is not considered in any of these guidelines.  
According to the PORT recommendations, combination of antipsychotics should only be 
used for a short period of time when switching medications.
16, 18-21, 52, 53
 
Unlike pharmacotherapy, however, there are few details about the application of 
psychotherapy in a treatment course.  The APA guideline recommends incorporating patient 
and family education into schizophrenia management.  Family education is recommended for 
both acute and stable phases for family members to understand the disease, and for 
physicians to better evaluate patients’ conditions through the interactions with patients’ 
family members.  Because studies have shown that psychosocial interventions are more 
effective in the continuation phase of treatment than the acute phase, patient level 
interventions, such as cognitive-behavioral psychotherapy (CBT) and social 
skills/employment training are recommended beginning in the stabilization phase and 
through the stable phase.
18, 20
  The PORT recommendations also suggest that patients with 
schizophrenia should receive psychotherapy in addition to pharmacotherapy to improve 
health outcomes.
19
   
Similar to the APA guideline, family interventions are recommended by the PORT 
group.  The individual-level intervention— CBT— is recommended as an adjunctive 
treatment for patients with adequate pharmacotherapy in the stable phase since evidence does 
not show that CBT is beneficial for the acute phase.
19
  Other behavioral interventions, such 
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as skills training, assertive community treatment, and supported employment, should also be 
provided, but psychoanalytic therapy, defined as ―therapies that use interpretation of 
unconscious material and focus on transference and regression,‖ is not recommended.19, 21  
Finally, like the other two guidelines, the Expert Consensus Guideline recommends starting 
patient and family education in the acute phase but initiating individual psychosocial 
treatments in the continuation phase.
16
  However, none of these guidelines specify the 
modalities of psychotherapy, or how to integrate psychotherapy with pharmacotherapy into a 
treatment course. 
 
2.1.3 Pharmacotherapy for Schizophrenia 
As mentioned above, pharmacotherapy is recommended as the first-line treatment for 
schizophrenia.
16-21
  Typical antipsychotics reduce positive symptoms effectively by blocking 
dopamine 2 (D2) receptors but often lead to side effects such as extrapyramidal symptoms 
(EPS) and tardive dyskinesia.
2, 7, 22, 23
  In the 1990s, numerous new agents, atypical 
antipsychotics, with a slightly different pharmacological mechanism were developed with 
fewer motor side-effects.  Evidence has shown that atypical antipsychotics are at least as 
effective for positive symptoms as typical antipsychotics, but whether atypical antipsychotics 
improve negative symptoms and cognitive functions is unclear.
2, 7, 22, 54-56
  Although atypical 
antipsychotics cause fewer motor side-effects, they are associated with higher incidence of 
metabolic syndromes (e.g. weight gain, hypertension, and hyperlipidemia).
16-21
   
While pharmacological treatment is easy to administer and reduces psychotic 
symptoms and signs effectively, it is not a perfect solution.  Non-adherence is a common 
problem for pharmacological treatment.  Patients may not adhere to treatment regimens due 
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to side effects or lack of efficacy.
11, 31, 32
  Up to 50% of patients do not fully remit even with 
adequate pharmacotherapy and may still suffer from relapse or residual symptoms.
10-12, 58
  In 
addition, pharmacotherapy alone does not improve cognitive and/or social functioning, which 
is important for patients’ long-term recovery.57  Therefore, how to improve medication 
adherence and functional recovery has become an important issue for patients receiving 
antipsychotic treatment.  By studying the effect of adjunctive psychotherapy on medication 
adherence, this dissertation provides more information about whether use of psychotherapy 
improves adherence.  
 
2.1.4 Psychotherapy for Schizophrenia  
In addition to pharmacotherapy, psychotherapy has been applied as an alternative 
form of treatment for patients with schizophrenia.  Although psychotherapy is less effective 
for acute symptoms of schizophrenia, it is believed that psychotherapy can improve patients’ 
medication adherence and long-term outcomes.
57
  However, because the effectiveness of 
psychotherapy has not been clearly demonstrated at the population level, with the 
introduction of antipsychotics (especially atypical antipsychotics), the use of psychotherapy 
has declined from 44.4% in 1996-1997 to 28.9% in 2004-2005.
58
  Using Medical 
Expenditure Panel Survey, Olfson and Marcus also found a non-statistically significant 
decrease in psychotherapy use and increase in pharmacotherapy between 1997 and 2008.
59
  
This decline may be attributable to both the introduction of atypical antipsychotics as well as 
the shift in financial incentives toward prescription management in recent years.
58-60
  Because 
of better understanding of the limitations of antipsychotic treatment in recent years, 
psychotherapy is now used as an adjunctive therapy with pharmacotherapy.  It is hoped that 
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adjunctive psychotherapy will be a helpful supplement to pharmacotherapy, which creates a 
synergistic effect to improve patient outcomes.
45, 57
   
Little is known about what affects physicians’ decision about psychotherapy referral.  
One study assessing referral to group therapy among patients with personality disorders in 
Italy found no association between psychotherapy referral and patients’ demographic or 
diagnostic factors.
61
  The authors suspected that patients’ negative attitude toward 
interpersonal interactions and physicians’ stereotypes about group therapy may play a role in 
the decision making process.
61
  Kingdon and Kirschen interviewed four psychiatrists in 
England reported that the most common reasons for not referring patients with schizophrenia 
to cognitive-behavioral therapy include a belief that patients are not likely to engage in 
therapy, that patients are doing well with medication treatment and do not need the therapy, 
and that patients refuse the referral.
62
  Among non-psychiatric specialists, a lack of 
knowledge about the disease and psychosocial treatments is the main reason for not 
referral.
63, 64
   
Even though many studies have evaluated the efficacy of different types of 
psychosocial interventions, clinically, there are no standardized interventions that have been 
applied as psychotherapy.  Because different psychosocial interventions often focus on 
different domains and may be delivered by various modalities, the effects of these 
interventions usually vary by modalities and outcome measures.  In general, patients 
receiving adjunctive psychotherapy have a lower risk of relapse, better adherence, and better 
symptom control.  Among different types of psychotherapy, family therapy seems to provide 
the most consistent results of lowering relapse rate.  Individual therapy tends to work when 
both behavioral and cognitive components are incorporated.  Unlike family and individual 
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therapy, evidence for group therapy is limited, and results are often mixed. The following 
sections introduce common types of psychosocial interventions that may be used in 
combination with antipsychotics at different levels. 
 
2.1.4.1  Individual-level Interventions 
Individual psychotherapy can be defined as ―interventions with one-to-one contact 
between a patient and a therapist.‖65  Psychoeducation, social skill training, cognitive 
therapy, and cognitive-behavioral therapy (CBT) are common types of individual 
interventions for patients with schizophrenia.  The aim of psychoeducation is to help patients 
to have a better understanding of their condition and treatments.
57
  Although 
psychoeducation may reduce the fear of side effects and improve patients’ confidence of 
treatment, it does not seem to improve medication adherence or reduce relapse rates.
27, 57, 66, 67
  
Psychoeducation may improve adherence in some cases, but only when it contains behavioral 
components and support services.
3, 68
 
 Cognitive therapy focuses on improving patients’ information processing ability as 
well as recognition of their environment and dysfunctional thoughts.
69
  The goal of cognitive 
therapy is to improve patients’ insight and their medication adherence by improving their 
cognitive function.
43
  Cognitive remediation is often achieved through repeated practice of 
certain tasks or techniques.
69
  Although cognitive therapy seems to improve cognitive 
functions and reduce the severity of delusion, it does not seem to improve other clinical or 
functional outcomes.
43, 69
  Because the focus of cognitive therapy is not on medication 
adherence, its effect on adherence is uncertain.
43
  In addition, because the results from 
cognitive interventions are often not generalizable beyond the setting and the scope of the 
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intervention,
57, 69
  cognitive therapy is often used as an integrated treatment in combination 
with other psychosocial interventions.
43, 69
 
Another common intervention, social skill training, helps to improve patients’ social 
behaviors and maximize their daily functioning, with a hope that social skill training will 
enhance patients’ employment rate and their long-term outcomes.  It often requires a longer 
training time (more than one year in some cases) to allow the positive outcomes to occur.
69
  
Evidence has shown that social skill training can improve patients’ social adjustment and 
reduce clinical symptoms, but it does not reduce relapse rates nor improve quality of life.
57, 69
  
Whether social skill training improves adherence is still unclear.
43
  Similar to 
psychoeducation and cognitive therapy, even though social skill training does not seem to 
have a significant effect on patients’ health outcomes, it may play a role in an integrated 
psychosocial intervention, such as CBT.
57
 
 Like all other interventions discussed above, CBT can exist in various forms.   The 
goal of CBT is to improve patients’ perception of their symptoms and behaviors to help them 
better respond to changes in their environment and/or their symptoms.
43, 57
  One central 
element of CBT is to build a strong alliance between patients and their therapists.
43, 57
  To 
reach this goal, CBT often integrates elements from different types of psychosocial 
interventions, such as psychoeducation, open discussion, and other treatment modalities.  By 
integrating these elements, CBT helps patients to explore their disease and symptoms, learn 
coping strategies, and receive cognitive training
43, 57
  Evidence has shown that CBT can 
effectively reduce overall symptoms, but the effect of CBT at different disease phases still 
needs to be determined.
19, 43, 57
  Despite limited evidence, some believe that CBT can also 
help to improve medication adherence and reduces relapse rates.
43
  However, whether CBT 
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improve patients’ insight remains unclear.43, 57  After the end of the treatment, the effects of 
CBT may last for six months to two years.
43
 
 
2.1.4.2  Family-level Interventions 
The goal of family-level intervention is to improve family members’ understanding of 
the disease and treatment, provide strategies for coping and disease management, and reduce 
stress and anxiety in the family.
1, 7, 34, 43, 57, 69
  It is hoped that family therapy can reduce the 
rate of relapse by improving interactions between patients and their family members.  Similar 
to individual therapy, the form and orientation of family therapy varies.  For example, 
psychoeducation, behavioral oriented therapy, and disease/medication management can all be 
applied at the family level.
69
  In addition to family members or key relatives, patients 
themselves can also be included in the treatment sessions.   
Compared to standard care, family intervention has been shown to reduce relapse 
rates and the duration of hospitalization.
34-36, 43
  It is reported that the two-year relapse rate 
for patients receiving family therapy ranged from 17% to 36%.
36
  On average, the relapse 
rate for patients with family therapy is around 24%, compared to 64% for those who receive 
routine care.
1
  Hogarty and colleagues found that family therapy successfully reduces the 
relapse rate during the first year (19% for the family intervention group and 41% for the 
drug-treated group), and the effect existed for two years (29%  for the intervention group 
versus 62% for the comparison group).
34, 35
  A similar effect was also reported in a meta-
analysis conducted by Pitschel-Walz et al.
70
  Their results indicated that family 
psychoeducation can reduce cumulative relapse and rehospitalization rates from 60% to less 
than 30% over two years.  In addition to reducing the risks of relapse, studies have also found 
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that family intervention can improve medication adherence and improve patients’ 
employment rate.
35
 
 Similar to certain individual interventions, the effects of family therapy may go 
beyond treatment duration and exist for a period of time after the end of the intervention.
57
  
The effect of relapse reduction from family interventions may last for one to two years, and it 
seems to be positively correlated with the duration of treatment.
69, 71
  In general, family 
therapy is more effective for patients who received more than ten sessions or six months of 
treatment.
57
   
 
2.1.4.3  Group-level Interventions  
Group therapy allows patients and/or their family members to seek support from their 
peers to improve outcomes, and it can be defined by three criteria: ―(1) a group of people is 
gathered for some therapeutic goal, (2) a professional expert leader is present to assist the 
group, and (3) the relationships and interactions between group members are used as tools for 
clarification, motivation, or behavioral change.‖3, 65  Most interventions at the individual or 
family levels can also be applied at the group level.   
Similar to some other psychological-treatment modalities, the goal of group therapy is 
to improve patients’ social skills and recognition of stress as well as focus on social/personal 
adjustment and quality of life.  Group therapy provides greater social support and social 
networking by enhancing patients’ relationship with others (e.g. health care providers, family 
members, and other patients), which facilitates information exchange and improves self-
esteem.
38
  A randomized trial comparing brief group CBT versus brief group 
psychoeducation demonstrated the short-term effect of group CBT on readmission reduction, 
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but no significant difference were found regarding symptom and adherence improvement.
72
  
Like other psychotherapies, the effects of group-level psychotherapies vary across study 
designs and populations.  Relatively few interventions have been conducted at the group 
level, and the results of group-level therapy are mixed.
57, 65, 69
  
 
2.1.4.4  Summary 
Overall, patients who receive both pharmacotherapy and psychotherapy have 
approximately 65% better response than those who only receive pharmacotherapy.
45
  Among 
the different types of interventions discussed above, more trials support the efficacy of 
family, followed by individual therapy.
45, 73
  In contrast, there is limited evidence for group 
therapy.
45
  Regarding intervention orientations, behavioral and cognitive-oriented 
interventions seem to consistently produce median effect sizes across trials, while verbal 
therapies produce a smaller average effect size with a wider variation across different 
delivery methods.
45
 
Given the heterogeneity of study interventions and outcome measures, there is no 
clear conclusion about the effect of psychotherapy on patients’ health outcomes.  
Nevertheless, the combined use of psychotherapy and pharmacotherapy is generally 
considered to have additive or synergistic effects compared to psychotherapy or 
pharmacotherapy alone.
43, 45, 73, 74
  Because most trials assessed the outcomes within one year 
(only few studies follow patients more than one year or up to two years), the long-term 
effects of psychotherapy are not clear.  With an 18-month follow-up period, this dissertation 
provides long-term evidence of psychotherapy.   
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In addition to implementing different types of psychotherapy for different treatment 
purposes, psychotherapy can also be applied at different stages of a treatment course to 
provide different support.  At the acute phase, psychotherapy can be used to help patients and 
their families to have a better understanding of the disease, recognize the necessity of 
medication treatment, and reduce their stress.
37
  During the stabilized phase, psychotherapy 
should continuously emphasize the importance of treatment, help patients identify new roles, 
and set reasonable treatment goals.
37
  Finally, at the maintenance phase, psychosocial 
interventions can help patients to maximize their social functioning and identify optimal 
coping strategies.
37
  Generally, psychosocial interventions seem to be effective for treatment-
resistant or for stabilized schizophrenia patients.
45, 75, 76
  By examining whether adjunctive 
psychotherapy improve patients’ adherence and reduce treatments costs, this dissertation 
extends our knowledge about the effectiveness of psychotherapy.   
 
2.2 Medication Adherence 
2.2.1 Definition of Medication Adherence 
Medication adherence, or compliance, can be defined as ―the extent to which a patient 
acts in accordance with the prescribed interval and dose of a dosing regimen‖.77  It should 
reflect whether a patient takes medications with the right dose at the right time.  There are 
many ways to measure adherence, such as patient or relative self-report, pill counting, and 
pharmacy refill records.
27
  However, there are currently no standard ways to measure 
medication adherence.  Because adherence is often not an all-or-none phenomenon, it is often 
difficult to have an appropriate and accurate measurement of adherence.   
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Many studies have evaluated medication adherence, and each has used different 
measurements and definitions of adherence.  Studies have found low correlations between 
adherence measures by self-rating, significant others’ rating, and pill count,25, 27, 78 which 
raises questions about the validity of self-report techniques.  In addition to self-report 
techniques, a growing method to measure medication adherence is to use pharmacy claims 
data.
28, 78-82
  However, challenges of using claims data include how to best estimate 
adherence and determining the most appropriate cut point to dichotomize medication 
adherence.
26, 78, 83, 84
  It is generally agreed that a cut point of 0.8 (or 80% of adherence) 
provides meaningful information to distinguish between adherent and non-adherent patients 
when using medication possession ratio (MPR) or proportion of days covered (PDC) as a 
measurement of adherence.
24, 28, 78, 80, 81
   One study has also reported it is valid to select a 
cut-point of 0.8 to distinguish adherent versus non-adherent patients when using subsequent 
hospitalization as the outcome of prediction.
85
 
 
2.2.2 Factors Associated with Medication Adherence 
There are several factors associated with non-adherence.  Forgetfulness is one 
common reason for low adherence, and many patients have indicated that a reminder would 
be helpful to improve their adherence.
1, 27, 86
  Lack of efficacy or poor response is another 
reason for low adherence.
13, 87
  Around 68% of patients stopped taking their medications 
during the first year of treatment because of loss of efficacy.
13
  Intolerable side effects, such 
as extrapyramidal symdromes and weight gain, can also lead to non-adherence.
31, 32
  Other 
factors that may contribute to poor adherence include shorter duration of disease, previous 
non-adherence, higher dose of antipsychotics, and poor alliance with therapists.
66, 87, 88
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Patients with substance abuse and lower family support were also found to be less likely to 
adhere to their regimens.
27, 86, 88, 89
   
Although patient demographics and type of antipsychotic use are generally believed 
to be associated with different adherence levels, no clear associations were found between 
non-adherence and age, gender, ethnicity, marital status, income, or education level.
26, 27, 88
  
Similarly, even though there is some evidence showing that patients with weaker perceived 
susceptibility of relapse and hospitalization or lower perceived benefit of medication 
treatment are more likely to be non-adherent to their regimen, it is not without controversy.
27
  
Use of atypical antipsychotics is another factor that is believed to be related to better 
adherence.  One study found that compared to typical antipsychotic users, patients receiving 
atypical antipsychotics are more likely to be adherent to their medication regimen and fill 
their prescriptions on time.
26
  However, this study did not adjust for potential confounders, 
and the definition of adherence was very loose (defined as PDC between 20% and 120%).
26
  
Despite this positive finding, another study reports an opposite finding,
81
  and many studies 
have not found atypical antipsychotics to significantly improve adherence compared to 
typical antipsychotics.
24, 29, 30, 33
  
Substance abuse is another factor associated with poor adherence.
27, 86-88, 90-93
  A 
Canadian study found patients who used cannabis were 0.46 (95% CI: 0.25-0.84) times as 
likely to adhere to their regimen as those who did not use cannabis.  However, alcohol use 
was not found to be significant in the adjusted model.
90
  Two studies conducted using 
Veterans Affairs (VA) data or in VA settings reported that substance abuse or alcohol and 
drug problems increase the odds of poor adherence significantly.
86, 91
  It has also been shown 
that substance abuse, including cannabis use, is a risk factor for medication discontinuation 
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or non-adherence among the first-episode patients.
87, 92
  The hazard ratio was estimated as 2.4 
(95% CI: 1.5-3.9) for non-adherence and 6.4 (95% CI: 1.2-35.6) for treatment dropout.
92
  
Finally, using data from the European Schizophrenia Outpatients Health Outcomes (SOHO) 
study, it is reported that alcohol dependence, substance abuse, and baseline adherence were 
all significant predictors of adherence during follow up.
93
  
Poor insight or negative attitudes toward the disease and treatment are also commonly 
cited reasons for poor adherence.
27, 86-88, 94-98
  Because insight can be measured in many 
different ways, different studies often have different definition of insight.  Two common 
ways to define insight are patients’ awareness of the disease or their beliefs about the 
treatment.  A study investigating patients with schizophrenia or bipolar disorder in Taiwan 
found that at the baseline interview, medication adherence was only significantly associated 
with insight into treatment but not insight into disease.
98
  However, neither of these factors 
were associated with adherence in the follow-up interview one year later.
98
   
Since patients with schizophrenia usually have cognitive and/or behavioral problems, 
they may not be able to follow the treatment regimens or may not recognize the importance 
of their medication treatment.
24, 27, 31, 88
  It is reported that patients with more severe 
symptoms or substance abuse are more likely to have poor insight,
87, 94, 95, 97
 and that these 
patients may not respond as well as others to psychotherapy.
94, 95
  Rittmannsberger et al. also 
pointed that poor insight can be either a cause or a result of non-adherence.
96
  Some have 
proposed to use psychosocial interventions, such as cognitive-behavioral therapy, or 
interventions guided by the Health Belief Model to improve patients’ insight.87, 88, 98   
Factors such as disease severity, other comorbid mental conditions, and current 
inpatient status have also been found to have mixed effects on medication adherence.
88
  No 
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consistent relationships have been found between medication adherence and schizophrenia 
subtypes and health beliefs.
27
  In addition, daily dose and administrative route of 
antipsychotics were not found to be related to non-adherence.
26, 27
  The relationship between 
dosage and adherence seems to be curvilinear given that low doses may lack efficacy and 
higher doses may produce intolerable side effect.
27
  Finally, the number of adjunctive 
psychotropic medications was not found to be associated with adherence.
26
 
Among environmental factors, greater social support has been shown to have a 
positive effect on adherence.
27
  Patients who receive support from relatives or friends are 
more likely to adhere to their antipsychotics.  However, the positive effect may be 
diminished if the relationship between the patients and their relatives/friends is stressful.
27
  
Financial burdens can be another environmental barrier for adherence.  Many patients 
discontinue their antipsychotics due to costs.
27
  In addition to costs, lack of transportation or 
access can also lead to partial or non-adherence.
27
  In this dissertation, the relationships 
between patients’ age, gender, race, and their adherence were evaluated.  We also tested 
whether types of initial antipsychotic received, treatment modification, and other comorbid 
conditions were associated with different adherence levels. 
 
2.2.3 Outcomes Associated with Non-adherence 
Patients with low adherence rates often experience negative outcomes, such as worse 
symptoms, lower social functioning, higher risk of relapse/hospitalization, longer hospital 
stay, and a higher frequency of emergency room visits.
13, 27, 28, 80-82, 89, 99-101
  Using California 
Medicaid claims data, Weiden et al. found a ―dose-response‖ relationship between 
medication gaps and risk of rehospitalization.  Compared to patients without any gaps during 
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a one-year observation, patients with a gap of 1 to 10 days, 11 to 30 days, or more than 30 
days were 1.98 (95% confidence interval, CI: 1.27-3.25), 2.81 (95% CI: 1.80-4.64), and 3.96 
(95% CI: 2.54-6.50) times as likely to have at least one mental-health related 
rehospitalization during the follow-up period, respectively.
82
  However, due to the cross-
sectional design, the causal relationship between medication gaps and hospitalization was not 
evident.  Figure 2.1 below illustrates the relationship between maximum gap days and 
rehospitalization. 
 
Figure 2.1. Association between Maximum Gap Days and Percentage of Patients 
Rehospitalized 
 
Source: Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization 
among California Medicaid patients with schizophrenia. Psychiatr Serv. Aug 2004;55(8):886-891. 
 
 
A study conducted by Weiden and Olfson , using the National Institute of Mental 
Health 1986 Client/Patient Sample Survey, estimated that the monthly relapse rate after 
hospital discharge was 3.5%, 11.0%, and 8.4% for patients who maintained their medications, 
who had discontinued their treatments (non-adherence), and who had their treatments 
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withdrawn by their clinicians, respectively.
13
  Compared to the 35% rehospitalization rate for 
patients who are adherent to their regimen, around 50% of non-adherent patients will be 
rehospitalized within one year after discharge, and by the end of the second year, over 80% 
of the non-adherent patients will be rehospitalized (compared to the less than 60% 
rehospitalization rate of adherent patients).
13
  It is also documented that the estimated risk of 
relapse for patients who withdraw from their medication treatment ranges from 60% to 80%, 
regardless of the duration of previous maintenance therapy.
11
  Instead of measuring 
medication adherence and hospitalization concurrently, Valenstein et al. found poor 
adherence as a predictor for future hospitalization.  Patients with poor adherence were 1.6 
times as likely to be admitted in the following year than those who were adherent.
81
 
Besides a higher risk of hospitalization, non-adherence is also related to a longer 
hospital stay.  A study found that among patients who were admitted, those who were not 
adherent had more psychiatric inpatient days than those who were adherent (33 vs. 24 days, 
p< 0.0001).
81
  Another study showed that the average number of inpatient days was 13.9 for 
patients with a 3-month gap and 3.6 for those who did not have a gap (p<0.01).
28
  In addition, 
poor adherence is associated with high inpatient costs.  Around 40% of the rehospitalization 
costs were attributable to non-adherence,
13
  and the estimated amount of hospital costs was 
$3,400 for non-adherent patients and $1,025 to $1,799 for adherent patients.
28, 80
  However, 
because of the higher pharmacy costs for adherent patients, even though the inpatient 
services costs were higher, the total costs for non-adherent patients may not be higher 
compared to adherent patients.
80, 101
  
Although not filling a prescription on time is an issue, ―excess filling‖ can be 
problematic as well.  Using cumulative possession ration as an adherence measurement, 
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Gilmer and colleagues found that both non-adherent patients (ratio<0.8) and ―excess fillers‖ 
(ratio>1.1)  had a higher hospitalization rate compared to patients who were adherent 
(psychiatric hospitalization rate: 34.9% for non-adherent patients, 24.8% for excess fillers, 
and 13.5% for adherent patients).
80
  Similar findings are also presented in a study conducted 
by Valenstein et al.  They found that patients with low adherence (MPR<0.8) were 2.4 times 
as likely to be admitted as those who had good adherence (0.8≤MPR≤1.1), and the odds for 
patients who excessively filled their prescriptions (MPR>1.1) was 3.0 times the odds for 
those with good adherence (p< 0.0001).
81
  Figure 2.2 illustrates the proportion of patients 
being hospitalized at different MPRs. 
 
Figure 2.2. MPR and Percentage of Patients with a Psychiatric Admission in  
Fiscal Year 1999 (N= 48,148) 
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Source: Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients 
with schizophrenia at increased risk for admission. Med Care. Aug 2002;40(8):630-639. 
  
 In contrast, Eaddy and colleagues did not find a higher odds of hospitalization for the 
―over compliant‖ group.101  In their study, medication compliance was measured by the 
continuous, multiple interval medications available (CMA) method, and patients were 
categorized as partially compliant (CMA<80%), compliant (80% ≤CMA≤ 125%), and overly 
compliant (CMA>125%).  Only the partial compliant group was found to have a higher risk 
of hospitalization than the compliant group (OR=1.49, p<0.001).
101
  However, unlike 
previous studies, which included only patients with schizophrenia, this study includes both 
schizophrenia and bipolar populations.  
 In summary, poor adherence is often associated with worse symptoms and a higher 
risk of relapse or hospitalization. Once admitted, non-adherent patients may have a longer 
inpatient stay than adherent patients.  Non-adherence is also associated with higher costs of 
inpatient services.  However, due to the higher pharmacy costs for adherent patients, the total 
cost for non-adherent patients may not be higher.  Given that non-adherence is often not 
attributed to a single factor, and it is not an all-or-none situation, it is necessary to study this 
problem from different angles and come up with multiple solutions.   
 
2.3 Adjunctive Psychotherapy and Health Related Outcomes 
2.3.1 Adjunctive Psychotherapy and Medication Adherence 
Regardless of some discrepancies, it is generally believed that psychotherapy can 
improve medication adherence.
3, 43, 57
  Compared to patients who only receive medication 
treatment, patients receiving interventions emphasizing medication taking behaviors are more 
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likely to fill their prescriptions on time.
25
  However, most interventions that have 
successfully improved adherence contain certain behavioral changing or problem-solving 
components.  Simply improving patients’ knowledge by psychoeducation without any 
motivation or supportive techniques does not seem to improve adherence effectively.
3, 27, 68, 
102, 103
 
 
2.3.2 Adjunctive Psychotherapy and Hospital Utilization 
Psychotherapy has been shown to effectively reduce relapse rates and risk of 
hospitalizations.  According to a meta-analysis conducted by Mojtabai et al., the frequency of 
relapse was around 20% lower for patients receiving psychotherapy in addition to 
pharmacotherapy than those who received pharmacotherapy alone.
45
  A similar result was 
reported in a study evaluating the effect of family intervention.  A study found that the two-
year relapse rate was 40% for patients receiving any form of family interventions and 75% 
for patients without the interventions.
36
   
Among different types of interventions, family interventions have shown the most 
promising results in reducing the risk of relapse and hospitalization.
41, 69, 73
  By improving 
patients and their family members’ knowledge of schizophrenia and treatment, 
psychoeducation can have a short-term effect on reducing relapse and rehospitalization 
rates.
27, 66
  In addition, psychotherapy may reduce inpatient days from approximately 8.5 
days to 6 days.
71
  Besides family therapy, individual-level interventions, especially CBT, 
have also been consistently shown to have positive effects on patients’ symptoms and relapse 
rates.
41, 43, 104
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2.3.3 Adjunctive Psychotherapy and Health Care Costs 
 There is limited evidence for the effect of psychotherapy on treatment costs. Among 
the Medicare population, the mean cost per person was estimated as $411, $158, and $688 
for individual, family, and group therapy in 1991, respectively.
46
  A significant decrease of 
psychotherapy expenditures was found between 1998 and 2007 from the Medical 
Expenditure Panel Survey (MEPS).  Annual expenditure for psychotherapy was $10.94 
billion (71% of outpatient mental-health expenditure) in 1998 and was $7.17 billion (44.7% 
of outpatient mental-health expenditure) in 2007 (p<0.01).
59
  Mean expenditures per 
psychotherapy decreased by 23% from 1997 to 2008 ($112.80 versus $94.95, p<0.001), and  
the mean expenditures for psychotherapy from Medicaid also declined by 17.3%.
59
   
One review article reports that the use of psychotherapy does not significantly 
increase health care costs for patients with psychosis.
71
  For patients who had stressful 
relationships their relatives, a 27% lower mean costs per patient was reported for those who 
received the family intervention compared to the usual care.
105
  Another study found a non-
significant reduction of total costs over a two-year follow-up for the intervention (CBT) 
group compared to the control group (treatment as usual).
106
  It is believed that the increased 
costs of the implementation of psychosocial interventions were offset by the decreased costs 
of other mental-health services.
71, 105
   
Although treatments costs have been evaluated in previous studies, each of them has 
its own limitations.  With claims data, Dixon et al. is considered to have a more accurate 
measurement of treatment costs, but the focus of the study is on the Medicare rather than the 
Medicaid population.
46
  As discussed previously, most patients with schizophrenia are 
covered under Medicaid.  Patients under Medicare can be a highly selected group with 
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limited generalizability.  The cost measurement may be less accurate for studies using MEPS 
because cost information in MEPS came from self-reports and imputation.  In addition, rather 
than focusing on schizophrenia, the study using MEPS grouped schizophrenia with other 
psychoses (ICD-9: 297-299) together to assess costs.
59
  Finally, two previous trial, one 
assessing the effective of family therapy for high expressed emotion families, and the other 
one assess the effect of CBT, were conducted with  small sample sizes (N<100).
105, 106
  In 
addition, the study evaluating CBT was conducted in United Kingdom, and instead of getting 
cost information directly from claims, costs were estimated based on interview information 
as well as external sources such Trust of the U.K. National Health Services.
106
  Given the 
limitations of these studies, a comprehensive evaluation of treatment costs associated with 
psychotherapy use in the United States is needed.  This dissertation improves the accuracy of 
diagnosis and cost information using Medicaid claims, and with a larger sample size, our 
results are more generalizable, especially to the Medicaid population.  
 
2.4 Conceptual Framework 
 The following sections describe the conceptual framework that is used to guide this 
dissertation.  The proposed framework is based on Andersen’s Behavioral model with 
modifications of some key components.   
 
2.4.1 Andersen's Behavioral Model of Health Services Use 
 Andersen’s Behavioral Model of Health Service Use was first developed in the late 
1960s to assess families’ use of health care, to evaluate access to health care, and to help 
develop policies that improve equitable access.
107
  It was developed to both predict and 
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explain health service use.
107
  Since the development of the initial model, it has been revised 
several times.  In the 1990s, the model incorporated health outcomes and revealed dynamic 
and recursive relationships among outcomes, health behavior, and population 
charactersitcs.
83, 84
  The most recent revision of the model was in 2008.  In addition to 
individual characteristics, the model emphasizes contextual characteristics, such as 
organization, community, and provider-relevant factors (Figure 2.3).
108
   
 
 
Figure 2.3.  Andersen’s Behavioral Model of Health Service Use 
 
Source: Andersen RM. National health surveys and the behavioral model of health services use. Med Care. Jul 
2008;46(7):647-653. 
 
 
 Three components from this model were used to guide the conceptual framework in 
this dissertation: individual characteristics, health behaviors, and health outcomes.  Under the 
individual characteristics, predisposing characteristics are factors that exist before the onset 
of the disease, which explain the likelihood of health service use.
107, 109, 110
  Such factors 
include demographics (age, gender, race), social structure (education, occupation, ethnicity), 
and health beliefs (attitudes, values, knowledge).
107, 110
  Because social structure and health 
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belief factors are unavailable in a claims dataset, this dissertation includes only age, gender, 
and race as predisposing variables. 
 Enabling resources are the ―means‖ that are available for individuals to use health 
services.
107, 109, 110
  These factors refer to the availability of health services.  Enabling 
resources include personal resources (income, health insurance, and regular source of care) 
and community resources (rural/urban residential area, provider types, and facilities).  
Although the patients in this study are all Medicaid beneficiaries, their health utilization may 
still be affected by different reimbursement methods.  In this study, a rural/urban indicator 
and an indicator for different coverage policies in different states (Illinois, Kansas, Minnesota, 
and North Carolina) are classified as enabling factors.  
 The third component under patient characteristics is need.  This factor describes the 
―illness level‖ of an individual and is the most immediate cause of health service use.109, 110  
Both patients’ self-perceived need and clinically evaluated need are included under this 
component.
107, 110
  Notice that in the latest revised model, perceived and evaluated health are  
also identified as health outcomes and can affect individual characteristics (especially the 
―need‖ component) and health behaviors.108  In this study, patients’ need is assessed by 
comorbid physical and mental conditions. 
 In addition to patient characteristics, several variables in this study are considered as 
health behaviors in the model.  Personal health practices (e.g. diet and exercise), process of 
medical care (e.g. counseling and prescriptions), and use of personal health services (e.g. 
physician visits and hospital services) are three components under health behaviors.
108
  These 
variables may interact with one another and influence health outcomes.  One dependent 
variable in this study, medication adherence, is considered as a process of medical care factor.  
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Another dependent variable, hospitalization, is considered as use of health services under 
health behaviors.  Independent variables, such as use of psychotherapy and types of 
antipsychotic used, can be list as factors under process of medical care and use of personal 
health services.  
 Finally, although the predisposing, enabling, and need factors are all important 
components of the determination of health service use, it is important to know that those 
factors may have different explanatory power when different types of services are evaluated.  
According to Andersen, because hospital services are often received for more serious 
problems, it is expected that predisposing and need characteristics are the primary 
explanation factors.
107, 108
  In contrast, ambulatory physician services are expected to be 
explained by all three components of patient characteristics, because conditions leading to 
physician services are often less serious and demanding.
107, 108
  
 
2.4.2 Proposed Conceptual Framework 
The proposed conceptual framework for this dissertation is based on Andersen's 
Behavioral Model of Health Services Use.  As mentioned previously, three key components 
(individual characteristics, health behaviors, and health outcomes) are used to guide this 
study.  Figure 2.4 shows the conceptual framework for this dissertation.
  
 
4
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Figure 2.4. Proposed Conceptual Framework 
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Following Andersen’s model, health behavior and health outcomes are determined by 
patients’ predisposing (age, gender, race), enabling (state indicator, metropolitan statistical 
area), and need (physical and mental comorbidities) characteristics.  In addition to social-
demographic factors, health belief is also placed as one of the predisposing factors according 
to Andersen’s model.  Unlike Andersen’s model, which lists health status and patient 
satisfaction as health outcomes, this proposed model considers health behavior (medication 
adherence) and use of health services (type of antipsychotic use and use of adjunctive 
psychotherapy) as ―health behaviors‖, while hospitalization and treatment costs are 
considered as ―health outcomes‖. 
In addition, the synthesized model incorporates two feedback loops from health 
outcomes to health behaviors and patients’ need.  It is assumed that patients’ health behaviors 
will change after experiencing certain health outcomes.  For example, a patient may become 
more adherent to his/her regimen after experiencing a hospitalization event.  A patient’s 
health status may also change after receiving certain inpatient services (e.g. a patient may 
receive more intensive treatment and become healthier/sicker after discharge).  Besides 
indirect effects, it is also assumed that enabling and need characteristics have a direct effect 
on health behaviors and health outcomes.  For instance, different states may have different 
policies, and patients living in different states may have different levels of access to health 
care services.  Need is assumed to directly affect health outcomes because a patient can 
experience an outcome (ex. hospitalization) regardless of his/her health behaviors (ex. 
adherence or non-adherence) if the patient’s condition becomes more severe.  Lastly, health 
outcomes are assumed to influence health beliefs directly.  Patients may have different health 
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beliefs after experiencing certain health outcomes.  For instance, a patient may perceive 
antipsychotics as being ineffective after being hospitalized several times.   
The key independent variable, use of adjunctive psychotherapy, is considered as a 
factor under health behaviors.  The assumption is that adjunctive psychotherapy changes 
patients’ health beliefs by improving patients and/or their family members’ attitude toward 
the disease and treatment.  Psychotherapy can also affect patients’ medication use behaviors 
(i.e. adherence) if it contains behavioral modification components or focuses on adherence 
improvement.  Although it can be argued that health beliefs may have a direct influence on 
health behaviors and outcomes, based on the Andersen Model, health beliefs do not affect 
health behavior or outcomes directly.  Therefore, in the proposed model, health beliefs can 
only affect health behaviors and outcomes through enabling and need factors.  
 CHAPTER 3: METHODS 
3.1 Data Source and Aims 
 Data for this study were obtained from the 2001 to 2003 Medicaid Analytic eXtract 
(MAX) files.  The person-level data contain records for individuals who were enrolled in 
Medicaid at least one day during the year, including demographic information (e.g. date of 
birth, gender, race), enrollment status, health service utilization, and treatment costs.  
Prescription drug information, such as prescription filling date, days supply, and payment, 
were identified from the claims.
111
  Four states were included for analyses: Illinois, Kansas, 
Minnesota, and North Carolina.  These four states were chosen because to the author’s 
knowledge, they did not have any major pharmaceutical policy change (such as prior 
authorization or number of prescription restricted) that could affect antipsychotic use and 
adherence during 2001 to 2003.  In addition, because the use of psychotherapy has declined 
in recent years, using 2001 to 2003 data may allow us to identify a larger sample of 
psychotherapy users.  Data from these states were used to accomplish the following aims: 
 
Aim 1: To describe the patterns and factors associated with the use of adjunctive 
psychotherapy. 
Descriptive statistics were first applied to evaluate the prevalence of psychotherapy 
and types of psychotherapy being used.  Frequency and percentage of psychotherapy use 
were reported.  In addition to the patterns of psychotherapy use, patient characteristics were
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compared across two groups (patients with both pharmacotherapy and psychotherapy versus 
patients with pharmacotherapy alone).  A logistic regression was performed to assess factors 
associated with psychotherapy use.   
 
Aim 2: To assess whether the use of adjunctive psychotherapy in combination with 
pharmacotherapy improves patients’ adherence to antipsychotic treatments. 
 Survival analyses were performed to assess time to treatment discontinuation (a gap 
excess 15 or 30 days) among the new antipsychotic users.  In addition, a sub-analysis was 
conducted to assess the likelihood of medication switching between psychotherapy users and 
non-users.   
 
Aim 3: To assess whether receiving adjunctive psychotherapy in combination with 
pharmacotherapy reduces hospitalization rates and health care costs.   
Due to a high proportion of zeros, a two-part count model (a hurdle model) was 
applied to evaluate the rate of hospitalizations between the two groups during follow-up.  
With non-normally distributed health care costs, generalized linear models were used to 
compare health care costs between psychotherapy users and non-users.   
 
3.2 Study Design and Sample 
 This study constructed a posttest-only design with nonequivalent groups using 2001 
to 2003 Medicaid claims data.  The study sample included patients who had been diagnosed 
with schizophrenia and who had at least one antipsychotic prescribed during the enrollment 
period.  Because antipsychotics could also be used to treat bipolar disorder, patients 
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diagnosed with bipolar disorders at any time during the study period were excluded to reduce 
confounding.  In addition, to avoid dual eligibility and to best capture health utilization, 
patients were excluded if they were younger than 18 or older than 62 years old in 2001.   
 Figure 3.1 describes the timeframe applied to Aim 2 and Aim 3.  Patients with 
schizophrenia were identified using the International Classification of Disease, Ninth 
version, Clinical Modification (ICD-9-CM) code of 295.xx.  To be included, a patient was 
required to have at least one inpatient or two outpatient diagnoses of schizophrenia any time 
during the study period.  Each patient was assigned an index-date, which is the date of their 
first antipsychotic prescription filled during the enrollment period (April 1
st
, 2001 to June 31
st
, 
2002).  A pre-index (or ―screening‖) period was assigned as 90 days before the index date, 
which was used to assess patients’ history of medication and health service use.  All patients 
were followed for 18 months (or 546 days) after the index date.  Specific inclusion/exclusion 
criteria are described in the following section. 
 
Figure 3.1. Study Design and Timeframe 
 
2001 2002 2003 
90 days before 
the index date 
Index date/follow-up starts 
(1
st
 antipsychotic 
prescription filled during 
the enrollment period) 
End of follow-up 
(18 months/546 days  
after the index date) 
Enrollment period  
(4/1/2001- 6/31/2002) 
Pre-index period Follow-up period 
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Inclusion/Exclusion Criteria for Incident Antipsychotic Users 
 This study investigated the effectiveness of psychotherapy using an incident cohort 
design (i.e. new-user design).  Using an incident cohort can eliminate some biases introduced 
by prevalent cohorts.  First, the new-user design eliminates the ―healthy user‖ effect.112  In 
this case, to be included as a prevalent case, a patient has to have at least one record of 
antipsychotic use during the pre-index period.  Therefore, we are more likely to include 
patients who are already stable (or better adherent) on their medications than those who are 
not.  This phenomenon not only leads to a selection bias but also confounds our results by 
patients’ immortal time (in this case, time that by definition, a patient has to stay on 
treatment).  In addition, the use of a treatment often co-varies with factors associated with the 
treatment itself.
112
  For example, the use of adjunctive psychotherapy is likely to be affected 
by previous adherence or outcomes.  A patient may receive psychotherapy because of his/her 
poor adherence.  The new-user design eliminates these two problems by implementing a 
washout period which ―washes out‖ the history of previous medication use behaviors and by 
measuring the baseline characteristics prior to the implement of the treatment.
112
  Incident 
cases (new antipsychotic users), were identified following the inclusion/exclusion criteria 
described below.   
 
Inclusion criteria: 
1. Patients with at least one inpatient or two outpatient diagnoses of schizophrenia 
(ICD-9-CM: 295.xx) any time during the study period. 
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2. Patients with no antipsychotic filled records during the ―pre-index‖ period (90 
days before the index date), and at least one antipsychotic filled during the 
enrollment period. 
3. Patients were required to have continuous eligibility from the pre-index period 
(three months before the index date) to the end of follow-up period (546 days 
after the index date).   
 
Exclusion criteria: 
1. Because antipsychotics could also be used to treat bipolar disorder, to reduce 
confounding by other indication, patients with a bipolar diagnosis (see Table 3.1 
for ICD-9 Codes) at any time during the study period were excluded. 
 
Table 3.1. ICD-9 Codes for Bipolar Disorder 
Diagnosis ICD-9-CM codes 
Bipolar I 296.0, 296.1, 296.4-296.7 
Bipolar II 296.89 
Bipolar Unspecified 296.80 
Cyclothymic Disorder  301.13 
 
2. Patients younger than age of 18 or older than age of 62 years in 2001 were 
excluded.  Because this study focuses on adults with schizophrenia, we excluded 
patients younger than 18 years old.  To fully capture health care utilization under 
Medicaid, we excluded those who would turn 65 years old and become eligible 
for Medicare during the study period. 
3. To best capture patients’ medication/health service utilization, patients who ever 
enrolled in a managed care plan or without full Medicaid benefits were excluded. 
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4. Patients with a record of a long-term care facility stay at any time during the study 
were excluded due to potential incomplete pharmacy records,.   
5. Patients who were hospitalized in the pre-index period were excluded because 
these patients were more likely to have more serious symptoms or to be treatment 
resistant compared to other patients. 
6. Patients with a record of psychotherapy in the pre-index period were excluded 
because previous psychotherapy might affect their medication use behaviors and 
thus confound our results.  
7. Patients with a claim of injection or long-acting antipsychotics, such as 
haloperidol decanoate or fluphenazine decanoate, were excluded because these 
patients might have different characteristics (i.e. non-adherent to oral agents or 
treatment resistant)
16, 18-20
 or potential inconsistent records of days supply.
80-82
  
 
3.3 Measurements 
3.3.1 Psychotherapy 
 The use of adjunctive psychotherapy served as the dependent variable for Aim 1 and 
key independent variable for Aim 2 and 3 (Table 3.3), and it was measured during the 
follow-up period.  Psychotherapy use was defined as a dichotomous variable to indicate 
whether a patient ever received psychotherapy (yes/no).  Due to limited sample sizes, our 
analyses were not stratified by the type of psychotherapy.   
The use of psychotherapy was identified by the Current Procedural Terminology and 
Healthcare Common Procedure Coding System codes (CPT/HCPCS).  Codes included in this 
study are 90804-90809 and 90875 (individual psychotherapy), 90846-90847 and 90849 
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(family psychotherapy), and 90853 as well as 90857 (group therapy).  Notice that 90849 
―multiple-family group psychotherapy‖ was categorized as family therapy here.  A sensitivity 
analysis was conducted to check how the results would change if 90849 is categorized as 
group therapy.  Interactive psychotherapy and psychoanalysis are not included in this study 
because interactive psychotherapy is often used in children, and psychoanalysis is not 
recommended by the guidelines.   
 
3.3.2 Dependent variables for Aim 2 and 3 
The dependent variables for Aim 2 and Aim 3 are medication adherence (Aim 2), 
hospitalizations, and treatment costs (Aim 3).  The following sections describe the 
measurements for medication adherence, hospitalizations, and treatment costs. 
 
3.3.2.1  Medication Adherence and Switching 
Medication Adherence 
Medication adherence was assessed as ―time to all-cause medication discontinuation.‖  
Number of days to discontinuation was calculated for each patient.  Although Cramer and 
colleagues have argued that medication adherence and medication persistency should be 
better defined and distinguished,
77
 in this dissertation, medication persistency is considered 
as one component of adherence.  Measuring medication persistency as a function of gaps 
between refills has been recommended by Sikka et al., for its ability to reflect medication 
continuity and suitability for survival analysis.
84
  Medication discontinuation is defined as a 
gap of 30 days or more between medication refills.  This definition is chosen based on the 
findings that a gap longer than 30 days increased the hazard of hospitalization by 50%,
113
 and 
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around 90% of rehospitalized patients had a gap of 30 (or more) days prior to their 
rehospitalization.
28
  Because there is currently no standard definition of medication 
discontinuation, to best reveal different scenarios of discontinuation and provide clinically 
meaningful information, a sensitivity analysis using a gap of 15 days or more was also be 
conducted.
82, 84, 113
  A 15-day gap is chosen because studies have shown that even a 10-day 
gap could be associated with a higher risk of hospitalization,
82, 113
 and it is also recommended 
to define a gap (15 days) as half of the days supply (30 days).
84
 
 
Antipsychotic Switching 
 The other dependent variable in Aim 2 was antipsychotic switching, measured as a 
binary variable which indicates whether a patient ever switched antipsychotics during the 
follow-up.  Based on a review, medication switching is often defined as using a different 
drug within a period of time after the initial treatment was filled.
114
  However, different 
studies usually apply different timeframe, and some of them may use additional criteria to 
define switching.
115-118
  In this study, switching was defined as initiating a different 
antipsychotic agent within 30 days after the end of the previous supply.  We choose to define 
switching as initiating a second drug after finishing the first drug supply because this 
approach allowed us to clearly separate switching from potential augmenting, defined as 
initiating a second drug before finishing the previous supply (see section 3.3.3 for details).  In 
addition, a sensitivity analysis was conducted using a 15-day window to define medication 
switching.  
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3.3.2.2  Hospitalizations 
 Hospitalizations were measured as the number of mental-health related inpatient 
admissions during follow-up.  Using Weiden and colleagues’ definition,82 mental-health 
related hospitalization was defined as having an inpatient record with a primary diagnosis 
code of schizophrenia, depression, anxiety, other psychoses, or dementia (Table 3.2).   The 
broad definition of mental-health related hospitalization allows us to capture all possible 
admissions associated with the index diagnosis of schizophrenia.
82
  This definition has been 
widely used in other studies as well.
85, 113, 119
  
 
Table 3.2. ICD-9 Codes for Mental-Health Related Hospitalizations 
Diagnosis ICD-9-CM codes 
Schizophrenia 295 
Depression 296.2, 296.3, 296.9, 300.4, 309.0, 311 
Anxiety 300.0, 300.2, 300.3, 306.9, 308, 309.2, 309.4, 309.9 
Other psychoses 297, 298, 299, 300.1, 302.8, 307.9 
Dementia 290, 291.2, 310.9, 331.0 
Source: Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization 
among California Medicaid patients with schizophrenia. Psychiatr Serv. Aug 2004;55(8):886-91. 
 
 
3.3.2.3  Treatment Costs 
 Treatment costs were measured as inpatient costs, outpatient costs, pharmacy costs, 
and total costs.  Inpatient costs were calculated as the total amount paid by Medicaid for 
mental-health related hospitalizations.  Outpatient costs included Medicaid payment for 
mental-health related visits and outpatient medical services, which were identified from 
outpatient claims with the ICD-9 codes presented in Table 3.2.  Pharmacy costs included all 
antipsychotic medications paid by Medicaid.  Finally, total costs were calculated as the sum 
of inpatient, outpatient, and pharmacy costs.  Because patients’ out-of-pocket costs are 
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usually low for Medicaid beneficiaries, the focus is on payer’s costs in this study.  All costs 
were adjusted to 2003 dollars using the U.S. Annual Consumer Price Index, Medical Care 
component.
120
  The dependent variables and key independent variable were summarized in 
Table 3.3. 
 
Table 3.3. Summary of the Dependent Variables and Key Independent Variable 
 Variable  Description Type 
Dependent Variables for Aim 2 and 3 
Aim 2 Adherence Time to all-cause discontinuation (number 
of days) 
Continuous 
 
Aim 2 Switching Whether a patient  had switched 
antipsychotic during the follow-up 
Dichotomous (yes/no) 
Aim 3 Hospitalizations Rate of hospitalization during the follow-up 
period (number of hospitalization/person-
time) 
Count  
Aim 3 Treatment 
Costs 
Sum of Medicaid payment for mental-
health related inpatient, outpatient, and 
antipsychotics 
Continuous 
Key Independent Variable (Dependent variable for Aim 1) 
All 
Aims 
Use of 
Adjunctive 
Psychotherapy 
Receiving psychotherapy during the follow-
up period  
Dichotomous (yes/no) 
 
 
3.3.3 Other adjusted variables 
 According to the proposed conceptual framework, several other factors may also 
affect the use of psychotherapy and/or the outcomes of interest.  Therefore, it is important to 
adjust these factors in our analyses.  Table 3.4 below describes other adjusted variables based 
on the proposed conceptual framework and aims.  
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Table 3.4. Description of Other Adjusted Variables 
 Variable  Description Type 
Other Independent Variables 
 Predisposing Characteristics 
All 
Aims 
Age Age in 2001 Categorical  
(18-35, 36-50, >50) 
Gender Gender Binary (Male/Female) 
Race Race/ethnicity Categorical  
(White, Black, Other) 
 Enabling Characteristics 
All 
Aims 
State indicator An indicator of different states (a proxy to 
control for different policies in different 
state) 
Categorical  
(IL, KS, MN, NC) 
Metropolitan 
Statistical Area 
(MSA) 
Indicates whether an Medicaid enrollee 
lives in a MSA 
Binary (MSA: yes/no) 
 Need Characteristics 
All 
Aims 
Comorbidities Physical: measured by Charlson 
Comorbidity Index 
Continuous 
Mental: dummies for depression, 
alcohol/substance abuse, and other 
psychosis  
Binary (yes/no) 
Health Behavior 
Type of Initial 
antipsychotic 
Treatment 
Type of the first antipsychotic filled  Binary (Atypical/Typical) 
Aim 
2&3 
Treatment 
Modification 
An indicator for medication modification 
(either medication switching, augmenting, 
or both) 
Binary (yes/no) 
Aim 3 Adherence 
Antipsychotic adherence during the follow-
up, measured by PDC 
Binary (Adherence: 
PDC≥0.8; non-adherence: 
PDC<0.8) 
 
 
 
 
Age was measured as the year of age in 2001.  We found no significant differences 
coding either age as a continuous or categorical variable.  Therefore, age was categorized 
into three groups (age from 18 to 35, 36 to 50, and older than 50 years old) to get a more 
meaningful estimates between age groups.  In addition to the percentage of patients in 
different age groups, mean age was also reported in the descriptive statistical table. 
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Race was categorized as White, Black, and others.  Black race was coded as an 
independent category because a previous study has shown that African Americans were less 
likely to receive psychotherapy than Causation patients.
46
  We separated other races from 
White and Black because patients with different races may have different perception of 
schizophrenia and its treatment.  However, due to small sample sizes, we grouped other race 
(including Asian, Hispanic, Pacific Islanders, and patients with multiple races) into one 
category.    
Because different states usually have different Medicaid policies, it is important to 
control for effects that are attributable to different benefit designs.  Small variation was found 
in the four states in this study, Illinois, Kansas, Minnesota, and North Carolina, in terms of 
physician and psychologist services.  In 2003, all of the four states covered physician 
services, and two of them covered psychologist services (Illinois and North Carolina did not 
cover psychologist services).  The copayment for physician and psychologist visits ranged 
from $1 to $3.  Illinois and Minnesota generally did not restrict the number of physician and 
psychologist visits.  In Kansas, patients were limited to 12 office visits and 32 hours of 
psychotherapy per year, and North Carolina covered up to 24 ambulatory visits per year.
121
   
Coverage for mental health/substance abuse rehabilitation and non-hospital 
public/mental health clinic services was similar across the four states.  All four states covered 
mental health/substance abuse rehabilitation as well as non-hospital public/mental health 
clinic services as of January 2003, and most of them did not limit the service or varied by 
different level of care.  Kansas limited substance abuse service to three treatment episodes 
over a lifetime, and North Carolina required prior approval if patients have more than eight 
outpatient psychiatric visits.  Regarding non-hospital public/mental health clinic services, 
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Kansas required a $3 copayment per visit and limited coverage to 40 hours of group or 
family therapy per year and 200 hours of psychotherapy and substance abuse services 
lifetime.  Public health clinic visits were not covered in Kansas, and patients in North 
Carolina were restricted to 24 ambulatory public health clinic visits per year (in limits with 
other specified practitioners).
121
   
All four states covered outpatient hospital services in 2003.  Kansas required a $3 
copayment for a non-emergency visit, and non-emergency visits counted toward the 
physician visit limit.  North Carolina required $3 per visit with a prior approval requirement 
for eight or more outpatient psychiatric visits, and the number of non-emergency visits per 
year was limited to 24 (alone with limits for other specified practitioners).  The copayment 
for a non-emergency visit in ER was $6 in Minnesota.
121
     
In terms of prescription drugs, all four states provided prescription drug coverage, and 
the copayment per prescription ranged from $1 to $3 in 2003.   Most states did not limit the 
number of prescriptions covered per month, except for North Carolina (a limit of six 
prescriptions per month).
121
  Table 3.5 summarizes different coverage under these four states.   
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Table 3.5. Summary of State Coverage for Mental-Health Related Services 
          States 
Coverage 
Illinois Kansas Minnesota North Carolina 
Physician Services 
(Coverage 
Limitations and Prior 
Authorization 
Requirement) 
$2/visit $2/visit 
(12 office visits/year, 
1 inpatient hospital 
visit/day, 1 office 
consultation/ 
2 months, 1 inpatient 
hospital consultation 
/10 days) 
$ 3/visit for non 
preventative 
service except 
mental health 
$3/visit  
(24 ambulatory 
visit/year included in 
limits with other 
specified 
practitioners) 
Psychologist Services 
(Coverage 
Limitations) 
Not covered $3/office visit 
(32 hours 
psychotherapy/year 
in combination with 
other providers) 
Covered, with no 
specified 
copayment or 
coverage 
limitations 
Not covered 
Mental Health and 
Substance Abuse 
Rehabilitation 
Services 
Covered, with no 
specified 
copayment 
(Limits for 
substance abuse 
services vary by 
established levels 
of care) 
Covered, with no 
specified copayment 
(Services limited to 
substance abuse and 
3 treatments 
episode/lifetime) 
Covered, with no 
specified 
copayment (Mental 
health service and 
visit limits vary) 
Covered, with no 
specified copayment 
(Prior authorization 
was required if more 
than 8 psychiatric 
visits) 
Non-Hospital 
Public/Mental Health 
Clinic Services   
Covered, with no 
specified 
copayment or 
coverage 
limitations 
$3/visit 
(32 hours individual 
psych therapy/year, 
40 hours group or 
family therapy/year, 
psych therapy and 
substance abuse 
$3/visit for non-
preventive services 
except mental 
health 
Covered, with no 
specified copayment 
(Limited to 24 
ambulatory 
visits/year to Public 
Health Clinic 
included in limits 
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services limited to 
200 hours/lifetime, 
Public Health Clinics 
not covered) 
with other specified 
practitioners. Prior 
authorization was 
required if more 
than 8 psychiatric 
visits) 
Outpatient Hospital 
Services 
Covered, with no 
specified 
copayment or 
coverage 
limitations 
$3/non-emergency 
visit 
(Non-emergency 
visits count toward 
physician visit limit, 
rehab must be 
restorative) 
$6/ non-emergency 
visit in ER 
$3/visit 
(24 non-emergency 
visits/year included 
in limits with other 
specified 
practitioners. Prior 
authorization was 
required if more 
than 8 psychiatric 
visits) 
Prescription Drugs $3/brand Rx, 
$1/generic Rx 
$3/Rx Covered, with no 
specified 
copayment 
(Prior authorization 
was required for 
non-preferred and 
brand Rx when 
generic available) 
$3/brand Rx, 
$1/generic Rx 
(6 Rx/month, Rx 
must be generic 
unless dispense as 
written) 
Source: The Henry J. Kaiser Family Foundation. Medicaid Benefits: Online Database.  http://medicaidbenefits.kff.org/index.jsp.  
Accessed Aug. 15, 2010. 
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Metropolitan Statistical Areas (MSAs) were identified using the 2009 list of 
metropolitan and micropolitan statistical areas defined by the U.S. Office of Management 
and Budget (OMB).  A MSA contains a core urban area with at least 50,000 or more people 
and its adjacent areas that are highly integrated with the core urban area.
122
  State and county 
codes were used to generate the Federal Information Processing Standard (FIPS) codes which 
allowed us to identify counties listed under a MSA in the Medicaid data.
122, 123
   
Comorbidities were also adjusted because comorbid conditions are likely to affect 
both treatment plans (i.e. the use of psychotherapy) and health outcomes (i.e. hospitalizations 
and treatment costs).  In this study, we used two approaches to measure physical and mental 
comorbid conditions.  Physical comorbidities were measured by Charlson Comorbidity Index 
(Deyo and Quan’s version)124-126, while mental comorbidities were adjusted using disease-
specific indicators for common comorbid mental conditions of schizophrenia (depression, 
alcohol/substance abuse, anxiety, and other psychoses).  Charlson Comorbidity Index (CCI) 
adjusts the risk of mortality by weighting selected conditions.
124
   Each patient got a 
summary score (Charlson comorbidity scores) based on the number and severity of his/her 
comorbid conditions.  
Charlson Comorbidity Index is chosen over other commonly used comorbidity 
indexes (such as the Elixhauser Index and Chronic Disease Score) for several reasons.  
Unlike Elixhauser Index, which does not weight different comorbidities and keeps them 
separately, CCI assigns weights to different conditions based on the risk of inpatient 
mortality, which should better reflect a patient’s overall disease severity.  In addition, 
because the Elixhauser Index includes several mental conditions (alcohol abuse, drug abuse, 
psychoses, and depression) that are not counted in CCI, using the Elixhauser Index will 
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prohibit us from separating the effects of these selected mental comorbidities from other 
physical comorbidities.  Since the outcomes of interest in this study are all mental-health 
related, the effect of these mental comorbidities may be different from physical comorbidities, 
and it may be inappropriate to count a mental condition the same as a physical condition.  
Finally, CCI is considered more stable than Chronic Disease Score because Chronic Disease 
Score uses pharmacy records for risk adjustment, which is more dynamic then diagnosis 
codes.  As a result, CCI was chosen over the Chronic Disease Score and the Elixhauser Index.  
Charlson Comorbidity Index was first developed and designed for medical records. 
Deyo et al. adapted it for administrative dataset research using ICD-9-CM diagnosis 
codes.
125
  Their codes were then updated by Quan and colleagues.
126
  Table 3.6 shows the 
ICD-9-CM codes for comorbid conditions.    
 
Table 3.6. ICD-9CM codes of Charlson Comorbidity Index 
Conditions ICD-9CM 
Myocardial infarct 410, 412 
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 
404.01, 404.03, 404.11, 404.13, 
404.91, 404.93, 425.4-425.9, 
428 
Peripheral vascular disease 093.0,437.3, 440-441, 443.1-
443.9, 47.1, 557.1, 557.9, V43.4 
Cerebrovascular disease 362.34, 430-438 
Dementia 290, 294.1, 331.2 
Chronic pulmonary disease 416.8, 416.9, 490-505, 506.4, 
508.1, 508.8 
 
Rheumatic Disease 446.5, 710.0-710.4, 714.0-
714.2, 714.8, 725 
Peptic ulcer disease 531-534 
Mild liver disease 070.22, 070.23, 070.32, 070.33, 
070.44, 070.54, 070.6, 070.9, 
570-571, 573.3, 573.4, 573.8, 
573.9, V42.7 
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Diabetes 250 
Hemiplegia or paraplegia 334.1, 342-343, 344.0-344.6, 
344.9 
Renal disease 403.01, 403.11, 403.91, 404.02, 
404.03, 404.12, 404.13, 404.92, 
404.93, 582, 583.0-583.7, 585-
586, 588.0, V42.0, V45.1, V56.0 
Any malignancy, including 
lymphoma and leukemia, except 
malignant neoplasm of skin 
140-172, 174-195.8, 200-208, 
238.6 
Moderate or severe liver disease 456.0-456.2, 572.2-572.8 
Metastatic solid tumor 196-199 
AIDS 042-044 
Source: Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining  
comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. Nov 2005; 
43(11):1130-9. 
 
 
 
Although CCI provides a good adjustment for physical comorbidities, it does not 
adjust for mental conditions.  Since this study examines health related outcomes among 
schizophrenia patients, it is important to adjust for common mental comorbidities in this 
group.  We therefore include four dummies to indicate whether a patient had depression, 
alcohol/substance abuse, anxiety, or other psychoses.  Codes used to identify depression and 
other psychoses were adopted from Weiden et al.,
82
 which were the same ICD-9-CM codes 
used to identify psychiatric hospitalizations.  For alcohol/substance abuse, we used the ICD-
9-CM codes proposed by Elixhauser and Quan.
126, 127
  Comorbid conditions were measured 
at baseline using the pre-index period to screen for comorbidities.  Table 3.7 shows the ICD-
9-CM codes used to identify mental comorbidities.  
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Table 3.7. ICD-9-CM Codes for Mental Comorbidities 
Diagnosis ICD-9-CM codes 
Depression 296.2, 296.3, 296.9, 300.4, 309.0, 311 
Substance Abuse 
(Alcohol/Drug Abuse) 
Alcohol abuse: 265.2, 291.1-291.3, 291.5-291.9, 303.0, 
303.9, 305.0, 357.5, 425.5, 535.3, 571.0-571.3, V11.3 
Drug abuse : 292, 304, 305.2-305.9, V65.42 
Anxiety 300.0, 300.2, 300.3, 306.9, 308, 309.2, 309.4, 309.9 
Other psychoses  
(including dementia) 
290, 291.2, 297, 298, 299, 300.1, 302.8, 307.9, 310.9, 
331.0 
Source: Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization 
among California Medicaid patients with schizophrenia. Psychiatr Serv. Aug 2004;55(8):886-91. 
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining  
comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. Nov 2005; 
43(11):1130-9. 
 
 
Another covariate controlled in this study was type of antipsychotic use because it 
could be associated with the use of psychotherapy as well as the outcomes of interest.  
Instead of measuring the type of antipsychotic use during the follow-up period, we chose to 
use the type of initial antipsychotic treatment as an indicator for type of antipsychotic use.  
Using the initial treatment assignment allowed us to assess the baseline antipsychotic 
assignment which occurred before or with the first psychotherapy.  Because many patients 
with schizophrenia switch or use different types of antipsychotic concurrently, this intent-to-
treat approach not only avoids the crossover and the endogeneity issues between the type of 
antipsychotic received and psychotherapy used during the follow-up, but also provides a 
clearer temporal association between the antipsychotic assignment and psychotherapy use.  
Medication adherence during the follow-up period was measured as proportion of 
days covered (PDC), defined as the proportion of days a patient had prescribed medications 
available during the follow-up period.  PDC has been found to have the highest predictive 
validity for hospitalization among patients with diabetes
128
 and has been used to assess 
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antipsychotic adherence among patients with schizophrenia in previous studies.
119, 129
  A 
study comparing eight different adherence measures, using Arkansas Medicaid claims data, 
found that PDC is one of the best predictors of all-cause and mental-health related 
hospitalization.
119
  In addition, unlike medication possession ratio, which may overestimate 
medication adherence, PDC provides a more conservative estimate of adherence.  PDC is 
therefore recommended as an adherence measure, especially when multiple drugs in a class 
are prescribed concurrently.
129
  Specifically, the formula used to calculate PDC is: 
 
PDC = 
                                         
                                             
      %, capped at 183, 119 
 
In this study, a cut-point of 80% was used to categorize full adherence (PDC≧80%) 
versus non-adherence (PDC<80%).  As discussed in section 2.2.1, PDC≧80% has been 
considered as a valid cut-point to distinguish adherence versus non-adherence,
24, 28, 78, 80, 81
 
and it has also been adopted by several other studies.
24, 28, 78, 80, 81
  Instead of predict mean 
adherence (PDC score), dichotomizing adherence allows us to predicting the probability of 
non-adherence given a set of characteristics of a patient, which is more clinically meaningful. 
Two special cases need to be considered when calculating PDC: polypharmacy and 
switching.  For patients who were on multiple antipsychotics, a given day was considered as 
covered if at least one antipsychotic was available on that day.  In other words, all follow-up 
days with at least one antipsychotic available were counted in the numerator of PDC.  For 
patients switching antipsychotics, if there was no gap before the switching occurred, the days 
covered by the new agent were treated as the days covered by the old agent and were counted 
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cumulatively in the numerator.  Gaps due to switching (i.e. patients start a new agent after the 
gap) are not counted in the numerator because the Expert Consensus Guideline does not 
recommend a gap before the initiation of the new agent.
16, 130
  Therefore, regardless of the 
initiation of a new agent, any given day was counted in the numerator of PDC as long as 
there was at least one antipsychotic agent available, and this calculation was consistently 
applied across all situations. 
In addition to PDC, an indicator of medication modification was also added to the 
regression models in Aim 3.  As discussed previously, PDC is capped at one and only count 
the proportion of days covered by antipsychotics.  Therefore, PDC does not count any 
potential switching or augmenting of antipsychotics that may affect the use of psychotherapy 
as well as outcomes of interests (hospitalizations and treatment costs).  To better capture the 
potential medication switching or augmenting, another dummy variable was added in Aim 3 
to indicate whether a patient had modified his/her treatment regimen during the follow-up.  A 
patient was considered as having modified his/her antipsychotic treatment if he/she had 
switched or augmented his/her antipsychotics during the follow-up period.  Antipsychotic 
switching was defined as having a different antipsychotic refilled within a 30 or 15-day 
window after the end of the previous antipsychotic supply (section 3.3.2.1).  In contrast to 
switching, medication augmenting was measured as an initiation of a different antipsychotic 
refilled before the end of the last antipsychotic supply.  By combining these two indicators 
together, the treatment modification dummy should be able to capture all the potential 
switching, augmenting, or concurrent use of antipsychotics.    
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3.3.3.1  Independent variables for Aim 1 
 Aim 1 evaluated patterns and predictors of adjunctive psychotherapy use (yes versus 
no).  The covariates included in the model for Aim 1 were: age, gender, race, states, MSA, 
comorbidities, and types of initial antipsychotic treatment.  According to the proposed 
conceptual model, age, gender, and race were considered as predisposing factors.  State 
indicator, which captured the effects of different policies among states, and MSA, which 
captured the effect of being in different geographic areas (rural versus urban), were 
considered as enabling factors.  Comorbidities (both physical and mental) were classified as 
need factors.   
Because some health behaviors can affect the use of psychotherapy during the follow-
up period (as discussed in section 2.4.2), type of initial antipsychotic use (atypical versus 
typical) were also included in the model for Aim 1.  Hypothetical associations between each 
independent variable and psychotherapy use are summarized in Table 3.8. 
 
     Table 3.8. Hypothetical Associations between Independent and Dependent Variables   
     for Aim 1 
 Use of adjunctive psychotherapy 
Older age - 
Female gender ?? 
Race – nonwhite  - 
State ?? 
MSA + 
Higher number of comorbidities - Physical + or no difference 
Higher number of comorbidities - Mental + 
Type of initial antipsychotic use - Typical + 
        (+) positive association, (-) negative association, (??) cannot be determined 
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3.3.3.2  Independent variables for Aim 2 
 Aim 2 assessed the association between psychotherapy use and antipsychotic 
adherence (time to discontinuation and antipsychotic switching).  Age, gender, and race were 
included as predisposing characteristics.  State and MSA indicators were classified as 
enabling factors.  Physical and mental comorbidities were included as need characteristics.  
Type of initial antipsychotic used was included in the model as a health behavioral factor that 
may affect both psychotherapy use and patients’ adherence levels.  Table 3.9 summarizes the 
relationships between the independent and dependent variables for Aim 2. 
 
Table 3.9. Hypothetical Associations between Independent and Dependent Variables for 
Aim 2 
 Use of adjunctive 
psychotherapy 
Adherence Switching 
Use of adjunctive 
psychotherapy 
 + - 
Older age - + or no difference + or no difference 
Female gender ?? + or no difference + or no difference 
Race – nonwhite  - - or no difference + or no difference 
State ?? ?? ?? 
MSA + + ?? 
Higher number of 
comorbidities – Physical 
+ or no difference - or no difference No difference 
Higher number of 
comorbidities – Mental 
+ - + 
Types of initial antipsychotics - 
Typical 
+ - + 
(+) positive association, (-) negative association, (??) cannot be determined 
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3.3.3.3  Independent variables for Aim 3 
Hospitalizations 
Aim 3 first examined the association between the use of adjunctive psychotherapy 
and the risk of hospitalization.  Age, gender, and race were classified as predisposing factors.  
State and MSA were classified as enabling factors for inpatient service use.  Similar to Aim 1 
and Aim 2, need characteristics was measured by comorbidities, and type of initial 
antipsychotic treatment was considered as a health behavioral factor.   
In addition, adherence and an indicator of treatment modification during the follow-
up were also included as health behavior factors in Aim 3 because the occurrence of 
hospitalization should be related to the concurrent medication using behaviors in the same 
period of time.  Table 3.10 describes the relationships between the independent and 
dependent variables for the hospitalization model in Aim 3. 
 
Table 3.10. Hypothetical Associations between Independent and Dependent Variables 
for the Hospitalization Model in Aim 3 
 Use of adjunctive 
psychotherapy 
Psychiatric 
hospitalization 
Use of adjunctive psychotherapy  - 
Older age - + 
Female gender ?? - or no difference 
Race – nonwhite  - + 
State ?? ?? 
MSA + ?? 
Higher number of comorbidities – 
physical 
+ or no difference + or no difference 
Higher number of comorbidities – 
mental 
+ + 
Types of initial antipsychotics - Typical + + 
Better adherence during the follow-up - - 
Modified antipsychotic treatments 
during the follow-up 
+ + 
(+) positive association, (-) negative association, (??) cannot be determined 
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Treatment Costs 
Regarding the cost model, age, gender, and race were considered as patient 
characteristics that could affect the use of adjunctive psychotherapy as well as treatment 
costs.  Similar to previous aims, state and MSA indicators were included in the model as 
enabling factors.  Because treatment costs were assessed from a payer’s perspective 
(Medicaid payment), and different states could have different reimbursement rates, we 
controlled for the state level effects.  Compare to patients living in a non-MSA, patients who 
lived in a MSA may have higher outpatient and medication costs because they have better 
access to health care and thus have a higher utilization rate of outpatient and pharmacy 
services.  However, patients living in a MSA may not have higher inpatient costs than 
patients lived in a non-MSA if patients lived in a MSA can better control for their conditions 
with better access to outpatient services. 
Physical and mental comorbidities were also included in the model as need factors 
that could also affect both psychotherapy use and treatment costs.  Type of initial 
antipsychotic use was included because it was directly associated with treatment costs.  In 
addition, medication adherence during the follow-up was included in the model because 
whether a patient adhered to his/her treatment could have a direct effect on health service 
utilization, which affected treatment costs.  Similar to the hospitalization model, an indicator 
of treatment modification was included in the cost model given that changes in regimens was 
directly associated with antipsychotic costs and could be indirectly associated with other 
treatment costs.  Table 3.11 summarizes the relationships between the independent and 
dependent variables for the cost model in Aim 3. 
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Table 3.11. Hypothetical Associations between Independent and Dependent Variables 
for the Treatment Cost Model in Aim 3 
 Use of adjunctive 
psychotherapy 
Inpatient 
Costs 
Outpatient 
Cost 
Medication 
Costs 
Total Costs 
Use of adjunctive 
psychotherapy 
 - + + - or no 
difference 
Older age ?? + + ?? or no 
difference 
+ 
Female gender ?? ?? + or no 
difference 
?? or no 
difference 
?? or no 
difference 
Race – nonwhite  - + - - ?? 
State ?? ?? ?? ?? ?? 
MSA + - + + + 
Higher number of 
comorbidities – 
physical 
+ or no difference + or no 
difference 
+ + + 
Higher number of 
comorbidities – 
mental 
+ + + + + 
Type of initial 
antipsychotics - 
Typical 
+ +  + - or No 
difference 
+ 
Better adherence 
during the follow-up 
- - - or no 
difference 
+ ?? 
Treatment 
modification during 
the follow-up 
+ + +/- - + 
(+) positive association, (-) negative association, (??) cannot be determined 
 
3.4 Statistical Analysis by Aims 
 This section explains the analytical plans by Aims.  Data construction, logistic 
regressions, and survival analysis were performed using SAS 9.2 (Cary, NC).  Hurdle models, 
generalized linear models, instrumental variable analyses, and bootsratp were performed 
using STATA 10 (College Station, TX).  Statistical significance was determined as alpha less 
than 0.05 using two-sided tests. 
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3.4.1 Aim 1: To describe the patterns and factors associated with the use of adjunctive 
psychotherapy. 
Aim 1 began with comparisons of two groups: 1) patients with both pharmacotherapy 
and psychotherapy and 2) patients with pharmacotherapy only.  Patient characteristics and 
other clinical factors were summarized for these two groups.  Due to insufficient sample size, 
our analyses were not further stratified by type of psychotherapy use.   
To better understand at what treatment stage patients initiated their psychotherapy, 
time of psychotherapy initiation was evaluated.  Incidence of different types of 
psychotherapy was summarized with frequency and percentage over a three-month interval 
(i.e. every three months in the follow-up period).  Time of psychotherapy initiation was 
reported as number and percentage of patients newly initiated on psychotherapy during each 
of the three-month intervals.   
For unadjusted statistical tests, t-tests and Chi-square tests were used to compare the 
distributions of continuous and categorical variables between the psychotherapy users and 
non-users.  For the adjusted analysis, a multiple logistic regression was used to identify 
factors associated with the use of psychotherapy (dichotomized as yes/no) during the follow-
up.  The model for Aim 1 is: 
 
                           
                                                
                                                       
 Age: a vector of age between 18 and 35, 36-50, and >50 years old as in 2001 
Gender: a vector of male and female gender 
Race: a vector of White, Black, and Other race 
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State: a vector of state indicators (IL, KS, MN, NC) 
MSA: a vector of MSA versus non-MSA 
Physical comorbidities: a scalar of Charlson Comorbidity Score 
Mental comorbidities: a set of scalar indicating whether a patient had specified 
mental comorbidities (depression, alcohol abuse, drug abuse, anxiety, dementia, 
other psychosis) 
 
3.4.2 Aim 2: To assess whether the use of adjunctive psychotherapy in combination with 
pharmacotherapy improves patients’ adherence to antipsychotic treatments. 
H2.1: Among new antipsychotic users, patients who receive adjunctive psychotherapy stay 
on medication treatment longer than patients who do not receive psychotherapy. 
H2.2 Patients receiving adjunctive psychotherapy are less likely to switch antipsychotics 
than patients without adjunctive psychotherapy. 
 
 Given that medication adherence was measured as number of days to antipsychotic 
discontinuation, a Cox proportional-hazard model was used to assess time to discontinuation.  
Because medication switching was a dichotomous variable, a logistic regression was used to 
assess the likelihood of switching.  Patients who were hospitalized before their 
discontinuation will be treated as censored cases at the time of hospitalization.   
Because the Cox proportional-hazard model assumes proportional hazard between the 
two groups, we first tested this assumption by plotting the log of cumulative hazard for each 
of the two groups.  In addition, an interaction term of time and psychotherapy use and log 
time [psychotherapy*log(t)] was added to the Cox model to check the proportional hazard 
assumption.  Since the interaction term was statistically significant, which meant the 
 73 
 
proportional hazard assumption was violated, the interaction term was kept in the Cox model 
to allow the hazard to be non-proportional over time.   
A lotgistic regression was used to assess medication switching, measured as ever 
switch versus never switch during the follow-up.  In addition to the original definition of 
switching (defined as an initiation of a different antipsychotic during a 30 or 15-day window 
after the end of the last supply), two sensitivities analyses were conducted using different 
definitions of switching.  In addition to the originally defined switchers, patients who 
initiated a second antipsychotic agent before the end of the last supply and never went back 
to use their first antipsychotic agent were also defined as switchers in the first sensitivity 
analysis.  However, because it was difficult to distinguish switching from augmenting in 
patients with multiple switching on one or more antipsychotics, among patients who filled a 
second antipsychotic drug before the end of the last supply of the initial antipsychotic, only 
patients who switched antipsychotic once were re-coded as switchers in the first sensitivity 
analysis model.  In the second sensitivity analysis, treatment modification (including both 
augmenting and switching) was used as the dependent variable instead of medication 
switching.  Although treatment modification includes both augmenting and switching, this 
variable should capture all of the switching activities which allows us to assess the effect of 
psychotherapy on medication switching (especially patients with multiple switching) from a 
different angle.  Models used to assess Aim 2 are: 
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         Switching 
        sychotherapy     Age                               
                                       Mental comorbidities 
                                               
 
Psychotherapy: an indicator of psychotherapy use 
Age: a vector  of age between 18 and 35, 36-50, and >50 years old as in 2001 
Gender: a vector of male and female gender 
Race: a vector of White, Black, and Other race 
State: a vector of state indicators (IL, KS, MN, NC) 
MSA: a vector of MSA versus non-MSA 
Physical comorbidities: a scalar of Charlson Comorbidity Index 
Mental comorbidities: a set of vectors indicating whether a patient had specified 
mental comorbidities (depression, alcohol abuse, drug abuse, anxiety, dementia, 
other psychosis) 
Type of initial antipsychotic treatment: a vector of the type of antipsychotics a patient 
initially received (atypical versus typical) 
 
 
3.4.3 Aim 3: To assess whether receiving adjunctive psychotherapy in combination with 
pharmacotherapy reduces total health care costs and hospitalization rates. 
H3.1: Patients receiving adjunctive psychotherapy have a lower rate of hospitalizations than 
patients who do not receive psychotherapy. 
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H3.2: Patients receiving adjunctive psychotherapy have lower inpatient and total costs, but 
higher outpatient and pharmacy costs compared to those who do not receive psychotherapy. 
 
 As described in section 3.3.2.2, hospitalization was measured as the number of 
hospitalizations during the follow-up period, and a hurdle model was used to compare the 
hospitalization rates between the two groups.  For the cost analyses, a generalized linear 
model (GLM) was applied because the distribution of treatment costs was highly skewed.  
The link function of the GLM model was chosen based on tests of normality.  Each 
dependent variable was transformed by different functional forms (e.g. log transformation or 
power transformation), and normality tests were then performed to assess whether the 
transformed dependent variable was normally distributed.  If the distribution of dependent 
variable was close to normal, the transformational form was selected as the link function.  
The distribution was tested using a modified Park test proposed by Manning and Mullahy.
131
  
 Due to the high proportion of zero inpatient costs, a two-part model was applied to 
compare the inpatient costs between psychotherapy users and non-users.  The first part of the 
model was a logistic regression which predicted the probability of having non-zero inpatient 
costs, and the second part was a GLM with a gamma distribution and a log link function.  For 
outpatient costs, a GLM model with gamma distribution and a log link function was applied, 
and models with gamma distribution and power link function were applied to medication 
costs and total treatment costs models. 
 In addition, the predicted values from each of the outcome models were calculated 
and reported.  The incremental costs for psychotherapy users versus non-users were also 
calculated.  For two-part models (hospitalizations and inpatient costs), the expected values 
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from the first-part, the second-part, and two parts combined were all reported.  The 
unconditional expected values from the two-part models were calculated as (the predicted 
probability from the first-part model)*(the expected number from the second-part model).   A 
bootstrap program with 1,000 replications was then used to calculate the bias corrected 95% 
confidence intervals.  The model used to assess hospitalization rate is: 
 
                         
                                                           
                                                            
                                            
                                              
The model used to assess treatment costs is: 
 
                                                                     
                                                            
                                                            
                              
Psychotherapy: an indicator of psychotherapy use 
Age: a vector of age between 18 and 35, 36-50, and >50 years old as in 2001 
Gender: a vector of male and female gender 
Race: a vector of White, Black, and Other race 
State: a vector of state indicators (IL, KS, MN, NC) 
MSA: a vector of MSA versus non-MSA 
Physical comorbidities: a scalar of Charlson Comorbidity Index 
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Mental comorbidities: a set of vectors indicating whether a patient had specified 
mental comorbidities (depression, alcohol abuse, drug abuse, anxiety, dementia, 
other psychosis) 
Type of initial antipsychotic treatment: a vector of the type of antipsychotics a patient 
initially received (atypical versus typical) 
Adherence: a vector indicating whether PDC ≥ 0.8 during the follow-up period 
 
 
3.5 Methodological Issues 
 In a randomized trial, study subjects are randomly assigned to either treatment or 
control groups, which ensures the balance of all observed and unobserved covariates between 
the two groups.  In an observational study, however, study subjects are often not randomly 
assigned to receive treatments, which can lead to systematic differences between groups.  If 
such differences are associated with both the treatment assignment and the outcome of 
interest, estimates can be biased.  Since the study subjects in this dissertation are not 
randomly assigned to receive adjunctive psychotherapy, it is important to adjust for 
systematic differences between the two groups.   
 In this study, we adjust the observed imbalanced factors by multivariate regression 
models.  However, this study may still suffer from confounding bias due to unobserved or 
un-measurable factors.  Disease severity may be one of the un-measurable confounding 
factors in this study.  Patients with more severe symptoms may be more likely to receive 
psychotherapy and more likely to be hospitalized.  In this case, failing to adjust for disease 
severity will bias the estimate upward and towards the null.  Unobservable confounding 
variables can also lead to an endogeneity problem.  Without observing disease severity, a 
physician may assign a patient to psychotherapy based on his/her risk of hospitalization.  As 
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a result, the use of psychotherapy and hospitalization are jointly determined, which can also 
result in biased estimates.  
 One way to address the unobserved confounding and endogeneity issues is to use an 
instrumental variable (IV) to estimate the effect of adjunctive psychotherapy.  Instrumental 
variables create a pseudo-randomization situation by inducing variation in the treatment, and 
this technique adjusts for both observable and unobservable confounders.  With the balance 
of all observed and unobserved covariates, the local average treatment effect can be assessed 
with an IV.
132-134
  However, a strong instrument relies on two assumptions: 1) the instrument 
is strongly associated with the treatment, and 2) the instrument does not have an effect on the 
outcome of interest other than through the treatment.
132-135
   
 Given the two critical assumptions of instrumental variables, it is usually hard to 
identify potential instruments that are strong enough and meet both criteria for successful IV 
estimates.  Another method to reduce confounding by indication is through the propensity 
score method.  Propensity score is a summary score describing the likelihood of a patient 
receiving treatment based on observed covariates.
134, 136, 137
  Grouping patients in the 
treatment and control groups by propensity score will balance the distribution of observed 
covariates.  For this to be true, a propensity score model must include all covariates that are 
associated with both the treatment and outcomes (i.e. confounders).
133
   
Similar to the IV approach, results from the propensity score matching may not be 
generalizable to the entire population because patients with extreme scores will not have 
comparable partners in the other group.  As a result, findings can only be generalized to 
patients represented in both groups.
137
  Because of the assumption that treatment is assigned 
based only on observed factors, the magnitude of bias due to omitted variables can be similar 
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to multiple regression adjustment.
134
  However, a propensity score model suffers less from 
misspecification than a multiple regression model given that there is no restriction on the 
number of covariates in the propensity score model.
133, 134
   
In addition to the propensity score approach, fixed-effect modeling can be another 
way to reduce treatment selection.  Using repeated observations, a fixed-effect model 
differences out the time-invariant effects (both measurable and un-measurable), and it 
compares patients who ever switched psychotherapy use (either from no psychotherapy to 
have psychotherapy, or the other way around) to those who never or always have 
psychotherapy at different time points.  To get a causal effect from a fixed-effect model, two 
conditions need to be held: 1) sufficient within group variation and 2) the switching between 
receiving and non-receiving psychotherapy is random (conditional on the covariates and un-
measurable fixed effects).
138
  A fixed-effect estimation will be biased if the unmeasured 
effects are time-variant (such as disease severity) or if measurement error occurs.  With 
claims data, our measurement bias should be small, or at least, consistent over time.  With 
consistent measurement errors, results from a fixed-effect model should not suffer from 
attenuation bias because the measurement errors will be differenced out.   
In this dissertation, IV technique was used to eliminate the potential confounding 
from both observable and unobservable factors.  Propensity scores and fixed-effect 
techniques were not applied because of two reasons.  First, the results with propensity score 
technique should be similar to the results from the multiple regression models because this 
technique only deals with observable confounders.  The results from this study, however, 
should be mostly threatened by unobservable confounders.  Second, because one of our 
outcomes (i.e. hospitalizations) is rare, there may not be enough within variations for fixed-
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effect estimates.  Given all the concerns above, IV was chosen over the propensity score and 
fixed-effect methods.  
 
3.6 Instrumental Variable Analysis 
3.6.1 Instrumental Variables 
 Two variables that may induce the variation in psychotherapy use but are not directly 
associated with adherence and hospitalization were considered as potential instruments in 
this study: 1) whether a provider provided psychotherapy to the schizophrenia patient seen 
prior to the current patient, and 2) whether a patient has seen a provider who provided 
psychotherapy to patients with major depressive disorder (MDD).  Both of these IVs are 
trying to capture the underlying providers’ preference.  
 According to Brookhart and his colleagues’ work, providers’ preference of treatment 
can be measured as the treatment assignment (yes/no) for a patient who is most recent prior 
to the next patient’s treatment.135, 139  Based on this idea, we constructed a variable which 
measures whether a patient received psychotherapy as a preference indicator of 
psychotherapy use for the next patient.  For this variable to hold as a valid IV, two 
assumptions must be true: 1) physicians’ choice of treatment must be directly associated with 
the assignment of psychotherapy, and 2) treatment choice is unrelated to the treatment 
outcomes except through psychotherapy use.  Patients without sufficient information to 
construct an IV were excluded from the IV analysis.  The final sample sizes for each 
instrument are summarized in Table 3.12 below. 
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Table 3.12. Sample Sizes for Each Instrumental Variable 
 Psychotherapy  
Instrumental Variables Users Non-Users Total 
Psychotherapy use for the last 
patient seen by the same provider 
585 2,818 3,403 
Psychotherapy use for MDD patients 
seen by the same provider 
585 2,814 3,399 
 
The validity of using physicians’ prescribing preference as an instrument has been 
proven in two of Brookhart’s previous studies.  One assessed the association between the 
types of antipsychotic use and short-term mortality, and another one evaluated the 
relationship between the use of COX-2 inhibitors and gastrointestinal complications.
135, 139
  
In both cases, physicians’ preference served as a good instrument because physicians’ choice 
of treatment can directly affect the medication assignment, but it is unlikely that physicians’ 
preference will affect patients’ morbidity or mortality rates.   
In our case, a physician’s preference of psychotherapy use should directly associate 
with the use of psychotherapy.  Since atypical antipsychotics are recommended as the first-
line treatment for schizophrenia patients, whether a physician preferred to use adjunctive 
psychotherapy should not affect his/her decision on medication treatment.  Therefore, the 
preference of psychotherapy use is unlikely related to patients’ adherence other than through 
the actual use of psychotherapy.    
The other IV constructed in this study is whether a patient has ever seen a provider 
who ever provided psychotherapy for his/her patients with major depressed disorder.  
Providing psychotherapy to MDD patients is used as an indicator of psychotherapy 
preference.  A provider was considered as preferring psychotherapy use if he/she ever 
provided psychotherapy to his/her MDD patients.  The assumption is that if a patient has seen 
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a provider providing psychotherapy to his/her patients with MDD at any time during the 
study period, the patient should be more likely to receive psychotherapy for that provider, 
and whether psychotherapy is provided to MDD patients should not be related to our 
outcomes of interest, which are medication adherence, hospitalizations, and treatment costs 
among patients with schizophrenia. 
  
3.6.2 Two-Stage Residual Inclusion Model and Specification Tests 
 Instead of using two-stage predictor substitution, we implemented two-stage residual 
inclusion (2SRI) models because the traditional linear IV method could be biased in non-
linear settings, and this bias would not attenuate even with a large sample size.
140, 141
  
Because a regular second-stage model did not account for the uncertainty carried from the 
first-stage predictions, the 95% confidence interval generated from the second-stage model 
was narrower than it should be.  We therefore used bootstrap to calculate the 95% confidence 
intervals to account for this under-estimation of confidence intervals.  As mentioned above, 
two instruments were constructed in this study: 1) whether a patient’s provider had provided 
psychotherapy for the previous patient seen by the same provider and 2) whether a patient 
had ever seen a provider who ever provided psychotherapy for his/her patients with MDD at 
anytime during the study.  Both IVs were dichotomous as yes (IV= 1) versus no (IV= 0).   
 Three specification tests were performed to test the validity of our IVs with respect to 
different outcomes (medication persistency, hospitalizations, and treatment costs).  We first 
tested the strength of each IV by checking the z-statistics in the first-stage logistic regression 
model.  In a linear regression model, an IV is considered to be strongly associated with 
psychotherapy use if the coefficient in the regression model is significant and the F-statistic 
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is large (F-statistic> 10).  Because we used a logistic regression as our first-stage model, 
instead of checking the F-statistics, we used a Wald test to evaluate the strength of our IVs.  
After running the first-stage model, we first checked the z-statistic and p-value of the 
instrument provided by the logistic regression output.  A Wald test was then performed to 
further test the strength of the instrument by checking the chi-square statistic and p-value 
from the test result.  Each instrument was first tested separately, and the strength of the two 
instruments was then tested jointly.  
 With the over-identification situation, we were able to test whether our IVs were 
validly excluded from the second-stage model (no direct or indirect associations between the 
IVs and outcomes other than through psychotherapy) using a Hausman over-identification 
test.
142
  If no test results could be obtained from a Hausman test due to non-inversable matrix 
or negative chi-square statistic, a Chow test was then used to compare the differences in 
coefficients between the two compared models.  In addition to Hausman tests, likelihood 
ratio (LR) tests were also performed to check the exclusion criteria of our IVs.  However, 
because LR tests evaluate all the IVs jointly, we can only conclude that not all of our IVs are 
validly excluded from the second-stage equation if we reject the null that all IVs are jointly 
excluded from the second-stage model, but we are unable to determine which IV is more 
valid.  Therefore, this test served as a second check of our IV selection for the Hausman test 
results.   
 Lastly, we used a Hausman test to check whether psychotherapy was endogeneous 
which could make the model become inconsistent.
142
  Similarly, if no test results could be 
obtained from the Hausman test, a Chow test was then used to check the endogeneity of 
psychotherapy use.  In addition, an alternative test of endogeneity was performed.  This test 
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utilized the second-stage regression model, which included both the actual psychotherapy use 
variable and the predicted residuals from the first-stage, to test the endogeneity of 
psychotherapy use.  The null hypothesis is that psychotherapy use is exogeneous, and hence, 
the predicted residuals should not have any explanatory power in the second-stage regression.  
Therefore, finding the predicted residuals significant and rejecting the null would indicate 
that psychotherapy use is endogeneous.
143
 
 Results from the final endogeneity test, however, were only used as a reference for 
several reasons.  First, as addressed above, Hausman tests may not be able to provide valid 
results given the non-inversable matrix or negative chi-square statistic problems.  Although a 
Chow test can be applied as an alternative of the Hausman test, a valid conclusion of 
endogeneity may not be reached by comparing the coefficients manually.  In addition, given 
the high variances of a 2SRI model, we may not have enough power to reject the null 
hypothesis of exogeneity.  Finally, even with the rejection of null, it is still unclear that 
whether this rejection is caused by the endogeneity of psychotherapy, or by other factors 
such as incorrect functional forms or measurement errors in psychotherapy.  Since the 
endogeneity tests are inconclusive, whether the use of adjunctive psychotherapy was 
endogeneous was mainly determined by assumptions, not by the test results. We assumed 
that all of our dependent variables were endogeneous and conducted IV estimations.  The 
results from the specification tests and IV models are discussed in the following sections.  
 
3.6.3 IV Limitations  
 Several limitations should be noticed when interpreting the results of IV estimates.  
First, the IV estimates are consistent when our instruments are strongly correlated with the 
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explanatory variable (i.e. psychotherapy use) and uncorrelated with the un-measurable 
confounders (i.e. IVs are not correlated with the unmeasurable confounders).  However, if 
the associations between our instruments and the explanatory variable are not strong, the 
results from our IV models can be in efficient and biased.
143, 144
  Since the test results showed 
that the two IVs were both strongly associated with psychotherapy use, weak instruments 
should not be a concern.   
 Second, although we were able to perform tests for the exclusion restriction criterion 
with the overidentification situation, whether these IVs are truly uncorrelated with the 
outcomes other than through psychotherapy use cannot be tested.  Our IV estimates can still 
be biased if the instruments are correlated with the outcomes.
145
  For example, patients with 
more severe conditions may be more likely to be referred to a provider who provides 
psychotherapy.  In this situation, provider preference is linked to disease severity and thus 
indirectly correlates with outcomes.  As aforementioned, some common reasons for not 
referring patients to psychotherapy include 1) providers’ belief that patients are unlikely to 
engage in psychotherapy, 2) patients are doing well with pharmacotherapy and therefore do 
not need psychotherapy, 3) patient refuse, and 4) providers’ lack of knowledge about 
psychotherapy.
61-64
 
 In the first situation, patients who are not referred to psychotherapy may be sicker 
because they are less likely to engage in psychotherapy, while in the second situation, 
patients who do not receive psychotherapy may be healthier because healthier patients are 
more likely to be well controlled by medication only.  In the third situation, however, both 
healthier and sicker patients can refuse to use psychotherapy for different concerns.  Sicker 
patients may lack of insight and thus refuse the treatment, whereas healthier patients may be 
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concerned about the time taken for the treatment and believe that they can do well simply by 
medication treatment.  In the last situation, if a provider does not have enough knowledge 
about psychotherapy and hence does not provide it to his/her patients, there should be no 
selection problem because all patients will not receive psychotherapy regardless of their 
disease severity. 
 In addition to provider referral, patients may actively seek psychotherapy.  Patients 
who seek psychotherapy should be relatively healthy and have some knowledge about 
psychotherapy.  Therefore, given all of the hypothetical situations and considerations above, 
the problem that our IVs are correlated with the outcomes of interest through un-measurable 
disease severity should be minor.  Nevertheless, if our IVs are actually correlated with the 
second-stage residuals through unobservable confounders, such as disease severity or 
physician practice patterns, the results from the IV models are biased.  Finally, because IV 
estimates require two-stage modeling, the insignificant findings can simply be due to the 
nature of wide confidence intervals caused by the two-stage estimation.  
 
 CHAPTER 4: RESULTS 
 
 Using Medicaid data from four states (IL, KS, MN, NC), our initial sample included 
84,180 patients with at least two outpatient or one inpatient diagnoses of schizophrenia.  
After applying all the inclusion/exclusion criteria, there were 3,696 patients included in this 
study.  We further excluded 160 patients with missing race.  The final sample size for this 
study was 3,536 with 606 (17.14%) patients as psychotherapy users and 2,930 (82.86%) as 
non-users (Figure 4.1).  The following sections describe the results by Aims.  
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Figure 4.1.  Sample Size Flow Chart 
 
Did not have any antipsychotic claims during the enrollment 
period 
N= 16,344 
Not continuously eligible for at least 3 months before and 18 
months after the index-date 
N= 8,032 
N= 61,673 
N= 45,329 
Had a bipolar diagnosis at any time during the study 
N= 21,539 
N= 42,422 
Younger than 18 or older than 62 in year 2001 
N= 2,817 
Enrolled in a managed care plan or did not have full Medicaid 
benefit coverage 
N= 6,235 
N= 34,390 
Had long-term care facility stay records during the 3 year 
study periods 
N= 6,881 
N= 28,155 
Final sample size  
(New antipsychotic users) 
N= 3,536 
N= 21,274 
Hospitalized in the pre-index period 
N= 2,388 
Patients with Schizophrenia 
N= 83,212 
N= 18,886 
N= 16,413 
Using psychotherapy in the pre-index period 
N= 2,473 
N= 16,312 
Patients who used antipsychotics during the pre-index period 
N= 12,616 
N= 3,696 
Patients with missing race 
N= 160 
Had long-term injectable antipsychotics claims 
N= 101 
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4.1 Aim 1: To describe the patterns and factors associated with the use of adjunctive 
psychotherapy 
  Aim 1 begins with descriptive statistics to summarize patient characteristics and 
patterns of psychotherapy use.  The sensitivity analysis showed that there was no difference 
to code 90849 either as group therapy or family therapy.  Because of insufficient sample size 
(Nindividual therapy= 555, Nfamily therapy= 16, Ngroup therapy=83), no formal statistical tests were 
performed to test the differences among different types of psychotherapy.  Patient 
characteristics were only compared descriptively across three different types of 
psychotherapy.  A logistic regression was used to assess factors associated with 
psychotherapy use.  
 Table 4.1 summarizes the characteristics of adjunctive psychotherapy users and non-
users.  Compared to the non-psychotherapy users, psychotherapy users tended to be younger 
(mean age: 39.61 for users vs. 41.20 for non-users, p<0.01), more likely to be White (43.23% 
of users vs. 37.58% of non-users, p<0.01), and less likely to live in a metropolitan statistical 
area (71.29% vs. 75.70, p<0.01).  Psychotherapy users were more likely to have depression 
(20.63% vs. 11.40%, p<0.01), anxiety (6.77% vs. 4.37%, p=0.01), and other psychoses 
(11.55% vs. 8.63%, p=0.02). In addition, a higher proportion of psychotherapy users received 
atypical antipsychotics as their initial treatment (88.28% vs. 85.02%, p=0.04).  
On average, psychotherapy users had 5.41 [Standard Deviation (SD)= 8.25] 
psychotherapy visits, and the average number of days between the first psychotherapy visit 
and last psychotherapy visit was 161.29 days (SD= 170.32).  However, the distributions for 
both the number of psychotherapy visits as well as the duration of psychotherapy were highly 
skewed.  More than 50% of the psychotherapy users had less than five psychotherapy visits, 
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and around 40% of the psychotherapy users had all of their treatment sessions within the first 
40 days (results not shown here).  
A higher percentage of psychotherapy users were adherent to their regimens than 
non-users (29.04% vs. 22.49%, p<0.01).  Compared to non-users, a higher percentage of 
psychotherapy users had switched their antipsychotics (21.45% vs. 15.19% in a 15-day 
window, p<0.01; 27.89% vs. 19.52% in a 30-day window, p<0.01) or augmented their 
antipsychotic treatment (39.11% vs. 29.32%, p<0.01) at sometime during follow-up.  When 
considering switching or augmenting together, a higher proportion of psychotherapy users 
were found to have modified their treatment regimens (i.e. either switched or augmented 
their medications). 
 
Table 4.1. Patient Characteristics of Psychotherapy Users and Non-Users    
 
Adjunctive Psychotherapy 
 
 
Users 
 
Non-users 
 
 
N= 606 
 
N= 2,930 
 
  %   % P-value 
Baseline Characteristics  
    
Age, Mean(SD) 39.61(10.98) 
 
41.20(10.23) <0.01 
Age Group 
   
<0.01 
18-35 35.81 
 
27.71 
 
36-50 46.20 
 
53.38 
 
>50 17.99 
 
18.91 
 
Gender 
   
0.16 
Male 54.62 
 
57.71 
 
Female 45.38 
 
42.29 
 
Race 
   
<0.01 
White 43.23 
 
37.58 
 
Black 49.01 
 
56.28 
 
Other 7.76 
 
6.14 
 
State 
   
0.35 
IL 35.64 
 
39.18 
 
KS 8.91 
 
7.71 
 
MN 10.56 
 
10.65 
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NC 44.88 
 
42.46 
 
MSA 
   
<0.01 
Yes 71.29 
 
75.70 
 
No 28.71 
 
24.30 
 
Charlson Score, Mean(SD) 0.19(0.60) 
 
0.18(0.60) 0.71 
Mental Comorbidities 
    
Depression 20.63 
 
11.40 <0.01 
Substance Abuse 8.25 
 
8.02 0.85 
Anxiety 6.77 
 
4.37 0.01 
Other Psychoses 11.55 
 
8.63 0.02 
Type of Initial Treatment 
   
0.04 
  Atypical 88.28 
 
85.02 
 
  Typical 11.72 
 
14.98 
 
Characteristics Measured During the Follow Up 
    
Number of Psychotherapy Visits, Mean(SD) 5.41(8.25) 
 
N/A 
 
Duration of Psychotherapy (Days)†, Mean(SD) 161.29(170.32) 
 
N/A 
 
Adherence 
   
<0.01 
Yes 29.04 
 
22.49 
 
No 70.96 
 
77.51 
 
Medication Augmentation 39.11 
 
29.32 <0.01 
Treatment modification- switching in 15 days or 
augmentation 
41.75 
 
31.88 <0.01 
Treatment modification- switching in 30 days or 
augmentation 
43.56 
 
33.41 <0.01 
SD: Standard Devisation; IL: Illinois, KS: Kansas, MN: Minnesota, NC: North Carolina; MSA: Metorpolitan 
Statistical Area; PDC: Proportion of Days Covered; N/A: Not Applicable  
† Duration of psychotherapy was defined as the number of days between the first psychotherapy visit to the 
last psychotherapy visit 
 
 
We next evaluated when patients began to use psychotherapy after the initiation of 
their pharmacotherapy.  Figure 4.2 shows the percentage of patients who initiated different 
types of psychotherapy by a 3-month interval.  About 40% of the patients initiated their 
psychotherapy in the first three months after antipsychotic treatment initiation.  The rate of 
all types of psychotherapy use dropped to 18% during month three to month six, and it then 
gradually declined through the end of the follow-up period.  
 92 
 
Figure 4.2. Percent of Patients Initiated Psychotherapy at Different Intervals  
 
 
 
In terms of the type of initial psychotherapy, among the 606 psychotherapy users, 540 
of them began with individual therapy, 8 of them began with family therapy, and 58 of them 
started with group therapy.  Most patients used only one type of psychotherapy.  Nine 
patients received both individual and family therapy, 37 patients received individual and 
group therapy, and one patient received all three types of psychotherapy. 
Because the three types of psychotherapy had relatively small sample sizes and were 
not mutually exclusive, we collapsed all three different types of psychotherapy into one 
group (as psychotherapy users) for the subsequent analyses.  Results from the logistic 
regression are summarized in Table 4.2.  Consistent with our hypotheses, older patients were 
less likely to use psychotherapy than younger patients (Odds Ratio [OR]Age 36-50= 0.69, 95% 
Confidence Interval [CI]Age 36-50= 0.56-0.84; ORAge>50= 0.73, 95% CIAge>50= 0.56-0.95),  and 
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Black patients were less likely to receive adjunctive psychotherapy than White patients (OR= 
0.75, 95% CI= 0.62-0.92).  Unlike the original hypothesis, we did not find patients living in a 
metropolitan area to be more likely to receive psychotherapy.  Patients with comorbid 
depression were more likely to receive psychotherapy (OR= 1.86, 95% CI= 1.47-2.36) then 
patients without depression, which was consistent with our original hypothesis.  Finally, we 
did not find patients initiating with typical antipsychotic to be more likely to receive 
psychotherapy as we originally hypothesized.  
 
Table 4.2. Factors Associated with Adjunctive Psychotherapy Use 
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
  OR 95% CI 
Age Group 
  
18-35 Reference - 
36-50  0.69** (0.56-0.84) 
>50 0.73* (0.56-0.95) 
Gender 
  
Male Reference - 
Female 1.12 (0.95-1.35) 
Race 
  
White Reference - 
Black 0.76** (0.62-0.93) 
Other 1.05 (0.74-1.51) 
State 
  
IL Reference - 
KS 1.18 (0.83-1.68) 
MN 0.96 (0.70-1.32) 
NC 1.20 (0.98-1.49) 
MSA 
  
Yes Reference - 
No 1.17 (0.95-1.45) 
Charlson Score 1.01 (0.86-1.17) 
Mental Comorbidities 
  
Depression 1.86** (1.47-2.36) 
Substance Abuse 0.98 (0.71-1.36) 
Anxiety 1.28 (0.88-1.87) 
 94 
 
Other Psychoses 1.33 (1.00-1.77) 
Type of Initial Treatment 
  
Atypical Reference - 
Typical 0.86 (0.65-1.13) 
OR: Odds Ratio; CI: Confidence Interval; SD: Standard Devisation; IL: Illinois,  
KS: Kansas, MN: Minnesota, NC: North Carolina; MSA: Metorpolitan  
Statistical Area; PDC: Proportion of Days Covered, measured in the follow-up period 
* p<0.05  
** p<0.01 
 
 
4.2 Aim 2: To assess whether the use of adjunctive psychotherapy in combination with 
pharmacotherapy improves patients’ adherence to antipsychotic treatments 
 Two dependent variables were evaluated in Aim 2: medication persistency and 
medication switching.  Medication persistency was measured as time to all-cause 
discontinuation which was defined as a gap greater than 30 days (or greater than 15 days for 
the sensitivity analysis).  Medication switching was defined as an initiation of a different 
antipsychotic agent within 30 days (or 15 days for the sensitivity analysis) after the end of the 
last supply, and the variable was dichotomous (ever switch versus never switch).  Cox 
proportional-hazard models were used to compare the discontinuation rates between 
psychotherapy users and non-users, and logistic regressions were used to assess the 
likelihood of switching between the two groups. 
 
4.2.1 Medication Persistency 
 Table 4.3 shows the unadjusted outcomes for Aim 2.  Results from t-tests showed that 
medication persistence was similar for psychotherapy users and non-users using either a gap 
in excess of 30 days (214 versus 220 days) or 15 days (159 versus 163 days) definition.  
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Results from chi-square tests indicated a higher percentage of patients receiving 
psychotherapy had switched their antipsychotics in either a 30-day (27.89% versus 19.52%, 
p<0.01) or 15-day (21.45% versus 15.19%, p<0.01) window.   
 
Table 4.3. Unadjusted Results for Outcomes in Aim 2- Medication Discontinuation and 
Switching 
 
Adjunctive Psychotherapy 
 
 
Users 
 
Non-users 
 
 
N= 606 
 
N= 2,930 
 
  %   % P-value 
Number of Days to a Gap >30 days, Mean(SD) 220.9(220.0) 
 
214.8(225.5) 0.54 
Number of Days to a Gap >15 days, Mean(SD) 159.4(192.2) 
 
163.1(203.4) 0.68 
Medication Switch – 30-day Window 27.89 
 
19.52 <0.01 
Medication Switch – 15-day Window 21.45 
 
15.19 <0.01 
 
 
 The unadjusted survival curves for the psychotherapy users and non-users are 
presented in Figure 4.3 and Figure 4.4 for a 30-day and 15-day gap definition, respectively.  
Using a 30-day or a 15-day gap to define discontinuation did not seem to greatly alter the 
results, and Log-Rank tests results indicated that there were no significant differences 
between the two groups using either definition (p=0.41 for a 30-day gap definition, and p= 
0.94 for a 15-day gap definition).  In both graphs, we can see a sharp drop followed by a 
gradual decrease in survival rate around day 30.  The gradual decrease before the sharp drop 
reflects the immortal time because by definition, patients are unable to discontinue their 
medications before the end of their first antipsychotic supply which is often 30 days.  The 
two graphs also show that psychotherapy users had better persistency in the beginning of the 
follow-up, but they also had a higher rate of discontinuation over time.   
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Figure 4.3. Survival Curves for A 30-day Gap Discontinuation 
 
Figure 4.4. Survival Curves for a 15-day Gap Discontinuation 
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Results from Cox proportional-hazard models are presented in Table 4.4.  In the main 
analysis (discontinuation defined as having a gap in excess of 30 days), we found that 
patients who received psychotherapy were less likely to discontinue their treatment than 
patients who did not receive psychotherapy (β= -0.593, p< 0.01), but this protective effect 
diminished and patients with psychotherapy became less persistent over time (βInteraction = 
0.154, p< 0.01).  Compared to White patients, non-white patients were more likely to 
experience a discontinuation (βBlack= 0.389, p< 0.01; βOther race= 0.308, p< 0.01).  Patients 
living in North Carolina were more likely to discontinue antipsychotics than patients in 
Illinois (β= 0.651, p= 0.02).  In addition, patients with typical antipsychotics as their initial 
treatment were also more likely to discontinue their treatment than patients who had begun 
their treatment with atypical antipsychotics (β= 0.651, p< 0.01).  Interestingly, patients who 
had modified their treatment were less likely to experience a gap longer than 30 days 
compared to patients who did not modify their treatment (β= -0.197, p< 0.01).   
The sensitivity analysis (discontinuation defined as having a gap in excess of 15 days) 
showed similar results as the main analysis (Table 4.4).  Patients with psychotherapy were 
less likely to discontinue their regimens than patients without psychotherapy (β= -0.701, p< 
0.01), but the interaction terms indicated this protective effect decreased over time (β= 0.194, 
p< 0.01).  Patients who were Black or another race were also more likely to discontinue their 
treatment than White patients (βBalck= 0.306, p< 0.01; βOther race= 0.247, p< 0.01).  We also 
found that patients living in rural areas were more likely to have a gap in excess of 15 days 
than patients living in urban areas (β= 0.114, p= 0.02).  Similar to the main analysis, patients 
initiated with typical antipsychotics were more likely to experience a discontinuation (β= 
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0.547, p< 0.01), and patients who had modified their regimens were less likely to discontinue 
their treatment (β= -0.114, p< 0.01).  
 
Table 4.4 Results from Cox Proportional-Hazard Models of Time to Discontinuation 
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
  A Gap > 30 Days A Gap > 15 Days 
 
β SE β SE 
Psychotherapy Use     -0.593** 0.217     -0.701** 0.206 
Age Group     
18-35 Reference - Reference - 
36-50 0.018 0.048 0.015 0.045 
>50      -0.019 0.064      -0.034 0.059 
Gender     
Male Reference - Reference - 
Female      -0.038 0.043      -0.011 0.040 
Race     
White Reference - Reference - 
Black     0.389** 0.047     0.306** 0.044 
Other     0.308** 0.089     0.247** 0.083 
State     
IL Reference -   
KS 0.052 0.083 0.011 0.077 
MN      -0.017 0.077      -0.063 0.070 
NC   0.117* 0.048 0.017 0.045 
MSA     
Yes Reference - Reference - 
No 0.094 0.050   0.114* 0.047 
Charlson Score 0.011 0.036 0.002 0.035 
Mental Comorbidities     
Depression      -0.099 0.065      -0.056 0.061 
Substance Abuse      -0.040 0.076      -0.070 0.072 
Anxiety 0.009 0.100      -0.022 0.093 
Other Psychoses      -0.090 0.072      -0.102 0.068 
Initial Treatment      
Atypical Reference - Reference - 
Typical     0.651** 0.055     0.547** 0.054 
Treatment Modification†      -0.197** 0.044      -0.114** 0.041 
Interaction Term‡     0.154** 0.053     0.195** 0.052 
SE: Standard Error; IL: Illinois, KS: Kansas, MN: Minnesota, NC: North Carolina; MSA: Metorpolitan Statistical 
Area; PDC: Proportion of Days Covered 
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† Treatment modification includes both medication switching and augmenting 
‡ Because the proportional hazard assumption was not met, an interaction term  
[psychotherapy use*log(number of days to the 1
st
 15-day gap)] was added to release the assumption 
* p<0.05   
** p<0.01  
 
 
 Because the model indicated that the hazard ratio changed over time, the adjusted 
results of the estimated hazard ratios for discontinuation at different time points is presented 
in Figure 4.5 below.  We can see that at the beginning of the follow-up, patients with 
psychotherapy are about 50% less likely to discontinue the treatment than patients without 
psychotherapy (hazard ratio ≈ 0.5 when t →0).  The protection effect then diminishes around 
day 50 (where the hazard ratio cross one), and after day 50, patients with psychotherapy 
become more likely to discontinue their treatment than patients without psychotherapy.  By 
the end of the follow-up, patients who received psychotherapy are over 1.4 times as likely to 
discontinue their antipsychotic treatment as patients who did not receive psychotherapy using 
a 30-day gap definition; the hazard ratio is over 1.6 when using a 15-day gap definition.   
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Figure 4.5. Adjusted Estimated Hazard Ratios over the Follow-Up Period 
 
 
 
4.2.2 Medication Switching 
 Table 4.5 shows factors associated with medication switching within 30 or 15 days of 
the end of the last supply.  In contrast to our hypothesis, we found that patients receiving 
psychotherapy were more likely to switch medications in both our main and sensitivity 
analyses.  In our main analysis (a 30-day switching window), patients who used 
psychotherapy were more likely to switch to another antipsychotic agent than patients who 
did not use psychotherapy (OR=1.57, 95% CI=1.29-1.93).  Compared to patients aged 18 to 
35 years old, patients who were over 50 years old were less likely to switch antipsychotics 
(OR=0.69, 95% CI=0.53-0.90).  The sensitivity analysis using a 15-day window definition 
showed the similar results as the main analysis.  Patients receiving psychotherapy were more 
likely to switch antipsychotics than patients not receiving psychotherapy (OR=1.52, 95% 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 100 200 300 400 500 600
H
a
z
a
rd
 R
a
ti
o
Days
Adjusted Hazard Ratios Over Time 
Hazard Ratio 
(30-day Gap)
Hazard Ratio 
(15-day Gap)
 101 
 
CI=1.22-1.90), and patients older than age 50 were less likely to switch antipsychotics than 
patients aged between 18 and 35 (OR=0.73, 95% CI=0.55-0.98, Table 4.5). 
 
Table 4.5. Logistic Regression Results – Medication Switching  
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
  Within a 30-day window Within a 15-day window 
 
OR 95% CI OR 95% CI 
Psychotherapy Use  1.57** (1.29-1.93)   1.52** (1.22-1.90) 
Age Group 
  
  
18-35 Reference - Reference - 
36-50 0.94 (0.78-1.13) 1.04 (0.85-1.28) 
>50         0.69** (0.53-0.90)    0.73* (0.55-0.98) 
Gender 
  
  
Male Reference - Reference - 
Female 0.88 (0.74-1.05) 0.93 (0.77-1.13) 
Race 
  
  
White Reference - Reference - 
Black 0.88 (0.73-0.95) 0.80* (0.66-0.98) 
Other 1.30 (0.93-1.81) 1.23 (0.86-1.77) 
State 
  
  
IL Reference - Reference - 
KS 1.02 (0.74-1.41) 1.03 (0.72-1.47) 
MN   0.71* (0.52-0.97) 0.83 (0.60-1.15) 
NC 0.97 (0.80-1.18) 1.08 (0.88-1.34) 
MSA 
  
  
Yes Reference - Reference - 
No 1.07 (0.87-1.30) 0.98 (0.79-1.23) 
Charlson Score 0.93 (0.80-1.09) 0.97 (0.82-1.14) 
Mental Comorbidities 
  
  
Depression 0.83 (0.64-1.07) 0.81 (0.61-1.08) 
Substance Abuse 0.93 (0.68-1.26) 0.96 (0.69-1.35) 
Anxiety 1.19 (0.82-1.72) 0.97 (0.63-1.49) 
Other Psychoses 1.20 (0.91-1.57) 1.21 (0.90-1.63) 
Type of Initial Treatment 
  
  
  Atypical Reference - Reference - 
     Typical 0.85 (0.66-1.09) 0.94 (0.72-1.23) 
OR: Odds Ratio; CI: Confidence Interval; SD: Standard Devisation; IL: Illinois, KS: Kansas, MN: Minnesota,  
NC: North Carolina; MSA: Metorpolitan Statistical Area; PDC: Proportion of Days Covered 
* p<0.05   
** p<0.01   
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 As mentioned previously, because medication switching was defined as an initiation 
of a second agent after the end of the previous supply, patients who switched antipsychotic 
before the end of their last supply were not considered as switchers nor included in the 
regression model.  Two sensitivity analyses were conducted to evaluate the use of 
psychotherapy on medication switching using different definitions of switching (regression 
outputs in Appendixes 6 and 7).  Although the odds ratios estimated in the sensitivity 
analyses were slightly smaller (OR ≈ 1.50 in all sensitivity models) than the odd ratios 
estimated in the original models, both of our sensitivity models showed that the use of 
psychotherapy was significantly associated with a higher chance of medication switching.  
Therefore, regardless of which definition of switching we used, all of our results indicated 
that psychotherapy use was associated with about a 50% increase in medication switching 
than non-users.  
 
4.3 Aim 3: To assess whether receiving adjunctive psychotherapy in combination with 
pharmacotherapy reduces total health care costs and hospitalization rates 
 Two types of outcomes were assessed in Aim 3: mental-health related 
hospitalizations and treatment costs. Hospitalizations were measured as number of 
hospitalizations during follow-up.  Because of a high proportion of zeros, hospitalizations 
were evaluated by a hurdle model.  Treatment costs were broken into four parts: inpatient, 
outpatient, pharmacy, and total costs.  A two-part model with GLM as the second part was 
applied to assess the inpatient costs.  All other cost variables were assessed by GLMs.     
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4.3.1 Hospitalizations  
 Table 4.6 shows the descriptive statistics of number of mental-health related 
hospitalizations and treatment costs.  Approximately 17% of the patients had been 
hospitalized.  On average, psychotherapy users had a higher mean number of hospitalizations 
than non-users in the entire study sample (0.38 vs. 0.23, p<0.01), or among patients who had 
be admitted at least once (1.70 vs. 1.42, p< 0.01).  The maximum number of hospitalizations 
was eight, and the median number of hospitalizations among patients who had been admitted 
was one. 
Table 4.6 also shows that psychotherapy users tended to have higher inpatient costs 
than non-users, which is contrary to our original hypothesis.  The higher inpatient costs can 
be caused by treatment and selection bias.  Selection may occur because patients with more 
severe mental-health conditions are more likely to use psychotherapy, and they are also more 
likely to be hospitalized.  Once they are hospitalized, these patients may require more 
inpatient care due to the severity of their conditions.   
 As we expected, the average outpatient treatment costs were also found to be higher 
for psychotherapy users than non-users.  Since psychotherapy users received additional 
outpatient services (i.e. adjunctive psychotherapy) than non-users, it is not surprising that 
they had higher outpatient costs.  In addition, as addressed above, patients with 
psychotherapy may be sicker and therefore require more outpatient services, which increased 
the costs. 
 The unadjusted finding that psychotherapy users had higher antipsychotic costs was 
consistent with our original hypothesis.  The higher costs of antipsychotics may due to the 
higher rate of medication switching among the psychotherapy users.  Finally, with higher 
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inpatient, outpatient, and antipsychotic costs, the average total costs for psychotherapy users 
were significantly higher for non-users. 
 
Table 4.6. Descriptive Statistics of Outcomes in Aim 3 – Mental Health Related 
Hospitalizations and Treatment Costs  
 
Adjunctive Psychotherapy 
 
 
Users Non-users 
 
 
N= 606 N= 2,930 
 
  Mean(SD) Mean(SD) P-value 
Number of mental-health related hospitalizations 
for all patients 
0.38(0.87) 0.23(0.62) <0.01 
Number of mental-health related hospitalizations 
among patients admitted at least once 
1.70(1.07) 1.42(0.83) <0.01 
Treatment Costs 
   
Inpatient 2043.9(7899.5) 725.2(3046.6) <0.01 
Outpatient 6203.4(15299.5) 3885.1(8611.3) <0.01 
Medication - Antipsychotics  3638.1(5073.8) 2592.0(3625.1) <0.01 
Total 11885.4(21327.7) 7202.3(10786.2) <0.01 
SD: Standard Deviation 
  
 Adjusted results of the comparison of number of hospitalizations between 
psychotherapy users and non-users are presented in Table 4.7.  The first part of the Hurdle 
model (logistic regression) indicates that patients with psychotherapy were 30% more likely 
to have a mental-health related hospitalization than patients without psychotherapy during 
the follow-up period (OR= 1.30, 95% CI= 1.03-1.62).  Patients aged between 36 and 50, and 
patients over 50 years old were 0.64 (95% CI= 0.53-0.79) and 0.41 (95% CI= 0.30-0.56) 
times as likely to be hospitalized as patients who were 18 to 35 years old, respectively.  
Compared to patients living in Illinois, patients living in Kansas or North Carolina were less 
likely to be hospitalized (ORKS= 0.48, 95% CI= 0.31-0.74; ORNC= 0.75, 95% CI= 0.60-0.92).  
Having comorbid depression increased the odds of hospitalization by a factor of 1.67 (95% 
CI= 1.29-2.16), and having other comorbid psychoses increased the odds by 1.45 times (95% 
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CI= 1.08-1.95).  Interestingly, patients who had begun with typical antipsychotics were less 
likely to be hospitalized than patients beginning with atypical antipsychotics (OR= 0.68, 95% 
CI= 0.50-0.92).  Patients who were adherent to their antipsychotic treatment were also less 
likely to be hospitalized than patients who were not adherent (OR= 0.72, 95% CI= 0.57-0.90).   
Finally, patients who had switched or augmented their antipsychotic treatments were more 
likely to experience a mental-health related hospitalization than those who did not modify 
their treatment regimens (OR= 3.42, 95% CI= 2.82-4.14). 
 According to the second part of the Hurdle model (a zero-truncated model), the use of 
psychotherapy was not associated with the number of hospitalizations among those who had 
been admitted at least once.  However, the interaction term of psychotherapy and adherence 
indicated that the number of hospitalizations for patients who used psychotherapy and had 
better adherence was estimated as 0.60 [exp(0.30-0.74+0.86-0.93)= 0.60] times the average 
number of hospitalizations for other patients.  Among those who had been admitted at least 
once, the number of hospitalizations for patients in North Carolina was 0.68 [exp(-0.39)= 
0.68] times the number of hospitalizations for patients in Illinois.  Patients who were 
adherent to their regimens were associated with a 52% [exp(-0.74)= 0.48] decrease in the 
number of hospitalizations compared to non-adherent patients.  Having treatment 
modification increased the number of hospitalizations by a factor of 1.58 [exp(0.46)= 1.58]. 
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Table 4.7. Results from the Hurdle Model– Number of Hospitalizations 
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
 
Part 1: Logistic Regression Part 2: Zero-Truncated Model 
  OR 95% CI β 95% CI 
Psychotherapy Use       1.30* (1.03, 1.62) 0.30 (-0.56, 0.66) 
Age Group 
    18-35 Reference - Reference - 
36-50        0.64** (0.53, 0.79) -0.23 (-0.53, 0.08) 
>50        0.41** (0.30, 0.56) -0.44 (-0.95, 0.08) 
Gender 
    Male Reference - Reference - 
Female 1.19 (0.98, 1.43) 0.12 (-0.18, 0.42) 
Race 
    White Reference - Reference - 
Black 1.02 (0.83, 1.26) 0.21 (-0.11, 0.53) 
Other 1.10 (0.76, 1.59) -0.06 (-0.57, 0.45) 
State 
    IL Reference - Reference - 
KS      0.48** (0.31, 0.74) -0.06 (-0.63, 0.52) 
MN 0.73 (0.52, 1.03) -0.02 (-0.56, 0.52) 
NC   0.75* (0.60, 0.92)   -0.39* (-0.73, -0.06) 
MSA 
    Yes Reference - Reference - 
No 0.93 (0.74, 1.18) 0.04 (-0.32, 0.40) 
Charlson Score 1.10 (0.96, 1.26) -0.20 (-0.47, 0.08) 
Mental Comorbidities 
    Depression     1.67** (1.29, 2.16) 0.18 (-0.15, 0.50) 
Substance Abuse 1.26 (0.92, 1.72) -0.15 (-0.64, 0.35) 
Anxiety 1.16 (0.77, 1.73) 0.13 (-0.49, 0.74) 
Other Psychoses   1.45* (1.08, 1.95) 0.13 (-0.27, 0.53) 
Initial Treatment  
    Atypical Reference - Reference - 
Typical   0.68* (0.50, 0.92) 0.08 (-0.50, 0.66) 
Adherence 
         Yes      0.72** (0.57, 0.90)     -0.74** (-1.21, -0.28) 
     No Reference - Reference - 
Treatment Modification†    3.42** (2.84, 4.12)     0.46** (0.15, 0.77) 
Psychotherapy*Adherence N/A -   0.86* (0.15, 1.58) 
Constant N/A -     -0.93** (-1.59, -0.27) 
OR: Odds Ratio; CI: Confidence Interval; IRR: Incidence Rate Ratio; IL: Illinois, KS: Kansas, MN: Minnesota,  
NC: North Carolina; MSA: Metorpolitan Statistical Area; PDC: Proportion of Days Covered; N/A: Not Applicable 
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† Treatment modification was defined as having either switched antipsychotics within a 30-day  
window or augmented treatment at anytime during the follow-up period  
*p<0.05        
**p<0.01        
  
 The predicted probabilities of hospitalization and number of hospitalizations are 
presented in Table 4.8.  The average predicted probability of hospitalization was 0.17 (SD= 
0.11), and the predicted probabilities of hospitalization were 0.20 (SD= 0.12) and 0.17 (SD= 
0.11) for psychotherapy users and non-users respectively.  The incremental effect of 
adjunctive psychotherapy on the probability of hospitalization was estimated as 0.03 (SD= 
0.02).  Consistent with the logistic regression results reported in Table 4.7 (ORpsychotherapy= 
1.30, 95% CI= 1.03-1.62), this incremental effect is marginally significant.  
 Based on the second part of the Hurdle model, the mean predicted number of 
hospitalizations (conditional on at least on admission) was 0.40 (SD= 0.20) for the 18-month 
follow-up period.  The average number of hospitalizations was 0.50 (SD= 0.22) for 
psychotherapy users and 0.40 (SD= 0.17) for non-users.  By subtracting the two numbers, the 
incremental effect of psychotherapy on hospitalizations was calculated as 0.13 (SD= 0.06), 
and this effect was statistically significant.  
 
Table 4.8. Predicted Values of Hospitalizations from the Hurdle Model 
  Mean SD Min Max 
Part 1- Predicted Probabilities of non-zero hospitalizations  
Predicted probability for all patients 0.17  0.11  0.02  0.66  
Predicted probability (set psychotherapy= 1) 0.20  0.12  0.03  0.71  
Predicted probability (set psychotherapy= 0) 0.17  0.11  0.02  0.66  
Incremental effect of psychotherapy on 
hospitalization probability 0.03  0.02  0.01  0.06  
Part 2- Predicted Number of Hospitalizations (Conditional on at least one admission) 
Predicted number of hospitalizations for all 
patients 0.40  0.20 0.03  1.42 
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Predicted number of hospitalizations 
(psychotherapy= 1) 0.50  0.22  0.04  1.42 
Predicted number of hospitalizations 
(psychotherapy= 0) 0.40 0.17  0.03 1.05  
Incremental effect of psychotherapy on number 
of hospitalizations 0.13  0.06  0.01  0.37  
SD: Standard Deviation 
 
 The unconditional predicted values of hospitalizations are presented below in Table 
4.9.  After combining the two parts of the Hurdle model, the mean unconditional predicted 
number of hospitalizations was 0.08 (95% CI= 0.04-0.12) with the original characteristics of 
the population.  With psychotherapy, patients were expected to have 0.13 (95% CI= 0.06-
0.20) hospitalizations during the follow-up, and the expected number of hospitalizations was 
0.07 (95% CI= 0.03-0.10) without psychotherapy.  The incremental number of 
hospitalizations was calculated as 0.07 for psychotherapy users, and the effect was 
marginally significant (95% CI= 0.01-0.12).  
 
Table 4.9. Predicted Number of Hospitalizations from the Hurdle Model (Unconditional) 
  Mean Bootstrap 95% CI 
Predicted number of hospitalizations for all patients 0.08 (0.04-0.12) 
Predicted number of hospitalizations (psychotherapy= 1) 0.13 (0.06-0.20) 
Predicted number of hospitalizations (psychotherapy= 0) 0.07 (0.03-0.10) 
Incremental effect of psychotherapy on number of 
hospitalizations 
0.07 (0.01-0.12) 
CI: Confidence Interval 
 
 
4.3.2 Treatment Costs – Inpatient Costs 
 The predicted values from the two-part model are summarized in Table 4.10.  
Because the first-part model evaluated the probability of having non-zero inpatient costs, 
which was identical as the first-part of the hospitalization model, the predicted values were 
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identical as the first-part predicted probabilities in Table 4.8.  Therefore, we only presented 
the predicted values from the second-part of the inpatients cost model, and the predicted 
values from the first-part inpatient cost model were skipped here.  
 Based the second part of the model (conditional on at least one admission), the 
average inpatient costs were calculated as $4,727.13 (SD= $2,931.73) for the entire 
population.  With adjunctive psychotherapy, the expected inpatient costs were $9,094.51 
(SD= $3,896.60), and the expected inpatient costs were $3,851.38 (SD= $1,650.14) without 
psychotherapy.  The conditional incremental costs among patients who had been hospitalized 
were estimated as $5,243.14 (SD= $2,246.45) for patients with psychotherapy.   
 
Table 4.10. Predicted Inpatient Treatment Costs from the Second-part Model
†
 
(Conditional on at least on admission, $) 
  Mean SD Min Max 
Predicted inpatient costs for all patients 4,727.13 2,931.73   876.21 29,695.67 
Predicted inpatient costs (psychotherapy= 1) 9,094.51 3,896.60 2,069.05 32,322.85 
Predicted inpatient costs (psychotherapy= 0) 3,851.38 1,650.14   876.21 13,688.19 
Incremental effect of psychotherapy on inpatient 
costs 
5,243.14 2,246.45 1,192.84 18,634.66 
SD: Standard Deviation 
† All costs are presented in 2003 dollars 
 
 Table 4.11 shows the unconditional predicted inpatient treatment costs.  After 
combining the two parts of the model, the average inpatient treatment costs were calculated 
as $956.75 (95% CI= $834.95-$1,114.79) for the study samples.  The estimated inpatient 
costs for patients with psychotherapy were $2,004.25 (95% CI= $1,529.33-$2,673.67), and 
the expected inpatient costs for patients without psychotherapy were $714.11 (95% CI= 
$607.92-$821.38).  Finally, the use of psychotherapy was associated with a $1,290.13 
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increase in inpatient treatment costs, which was significantly different from zero (95% CI= 
$803.35-$1,927.39). 
 
Table 4.11. Predicted Inpatient Treatment Costs
†
 (Unconditional, $) 
   Mean   Bootstrap 95% CI  
 Predicted inpatient costs for all patients    956.75    834.95 1,114.79 
 Predicted inpatient costs (psychotherapy= 1)  2,004.25 1,529.33 2,673.67 
 Predicted inpatient costs (psychotherapy= 0)    714.11    607.92    821.38 
 Incremental effect of psychotherapy on inpatient costs  1,290.13    803.35 1,927.39 
CI: Confidence Interval 
† All costs are presented in 2003 dollars 
 
 Finally, Table 4.12 shows the regression outputs from the two-part inpatient cost 
model.  Because there were two patients who had been admitted but with zero inpatient costs, 
the odd ratios estimated in the first-part model here were slightly different from the odds 
ratios in the first-part hospitalization model.  Based on the second-part model, the use of 
psychotherapy was associated with a 136% [exp(0.86)= 2.36] increase in inpatient costs 
among patient who had been admitted.  The inpatient costs for black patients were 1.58 
[exp(0.46)= 1.58] times the inpatient costs of white patients, and the inpatient costs for 
patients with other races were 1.46 [exp(0.38)= 1.46] times the costs of white patients.  The 
inpatients costs for patients in Kansas were 1.46 [exp(0.38)= 1.46] times the costs for 
patients in Illinois , and the inpatient costs in North Carolina were 0.69 [exp(-0.38)= 0.69] 
times the costs in Illinois.  Having other psychoses increased the inpatient costs by a factor of 
1.42 [exp(0.35)= 1.42], while being adherent to the regimens decreased the inpatient costs by 
a factor of 0.72 [exp(-0.33)= 0.72].  Patients who had modified their treatments had 27% 
higher inpatient costs than patients who had not modified their treatments [exp(0.24)= 1.27]. 
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Table 4.12. Results from the Two-Part Model- Inpatient Treatment Costs 
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
 
Part 1: Logistic Regression Part 2: GLM Model‡ 
  OR 95% CI β Robust SE 
Psychotherapy Use 1.27* (1.01-1.59)     0.86** 0.12 
Age Group 
   
 18-35 Reference - Reference - 
36-50  0.64** (0.53-0.79) -0.05 0.11 
>50    0.41** (0.31-0.56) -0.27 0.16 
Gender 
   
 Male Reference - Reference - 
Female 1.18 (0.97-1.42) 0.13 0.10 
Race 
   
 White Reference - Reference - 
Black 1.01 (0.82-1.24)     0.46** 0.11 
Other 1.10 (0.76-1.59)   0.38* 0.18 
State 
   
 IL Reference - Reference - 
KS     0.47** (0.31-0.73)     -0.41 0.21 
MN   0.69* (0.49-0.98)   0.38* 0.18 
NC   0.75* (0.60-0.92)    -0.38** 0.11 
MSA 
   
 Yes Reference - Reference - 
No 0.94 (0.74-1.18) -0.21 0.13 
Charlson Score 1.10 (0.96-1.26) -0.03 0.08 
Mental Comorbidities 
   
 Depression     1.64** (1.26-2.12) -0.10 0.12 
Substance Abuse 1.26 (0.92-1.73) -0.11 0.16 
Anxiety 1.16 (0.78-1.74) -0.35 0.19 
Other Psychoses   1.43* (1.06-1.92)   0.35* 0.17 
Initial Treatment  
   
 Atypical Reference - Reference - 
Typical   0.68* (0.50-0.92) -0.15 0.20 
Adherence 
   
      Yes      0.71** (0.57-0.89)     -0.33** 0.11 
     No Reference - Reference - 
Treatment Modification†     3.45** (2.85-4.18)   0.24* 0.10 
Constant N/A -      8.14** 0.15 
OR: Odds Ratio; SE: Standard Error; IL: Illinois, KS: Kansas, MN: Minnesota, NC: North Carolina;  
MSA: Metorpolitan Statistical Area; PDC: Proportion of Days Covered; N/A: Not Applicable   
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† Treatment modification was defined as having either switched antipsychotics within a  
30-day window or augmented treatment at anytime during the follow-up period     
‡ Generalized Linear Model with a log link function and gamma distribution  
*p<0.05         
**p<0.01         
 
 
4.3.3 Treatment Costs – Outpatient Costs 
 The predicted costs for mental-health related outpatient services are presented in 
Table 4.13 below.  The mean predicted outpatient costs were $4,301.83 (SD= $2,479.07).  
The expected population-level outpatient costs for psychotherapy users were $5,562.95 (SD= 
$2,851.42), and the population-level outpatient costs for non-psychotherapy users were 
estimated as $4,022.85 (SD= $2,219.49).  By subtracting the two numbers, we found that the 
incremental outpatient costs for psychotherapy use were $1,540.10 (SD= $633.40).  
 
Table 4.13. Predicted Outpatient Treatment Costs
†
 ($) 
  Mean SD Min Max 
Predicted outpatient costs for all patients 4,301.83 2,479.07 848.92 21,663.16 
Predicted outpatient costs (psychotherapy= 1) 5,562.95 2,851.42 1,325.41 27,484.68 
Predicted outpatient costs (psychotherapy= 0) 4,022.85 2,219.49 848.92 21,663.16 
Incremental effect of psychotherapy on 
outpatient costs 
1,540.10 633.40 476.49 5,821.52 
SD: Standard Deviation 
† All costs are presented in 2003 dollars 
 
 
 Outputs from the outpatient cost model are presented in Table 4.14.  The outpatient 
costs for patients with psychotherapy were 1.43 [exp(0.36)= 1.43] times the outpatient costs 
for non-psychotherapy users.  The outpatient costs for patients living in Kansas were 1.99 
[exp(0.69)= 1.99] times the outpatient costs for patients living in Illinois, while the outpatient 
costs for patients in North Carolina were 0.77 [exp(-0.26)= 0.77] times the outpatient costs 
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for patients in Illinois.  Interestingly, patients with comorbid anxiety had 30% [exp(-0.35)= 
0.70] lower outpatient costs than patients without comorbid anxiety, but patients with other 
comorbid psychoses had  35% [exp(0.30)= 1.35] higher outpatient costs than patients without 
other comorbid psychoses.  Compared to patients who had begun with atypical 
antipsychotics, patients beginning with typical antipsychotics had 95% [exp(0.67)= 1.95] 
higher outpatient costs.  The outpatient costs for patient who were adherent to their 
treatments were 1.87 times the outpatient costs for patients who were not adherent.  Finally, 
the outpatient costs for patients who had modified their regimens were 1.57 [exp(0.45)= 
1.57] times the outpatients costs for patients who did not modify their regimens. 
  
Table 4.14. Results from the GLM Model
‡
- Outpatient Costs 
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
  β Robust SE 
Psychotherapy Use   0.36* 0.13 
Age Group 
  18-35 Reference - 
36-50 -0.14 0.09 
>50 -0.20 0.12 
Gender 
  Male Reference - 
Female -0.02 0.08 
Race 
  White Reference - 
Black 0.11 0.09 
Other         -0.22 0.14 
State 
  IL Reference - 
KS     0.69** 0.14 
MN 0.17 0.12 
NC -0.26* 0.09 
MSA 
  Yes Reference - 
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No 0.15 0.08 
Charlson Score         -0.01 0.06 
Mental Comorbidities 
  Depression 0.07 0.10 
Substance Abuse 0.05 0.13 
Anxiety  -0.35* 0.15 
Other Psychoses   0.30* 0.12 
Initial Treatment  
  Atypical Reference - 
Typical     0.67** 0.12 
Adherence 
       Yes     0.63** 0.09 
     No Reference - 
Treatment Modification†     0.45** 0.08 
Constant     4.80** 0.13 
SE: Standard Error; IL: Illinois, KS: Kansas, MN: Minnesota, NC: North Carolina;  
MSA: Metorpolitan Statistical Area; PDC: Proportion of Days Covered 
† Treatment modification was defined as having either switched antipsychotics within a  
30-day window or augmented treatment at anytime during the follow-up period 
‡ Generalized Linear Model with a log link function and gamma distribution 
*p<0.05         
**p<0.01 
 
 
4.3.4 Treatment Costs – Antipsychotic Costs 
Table 4.15 below summarizes the predicted costs for antipsychotics.  The average 
predicted antipsychotic costs were $2,861.89 (SD= $2,454.39).  The predicted antipsychotic 
costs for psychotherapy users at the population level were $3,166.64 (SD= $2,630.32), and 
the predicted antipsychotic costs for non-users at the population level were $2,788.41 (SD= 
$2,380.67).  The expected incremental antipsychotic costs for psychotherapy use were 
calculated as $378.23 with a standard deviation of $250.28. 
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Table 4.15. Predicted Antipsychotic Drug Costs
†
 ($) 
  Mean SD Min Max 
Predicted antipsychotic costs for all patients 2,861.89 2,454.39 350.08 12,838.91 
Predicted antipsychotic costs  
(with psychotherapy) 3,166.64 2,630.32 427.79 12,838.91 
Predicted antipsychotic costs  
(without psychotherapy) 2,788.41 2,380.67 350.08 11,611.01 
Incremental effect of psychotherapy on 
antipsychotic costs 378.23 250.28 77.71 1,227.90 
SD: Standard Deviation 
† All costs are presented in 2003 dollars 
 
 Table 4.16 shows the results of Medicaid payments for antipsychotics.  According to 
the results from the GLM model, antipsychotic costs for psychotherapy users were 1.14 
[exp(0.13)= 1.14] times the costs for non-users.  Compared to patients aged between 18 and 
35 years old, the costs of antipsychotics were 15% [exp(-0.16)= 0.85] lower for patients aged 
between 36 and 50 years old and 27% [exp(-0.31)= 0.73] lower for patients aged 51 and 
older.  The costs for female were 14% [exp(-0.15)= 0.86] less than the costs for males.  Black 
patients and patients with other races had 12% [exp(-0.13)= 0.88] and 17% [exp(-0.19)= 0.83] 
lower antipsychotic costs than white patients.  Patients living in North Carolina had 10% 
[exp(-0.10)= 0.90] lower antipsychotic costs than patients living in Illinois.  Patients who 
initiated with typical psychotherapy had 46% [exp(-0.62)= 0.54] lower antipsychotic costs 
than patients starting with atypical antipsychotics.  Being adherent increased the 
antipsychotic costs by a factor of 3.10 [exp(1.13)= 3.10], and treatment modification 
increased the costs by a factor of 2.03 [exp(0.71)= 2.03]. 
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Table 4.16. Results from the GLM Model
‡
- Antispsychotic Costs 
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
  β Robust SE 
Psychotherapy Use   0.13* 0.05 
Age Group 
  18-35 Reference - 
36-50   -0.16** 0.05 
>50   -0.31** 0.06 
Gender 
  Male Reference - 
Female     -0.15** 0.04 
Race 
  White Reference - 
Black     -0.13** 0.04 
Other  -0.19* 0.07 
State 
  IL Reference - 
KS 0.10 0.07 
MN 0.10 0.06 
NC  -0.10* 0.05 
MSA 
  Yes Reference - 
No 0.03 0.05 
Charlson Score 0.06 0.03 
Mental Comorbidities 
  Depression         -0.01 0.05 
Substance Abuse         -0.08 0.07 
Anxiety         -0.08 0.13 
Other Psychoses 0.02 0.06 
Initial Treatment  
  Atypical Reference - 
Typical     -0.62** 0.06 
Adherence 
       Yes     1.13** 0.04 
     No Reference - 
Treatment Modification†     0.71** 0.04 
Constant     4.53** 0.06 
SE: Standard Error; IL: Illinois, KS: Kansas, MN: Minnesota, NC: North Carolina;  
MSA: Metorpolitan Statistical Area; PDC: Proportion of Days Covered 
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† Treatment modification was defined as having either switched antipsychotics within a  
30-day window or augmented treatment at anytime during the follow-up period 
‡ Generalized Linear Model with a power link function and gamma distribution 
*p<0.05         
**p<0.01 
 
 
4.3.5 Treatment Costs – Total Costs 
 The predicted total treatment costs were presented in Table 4.17.  The average 
predicted total treatment costs over the follow-up period were $8,049.17 (SD= $4,726.79).  
The expected total costs at the population level were $10,303.54 (SD= $5,395.86) for 
psychotherapy users and $7,534.33 (SD= $4,225.91) for non-users.  The incremental total 
costs for psychotherapy users were estimated as $2,769.21 (SD= $1,171.82).  Table 4.18 
summarizes the incremental costs for different types of services.   
 
Table 4.17. Predicted Total Treatment Costs
†
 ($) 
  Mean SD Min Max 
Predicted total costs for all patients 8,049.17 4,726.79 2,085.33 37,436.99 
Predicted total costs (psychotherapy= 1) 10,303.54 5,395.86 3,139.39 37,436.99 
Predicted total costs (psychotherapy= 0) 7,534.33 4,225.91 2,085.33 29,296.59 
Incremental effect of psychotherapy on 
total costs 
2,769.21 1,171.82 1,054.06 8,140.40 
SD: Standard Deviation 
† All costs are presented in 2003 dollars 
 
Table 4.18. Summary of the Predicted Incremental Costs for Different Types of 
Services
†
 ($) 
  Mean SD 
Incremental Costs- Inpatient Costs 1,290.13 284.78‡ 
Incremental Costs- Outpatient Costs 1,540.10     633.40 
Incremental Costs- Antipsychotic Costs    378.23     250.28 
Incremental Costs- Total Costs 2,769.21 1,171.82 
SD: Standard Deviation 
 118 
 
† All costs are presented in 2003 dollars 
‡ Bootstrap standard error 
 
 
 Finally, the regression outputs for total treatment costs (sum of inpatient, outpatient, 
and antipsychotic costs) are shown in Table 4.19.  The use of psychotherapy was associated 
with an increase in total treatment costs by a factor of 1.48 [exp(0.39)= 1.48].  Compared to 
patients who were 18 to 35 years old, the total treatment costs were 18% [exp(-0.20)= 0.82] 
lower for patients aged between 36 and 50 and 30% [exp(-0.36)= 0.70] lower for patients 
over 50.  Compared to patients in Illinois, the total costs were 46% [exp(0.38)= 1.46] higher 
for patients in Kansas and 29% [exp(-0.34)= 0.71] lower for patients in North Carolina.  
Having other comorbid psychoses was associated with a 1.35 [exp(0.30)= 1.35] times 
increase in total costs.  The total costs for patients having typical antipsychotics as their 
initial treatment were 1.30 [exp(0.26)= 1.30] times the total costs for patients having atypical 
antipsychotics as their initial treatment.  Being adherent to antipsychotic treatments was 
associated with an increase in total costs by a factor of 2.27 [exp(0.82)= 2.27], and having 
modified the treatment during the follow-up was associated with an increase in total costs by 
a factor of 2.05 [exp(0.72)= 2.05]. 
 
Table 4.19. Results from the GLM Model
‡
- Total Treatment Costs 
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
  β Robust SE 
Psychotherapy Use    0.39** 0.10 
Age Group 
  18-35 Reference - 
36-50 -0.20* 0.07 
>50   -0.36** 0.09 
Gender 
  Male Reference - 
Female 0.05 0.06 
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Race 
  White Reference - 
Black 0.04 0.07 
Other     -0.19 0.11 
State 
  IL Reference - 
KS     0.38** 0.13 
MN 0.12 0.10 
NC    -0.34** 0.07 
MSA 
  Yes Reference - 
No 0.08 0.07 
Charlson Score 0.02 0.05 
Mental Comorbidities 
  Depression 0.11 0.08 
Substance Abuse 0.01 0.10 
Anxiety          -0.22 0.17 
Other Psychoses      0.30** 0.10 
Initial Treatment  
  Atypical Reference - 
Typical    0.26* 0.11 
Adherence 
       Yes     0.82** 0.06 
     No Reference - 
Treatment Modification†    0.72** 0.06 
Constant    5.58** 0.10 
SE: Standard Error; IL: Illinois, KS: Kansas, MN: Minnesota, NC: North Carolina;  
MSA: Metorpolitan Statistical Area; PDC: Proportion of Days Covered 
† Treatment modification was defined as having either switched antipsychotics within a  
30-day window or augmented treatment at anytime during the follow-up period 
‡ Generalized Linear Model with a power link function and gamma distribution 
*p<0.05         
**p<0.01 
 
 
4.4 Results from Instrumental Variable Estimations  
 Around 4% of the final sample did not have enough information to construct an 
instrumental variable and therefore was excluded in the IV analyses (psychotherapy use for 
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MDD patients: 137 missing; psychotherapy use for the previous patient: 133 missing).  When 
test the two IVs separately in the first-stage logistic regression, the results indicated that both 
of our IVs were strongly associated with psychotherapy use (psychotherapy use for MDD 
patients, z= 7.69, p< 0.001; chi-square = 59.15, p< 0.001; psychotherapy use for the previous 
patient z= 14.84, p< 0.001; chi- square= 220.24, p< 0.001).  When both IVs were included in 
the first-stage regression model, both of our IVs were still significantly associated with 
psychotherapy use although the strength of psychotherapy use for MDD patients became 
weaker (z= 2.44, p< 0.015 for psychotherapy use for MDD patients; z= 12.29, p< 0.001 for 
psychotherapy use for the previous patient).  The Wald test result showed that the two IVs 
were jointly significant in the first-stage model (chi-square= 218.96, p<0.001).  Since both 
IVs seemed to be strongly associated with the use of psychotherapy, the IV selection was 
then mainly based on the exclusion restriction criterion.  Table 4.20 summarizes the IV 
selection for each dependent variable based on the results of Hausman tests, and the 
specification tests results are shown in Appendix 5. 
 
Table 4.20. IV Selection for Each Dependent Variable 
 Psychotherapy use 
for MDD patients 
Psychotherapy use for 
the previous patient 
Medication discontinuation  X 
Medication Switching X X 
Hospitalizations   
part 1 model  X 
part 2 model  X 
Inpatient costs    
part 1 model  X 
part 2 model X X 
Outpatient costs  X 
Prescription drug costs X X 
Total costs  X 
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Notice that except for four dependent variables: medication switching, the second part 
of the hospitalizations, the second part of the inpatient costs, and total treatment costs, at least 
one IV can be considered as valid instrument for all other dependent variables using 
Hausman tests.  Because of negative chi-squared statistics, whether the two IVs meet the 
exclusion restriction from Hausman tests was unable to be determined for these four outcome 
models.  The decision of including both IVs in these two models was instead based on the 
results from Chow tests as well as the LR test which indicated that both IVs should be validly 
excluded from the second-stage model.  While for the second-part hospitalization model and 
total cost model, we only included the use of psychotherapy for the previous patient in the 
model because the LR tests reject the null that both IVs were validly excluded from the 
second-stage of the IV model.  Since the first-stage test showed that the use of psychotherapy 
for the previous patient was a stronger IV than psychotherapy use for MDD patients, only the 
use of psychotherapy for the previous patient was used as an IV in the second-stage model.   
 Finally, because the Hausman test for the endogeneity of psychotherapy did not 
provide valid test results for all of the outcome models, using a formal test to check whether 
psychotherapy was endogeneous was not feasible.  Therefore, the use of adjunctive 
psychotherapy was assumed to be endogeneous with respect to all of the outcomes, and IV 
estimates were constructed for all the outcome models.  The results from the naïve regression 
models and IV models are summarized in Table 4.21. 
 
 
 
 
 
 
 122 
 
Table 4.21. Point Estimates and Confidence Intervals of Adjunctive Psychotherapy Use 
 Original Model IV model 
 β 95% CI β Bootstrap 95% CI 
Medication discontinuation† -0.59* (-1.02, -0.17)  -0.53* (-0.97, -0.07) 
Medication switching†  0.45* (0.25, 0.66)   0.48* (0.20, 0.69) 
Hospitalizations     
part 1 model  0.26* (0.03, 0.48) 0.23 (-0.07, 0.49) 
part 2 model      0.30 (-0.56, 0.66) 0.13 (-0.55, 0.44) 
Inpatient costs      
part 1 model  0.24* (0.01, 0.47) 0.23 (-0.08, 0.49) 
part 2 model  0.86* (0.62, 1.09)   0.72* (0.28, 0.96) 
Outpatient costs  0.36* (0.10, 0.62)   0.42* (0.14, 0.73) 
Antipsychotic costs  0.13* (0.04, 0.23)   0.37* (0.06, 0.68) 
Total costs  0.39* (0.19, 0.59)   0.42* (0.14, 0.73) 
CI: Confidence Interval 
† Both medication persistency and medication switching were measured using a 30-day gap/window definition 
* Significant at α= 0.05 level  
 
 
 In Table 4.21, we can see that the point estimates of psychotherapy use do not change 
much after applying the IV technique.  The effect of psychotherapy on most outcome 
variables increased in the IV models compared to the estimates in the naïve models with the 
exception of coefficients in the discontinuation, hospitalization, and inpatient cost models.  
Use of adjunctive psychotherapy significantly decreased the likelihood of discontinuation at 
the beginning of the follow-up.  Unlike the results from the naïve regressions, psychotherapy 
use did not significantly increase the likelihood of hospitalization.  However, according to 
the second-stage IV inpatient cost model, among patients who had been admitted, the use of 
psychotherapy led to an 2.05 [exp(0.72)= 2.05] times increase in inpatient costs.  After 
combining both parts of the inpatient cost models and calculating the unconditional 
incremental costs, we found patients with psychotherapy still had significantly higher 
inpatient costs (mean incremental cost= $1,045.43, 95% CI= $513.63-$1,652.30) although 
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this result was slightly lower than the result from the original model without IVs (mean = 
$1,390.13, 95% CI= $803.35-$1,927.39).   
   Similar to the naïve estimates, results from the IV model indicated that the use of 
adjunctive psychotherapy increased outpatient costs by 52% [exp(0.42)= 1.52].  After 
accounting for the potential endogeneity, the IV estimates showed that psychotherapy use 
caused a 45% [exp(0.37)= 1.45] increase in antipsychotic costs compared to a 14% 
[exp(0.13)= 1.14] increase from  the naïve estimate.  Finally, the IV estimate suggested that 
psychotherapy increased the total treatment costs by a factor of 1.52 [exp(0.42)= 1.52] which 
was slightly higher than the naïve estimate [exp(0.39)= 1.48].   
 When comparing the IV estimates to the naïve estimates, it is important to know that 
IV provides the local average treatment effect (LATE), which estimates the effect of 
psychotherapy on marginal patients (i.e. patients can be treated either with or without 
psychotherapy), while the naïve model estimates average treatment effect as the difference 
between the average treatment effect as treated and the average treatment effect as non-
treated, which compares the effect of psychotherapy between those who received it versus 
who did not.
145-147
  Therefore, the differences between IV estimates and naïve estimates may 
be caused by different populations being used for the estimations, and both estimates could 
be accurate.  On the other side, since 1) the naïve models could suffer from un-measurable 
confounding (as discussed in section 3.5), and 2) our IVs could still be correlated with the 
outcomes through unobservable routes (as discussed in section 3.6.3) and thus bias the IV 
results, it is possible that both our naïve estimates and IV estimates are biased.   
 Finally, except for the second-part of the hospitalization model, outpatient costs, and 
total treatment costs, most of our results failed to reject the null hypothesis that the use of 
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psychotherapy was exogeneous.  This indicates that the use of psychotherapy may not be 
endogeneous with respect to most of our outcomes.  However, as discussed before, the 
exogeneity test is inconclusive.   We may fail to reject the null because of weak or invalid 
instruments.  Given the high variance in the second-stage model, we often fail to reject the 
null because of low power.  Even if the null hypothesis is rejected, it can be caused by 
measurement errors or incorrect functional form.  As a result, failing to reject the null does 
not conclude the exogeneity of psychotherapy use.  We should treat these test results as 
references, and keep in mind that the use of psychotherapy can still be endogeneous.  
 
4.5 Summary   
 In summary, only a few patients (17%) received psychotherapy during the 18-month 
follow-up period, and most patients had a relatively short treatment duration for 
psychotherapy (mean psychotherapy visits= 5.4 and mean treatment duration= 160 days).  
Our naïve estimates showed that the use of adjunctive psychotherapy was associated with 
better antipsychotic persistency at the beginning of the follow-up.  However, this protective 
effect diminished within the first two months of follow-up, and patients with psychotherapy 
became less persistent than patients without psychotherapy after the first two months.  
Patients with adjunctive psychotherapy were also found to be more likely to switch their 
antipsychotics and had higher treatment costs.  However, we found the use of adjunctive 
psychotherapy was associated with a small but significant increase in hospitalizations.    
 Consistent with our naïve estimates, the IV estimates showed that patients receiving 
psychotherapy had significantly better persistency at the beginning of the follow-up.  Patients 
with psychotherapy were still found to be more likely to switch medications, and they had 
 125 
 
higher outpatient, pharmacy, and total treatment costs compared to patients without 
psychotherapy.  In contrast, results from IV models did not show that the use of adjunctive 
psychotherapy leads to a higher risk of hospitalization.  If our IVs are strong and truly valid, 
we can conclude that the use of adjunctive psychotherapy increase patients’ persistency and 
treatment costs, but it does not significantly increase the risk of hospitalization.  
 CHAPTER 5: DISCUSSION 
 
 To the author’s knowledge, this is the first study looking at the effectiveness of 
adjunctive psychotherapy among patients with schizophrenia among Medicaid populations.  
The results showed that only 17% of patients received adjunctive psychotherapy during the 
18-month follow-up period, and individual therapy was the most common type of 
psychotherapy.  Compared to patients receiving pharmacotherapy alone, patients with 
adjunctive psychotherapy had better medication persistency in the first two months of the 
follow-up, but they became less persistent after the first two months.  Patients with 
adjunctive psychotherapy were also found to have a higher number of hospitalizations and 
treatment costs than patients without psychotherapy.  However, the IV results indicated that 
the use of psychotherapy did not lead to a higher risk of hospitalization nor higher inpatient 
treatment costs.  The following sections discuss the results in detail by each aim.  
 
5.1 Discussion of results by Aims 
5.1.1 Aim 1: Patterns and predictors of adjunctive psychotherapy use 
 The 18-month prevalence of adjunctive psychotherapy use was estimated to be 17% 
in this study, which is similar to  the six-month prevalence (16%) calculated from Olfson and 
colleagues’ previous work.47  Although the follow-up period is longer in our study, given that 
most patients initiated their psychotherapy in the first six months of the follow-up period, we
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should capture most psychotherapy users in the first six months of the follow-up.  Therefore, 
the prevalence estimated in this study is consistent with the prevalence estimated in Olfson et 
al.’s study which was also conducted among Medicaid populations.47 
 Interestingly, the estimated 18-month prevalence in this study is comparable to the 
prevalence estimated in a previous study using National Ambulatory Medical Care Survey 
(NAMCS),
58
 but it is much lower than the prevalence estimated in another study using 
Medical Expenditure Panel Survey (MEPS).
59
    The prevalence of psychotherapy use among 
patients with schizophrenia in the study using NAMCS was 14.3% in 2004-2005, and the 
prevalence of psychotherapy use for schizophrenia patients was estimated as 74.4% in 2007 
in the study using MEPS.  Both studies used a questionnaire which asked whether a patient 
was provided psychotherapy or counseling during a visit (defined as verbal interactions 
between patients and providers), and the broad definition of psychotherapy can include 
services that are not reimbursed by the third party.  With a broad definition of psychotherapy, 
the low prevalence estimated in the study using NAMCS may indicate that psychotherapy is 
under-utilized in patients with schizophrenia.   
 On the other hand, the high prevalence estimated in the study using MEPS may show 
that most patients with schizophrenia received certain types of psychosocial treatment or 
counseling during their visits, which may not be captured in the claims.  However, the higher 
prevalence estimated in the study using MEPS may also due to an even broader definition of 
psychotherapy, and the fact that the study population includes both schizophrenia as well as 
other related disorders.  Finally, because NAMCS surveyed physicians, they may provide 
more accurate responses about psychotherapy use since physicians should better understand 
the definition of psychotherapy.  Since MEPS surveyed patients, they may potentially 
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misclassify medication education or counseling as psychotherapy.  Moreover, because MEPS 
only surveyed one adult per household, the person being surveyed may misrepresent the 
satiation of health service utilization for other family members.  Both situations could lead to 
an overestimation of psychotherapy use.      
 In addition, using NAMCS, Mojtabai et al. also found a higher percentage of patients 
covered under Medicaid or managed care did not receive psychotherapy during a visit, while 
a higher percentage of patients who paid themselves for psychotherapy during a visit 
received psychotherapy.
58
  Our study may underestimate the prevalence of psychotherapy use 
since we are unable to capture the psychotherapy visits that were paid by patients’ out-of-
pocket costs.  However, given that our study samples are all Medicaid beneficiaries, it is less 
likely that patients paid on their own for psychotherapy.   
In the previous study, fewer patients had a visit that involved psychotherapy if there 
were medications prescribed on that visit.
58
  Since our study population consists of Medicaid 
patients with antipsychotic treatment, the prevalence of psychotherapy use in our study may 
be lower than the general schizophrenia population.  The lower psychotherapy visits rate 
among patients under Medicaid can be the result of financial considerations as well as the 
shift towards managed care.
58-60
  Although antipsychotic agents were not specified as the 
medication prescribed during the visit in Mojtabai et al.’s study,58 for patients with 
schizophrenia, it is likely that antipsychotics were prescribed in a visit.  Since the 
effectiveness of psychotherapy remains unclear, patients and/or physicians may prefer 
pharmacotherapy over psychotherapy, which explains the lower rate of psychotherapy use 
among patients receiving medication treatment.
58
  Finally, the low rate of psychotherapy use 
may come from the fact that most  treatment for schizophrenia patients focus on clinical and 
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functional improvement, with little attention being paid to patients’ humanistic needs (e.g. 
friendship and self-confidence).
38
   
 Similar to the findings in two previous studies,
46, 58
 our descriptive statistics show that 
adjunctive psychotherapy users tend to be younger, White, and have comorbid depression, 
anxiety, or other psychoses.  The descriptive results also show that patients receiving 
psychotherapy are more likely to come from rural areas and have atypical antipsychotics as 
their initial treatment.  However, in the adjusted model, only comorbid depression was 
significantly associated with psychotherapy use, and rural/urban residency and type of initial 
treatment became insignificant.   
 The finding that younger patients are more likely to receive psychotherapy might be 
due to the fact that the onset of schizophrenia usually occurs between ages of 16 and 30.
2, 6, 7
    
Patients who are diagnosed with schizophrenia at an elderly age may have different 
characteristics than younger patients and therefore have different treatment needs, which 
decreases the use of psychotherapy for older patients.  In addition, because we used a three-
month washout period to screen new users, some of our patients may not be true new users 
and have a history of medication use prior to the three-month window.  This ―pseudo new 
user‖ phenomenon may be more likely to occur among older patients.  If older patients in this 
study are actually prevalent users rather than new users, they are more likely to be stabilized 
with their treatments, and therefore, may not need additional psychosocial treatments.  We 
may not find this difference if we had a longer wash-out period to identify true new users 
among the elder patients.   
 The fact that non-white populations are less likely to receive psychotherapy than 
White populations may indicate that these populations are under served, especially the Black 
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population.  Although we are unable to assess the severity of schizophrenia, our results show 
that patients with additional mental health conditions are more likely to receive 
psychotherapy, which may indicate that patients with worse mental-health status are more 
likely to receive psychotherapy.  Similar to the previous finding,
46
  we found high 
percentages of atypical antipsychotic use in both groups. Since atypical antipsychotics are 
recommended as the first line treatment choice, the high proportion of antipsychotic use is 
concordant with guidelines.
16-21
   
 Regarding the type of psychotherapy used, consistent with Dixson et al.’s study,46 
individual therapy was found to be the most prevalent type of adjunctive psychotherapy used, 
followed by group therapy; family therapy was the least prevalent type of psychotherapy 
among the three.  This finding suggests that family therapy may be underutilized since more 
evidence supports the efficacy of family therapy over the other two types of psychotherapy.
45, 
73
  In addition, family therapy has been recommended by most guidelines as an adjunctive 
psychosocial treatment, especially for the acute phase.
17-20
  With a cohort of schizophrenia 
patients who are newly treated with antipsychotic treatments, the prevalence of family 
therapy is lower than we expected.   
 When looking at the time of psychotherapy initiation over a three-month interval, we 
found that most patients initiated their psychotherapy during the first three to six months after 
their antipsychotic initiation, and that the rate of psychotherapy initiation declined over time.  
Since the first three to six months of antipsychotic initiation may be the acute phase of 
schizophrenia, it is reasonable that more patients initiate their adjunctive psychosocial 
treatment during their early acute phase rather than the later maintenance phase.  However, 
even in the first three months of the follow-up, the initiation rate for all types of 
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psychotherapy was still below 40%.  As discussed previously, psychotherapy, especially 
family therapy, is recommended to be used during the acute phase to improve patients and 
their families’ understanding of disease and treatments.17-20   Even in the stabilizing or 
maintenance phase, other types of cognitive or behavioral treatments (e.g. individual 
psychotherapy) are still recommended.
16, 18, 20
  Therefore, our findings reveal that most 
schizophrenia patients do not receive adequate psychotherapy, which could affect their 
physical and functional recovery. 
 
5.1.2 Aim 2: The effect of adjunctive psychotherapy use on medication persistency and 
switching 
5.1.2.1  Medication Persistency 
 Results from the survival analyses showed that patients receiving psychotherapy were 
less likely to discontinue their medication treatment initially.  This protective effect, however, 
diminished during the first two months of the follow-up, and patients with psychotherapy 
became more likely to discontinue their treatment after the first two months of the follow-up.  
Given the average number of psychotherapy visits in this study is 5.4, if we assume patients 
have an average of one visit per week, their psychotherapy is likely to be ended around the 
fifth or sixth week following their initial psychosocial treatment.  Additionally, we found that 
around 40% of patients received their first psychotherapy treatment session within the first 
three months of pharmacotherapy initiation, and most patients had all of their psychotherapy 
visits within the first 40 days in Aim 1.  The finding in Aim 2 that psychotherapy users were 
more persistent in the first 60 days of the follow-up may reflect the effect of psychotherapy 
when patients are regularly receiving psychosocial treatments.   
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 After the first two months, patients may complete their five or six psychosocial 
treatment sessions and no longer have psychotherapy.  Since patients receiving 
psychotherapy often have worse mental health conditions (as shown in the descriptive 
statistic results), they could be less adherent to their regimens than their non-psychotherapy 
receiving counterparts.  This may explain the increased hazard of medication discontinuation 
for the psychotherapy group after the first two months of the follow-up.  Therefore, our result 
from the survival analysis may indicate that 1) psychotherapy is effective when continuously 
used, and 2) once patients stop psychotherapy, the effect of psychotherapy lasts only for a 
short period of time.   
The result that patients with psychotherapy had better adherence in the first two 
months may be also explained by other services provided to the patients that could not be 
captured in the claims data.  As discussed in section 5.1.1, a previous study using MEPS 
found a high proportion of patients had mental-health related psychotherapy or counseling 
services during an outpatient visit in 2007.
59
  Since the definition of psychotherapy in this 
previous study was ―a treatment technique for certain forms of mental disorders relying 
principally on talk/conversation between the mental health professional and the patient‖, 
many of these services can be an informal treatment and thus do not show up in the claims.  
Given that the patients in our study are new antipsychotic users, they may receive more 
psychosocial interventions or counseling services that cannot be identified in the claims at 
the beginning of their antipsychotic treatment, which also explains the better persistency in 
the first three months of the follow-up.   
 In addition, the short effect of psychotherapy on medication persistency may simply 
be due to the underuse of psychotherapy since the effect of psychotherapy usually appears 
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after patients received a minimum number of treatments.
57, 148
  For example, it is suggested 
that patients need to attend at least ten treatment sessions for psychotherapy in order for 
psychotherapy to be effective.
57, 148
  It is reported that only attending one session of treatment 
may worsen medication adherence.
38
  Therefore, the patients in our study may not receive 
enough treatment sessions to make a clinically significant improvement.   
 Another potential explanation of the lack of effectiveness of psychotherapy after the 
first two months is that since more than 70% of the first-episode patients will achieve a full 
remission in the first three to four months,
17, 18
 psychotherapy initiated after the first three 
months may have different focus from medication use and therefore has limited effect on 
medication persistency. 
In addition to the effectiveness of psychotherapy use, we found that non-white 
patients were more likely to stop taking their medications.  This may be caused by a lack of 
access to health care or by different cultural backgrounds, which lead to different perceptions 
of disease and treatment.  We also found that patients living in North Carolina were more 
likely to discontinue their antipsychotic treatment compared to patients in Illinois, when 
using a gap excess of 30 days to define discontinuation.  However, this effect is not 
significant when using a gap greater than 15 days to define discontinuation.  The slightly 
higher rate of 30-day discontinuation in North Carolina might be due to the monthly 
prescription cap (6 prescriptions per month) as in 2003.    
 Another interesting finding in the Cox model is that patients who had modified their 
antipsychotic treatment were less likely to experience a discontinuation.  This result may 
indicate that patients receiving psychotherapy have more chances to provide feedback on 
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their conditions or treatments to their health care professionals, and therefore, the clinicians 
can better adjust their regimens, which improves persistency. 
 
5.1.2.2  Medication Switching 
 The logistic regression models showed that patients with psychotherapy were more 
likely to switch their antipsychotics using either a 30-day or 15-day window to define 
switching, and this result remained unchanged in the IV model with a 30-day switching 
window.  Because the use of psychotherapy and medication switching were measured during 
the same period of time, the results from the naïve model can only be interpreted as an 
association, not causation.  However, our IV results still indicate the use of psychotherapy 
leads to a higher probability of antipsychotic switching.  Since the use of psychotherapy is 
recommended before and after a change in antipsychotics,
39, 40
 to facilitate switching, 
physicians may be more likely to provide psychotherapy to their patients before changing 
patients’ antipsychotics.  Therefore, our findings may indicate that most patients were 
receiving psychotherapy before antipsychotic switching, rather than indicating that the use of 
psychotherapy increases the risk of medication switching. 
    Similar to the previous discussion in section 5.1.1.1, another potential explanation 
of the higher chance of switching could be that patients with psychotherapy may have more 
chances to interact with health care professionals, which provides them more opportunities to 
discuss the effectiveness of their current medication treatment.  As a result, a physician may 
be more likely to be aware of problems associated with medication treatment for patients 
with psychotherapy and hence switch these patients to another antipsychotic agent.  In this 
case, the use of psychotherapy serves as a channel for patients to reveal their problems with 
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antipsychotic treatment, and the higher chance of medication switching can be viewed as a 
positive outcome.  When we consider medication persistency and switching together, the 
better medication persistency among patients with psychotherapy may be due to the fact that 
patients using psychotherapy were more likely to switch to a suitable antipsychotic agent. 
  
5.1.3 Aim 3: The effect of adjunctive psychotherapy use on hospitalizations and treatment 
costs 
5.1.3.1  Hospitalizations 
 Without an IV, the naïve hurdle model showed that the use of psychotherapy was 
associated with a small but significantly higher chance (3%) of being hospitalized, but it did 
not significantly affect the number of hospitalizations among patients who had been admitted 
at least once.  One possible explanation of this result is unobservable confounding.  For 
example, patients with worse mental-health status may be more likely to receive 
psychotherapy and also have a higher rate of hospitalizations.  On the other hand, patients 
who used psychotherapy may have more chance to interact with their health care providers, 
and the higher frequency of provider-patient interactions may allow the clinicians to better 
detect health problems or identify symptoms early on.  This closer monitoring may also lead 
to a higher rate of hospitalizations.  In this case, however, a higher hospitalization rate may 
be a positive outcome since patients’ problem can be identified early on and receive 
necessary treatment.  
 After applying IVs to adjust for un-measurable confounding, we did not find 
psychotherapy to significantly increase the risk of hospitalization, nor the number of 
admissions.  With the ―natural experiment‖ situation created by IV techniques, the results 
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from IV models should not be biased by un-measurable confounding and therefore can be 
interpreted as causal relationships.  If our IVs are truly valid, we can conclude that 
psychotherapy does not significantly increase the rate of hospitalizations. 
 Another possible explanation of the difference between the naïve estimates and IV 
estimates is that without the IVs, we estimate the effect of psychotherapy on hospitalizations 
for the entire population, while with the IVs, we only estimate the local average treatment 
effect, which gives us the average effect of psychotherapy among marginal patients (i.e. 
patients’ use of psychotherapy is dependent on provider’s preference).145-147   Figure 5.1 
below shows a graphic illustration of the populations used for the naïve and IV estimations.   
 Since patients who will always (or never) be treated with psychotherapy may have 
different characteristics and different severities than patients who can be treated with or 
without psychotherapy (i.e. marginal patients), these non-marginal patients may have 
different patterns of inpatient service utilization.  For example, patients who will always be 
treated with psychotherapy may have worse underlying mental-health status and hence have 
a higher chance to be admitted; while patients who will never be treated with psychotherapy 
may be much healthier and thus have a lower chance of hospitalization.  As a result, the true 
effect of psychotherapy can be biased, or masked, by underlying heterogeneity between the 
psychotherapy users and non-users.  Excluding these extreme patients and only looking at 
marginal patients will help to eliminate this ―treatment selection‖ or confounding by 
indication issue and make the two groups more comparable.  Therefore, the IV results should 
be a better reference for clinicians when determining whether to provide psychotherapy to a 
marginal patient.   
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 Figure 5.1. Populations Used for Naïve versus IV Estimations 
 
 
Interestingly, using typical antipsychotics as the initial treatment was found to be 
associated with a lower chance of hospitalization, which is contrary to the original hypothesis.  
Since typical antipsychotics are often used as the second-line treatment, we expected patients 
receiving typical antipsychotics to have worse symptoms and therefore more likely to be 
hospitalized.  A possible explanation of this finding is that we may have some prevalent 
antipsychotic users in our study sample, as discussed in section 5.1.1.  With only a short 
washout period, patients who had typical antipsychotics as their initial treatment are likely to 
have a history of antipsychotic treatment and get stabilized with their treatment.  If patients 
using typical antipsychotics are more likely to be prevalent users and stabilized in their 
treatment, it is plausible that they are less likely to be hospitalized.   
Even if our sample contains only new users, patients who started with typical 
antipsychotics can have very different characteristics since atypical antipsychotics are 
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recommended as the first line treatment.  Patients initiated with typical antipsychotics may 
have more severe symptoms and may skip their treatments or regular check-ups.  Therefore, 
these patients may be less willing to receive treatment and under-utilize inpatient services, 
which leads to a lower probability of hospitalization.  On the other side, patients with less 
severe symptoms may begin with typical antipsychotics since these agents are often cheaper 
than the atypical agents and can still control for patients’ conditions.  If this is the case, 
patients initiating with typical antipsychotics should have a lower risk of hospitalization 
given the lower severity of their disease.  
 In addition, our results suggest that patients living in Kansas and North Carolina were 
less likely to be hospitalized compared to patients in Illinois, but among those who had been 
admitted, patients in North Carolina seemed to have a lower number of hospitalizations than 
patients in Illinois.  Given the limited information available, we did not find notable 
difference in terms of mental-health related hospitalization services among these states (only 
North Carolina was found to require prior authorization for mental-health related inpatient 
services
149
).   Nevertheless, without specific information about cost sharing or reimbursement 
rate for inpatient services, it is hard to determine whether the lower rate of hospitalization 
was due to different coverage among these states.   
 
5.1.3.2  Treatment Costs – Inpatient Costs 
 Results from the naïve two-part model for inpatient costs showed that the use of 
psychotherapy was associated with a higher likelihood of non-zero inpatient costs as well as 
higher average inpatient costs among those who had been admitted.  As discussed in section 
5.1.3.1, our findings suggested that patients receiving psychotherapy had a higher number of 
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expected hospitalizations.  Not surprisingly, the findings from the inpatient cost model 
correspond with the hospitalization model, given that the higher inpatient treatment costs can 
be viewed as a consequence of the higher hospitalization rate.   
 Unlike the results from the naïve models, results from the IV models did not show 
psychotherapy use increased the likelihood of positive inpatient costs, but psychotherapy use 
still led to significantly higher inpatient costs.  Since patients receiving psychotherapy tend to 
have more comorbid mental conditions and thus may have worse mental-health status at 
baseline, once hospitalized, these patients may require more intensive care which leads to 
higher inpatient costs.   
 
5.1.3.3  Treatment Costs – Outpatient Costs 
 Results from both the original regression and IV regression indicated that the use of 
adjunctive psychotherapy increased outpatient costs.  The average incremental outpatient 
costs was $1,540 for patients receiving psychotherapy in the 18-month period, which was 
around $86 per month.  Since adjunctive psychotherapy is an additional service, it is 
expected that patients using adjunctive psychotherapy had higher outpatient costs.  In 
addition, given that our descriptive results showed that patients using psychotherapy were 
more likely to have other comorbid mental conditions, psychotherapy users may be sicker 
than non-users.  Therefore, other than psychotherapy, these patients may generally have a 
higher utilization rate of the outpatient services, which raises their outpatient costs.   
 Another interesting finding is that patients with comorbid anxiety had significant 
lower outpatient costs compared to patients without comorbid anxiety, which is contrary to a 
general expectation.  This finding may be the results of the modeling given that comorbid 
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anxiety was not found to be significantly associated with outpatient costs when a log link was 
used instead of a power link in the model.  Since there is no clinically plausible explanation 
of the lower costs for patients with comorbid anxiety, the significant finding from the 
original GLM may simply be caused by the particulars of our modeling and is not a true 
effect.   
 
5.1.3.4  Treatment Costs – Antipsychotic Costs 
 The result from the naïve GLM showed that patients with psychotherapy had 14% 
higher antipsychotic costs than patients without psychotherapy, and this effect became even 
larger (a 45% increase in antipsychotic costs) after adjusting for unobservable confounders 
with IVs.  The higher antipsychotic costs caused by psychotherapy use may indicate that the 
use of psychotherapy improves medication adherence and hence increases the medication 
costs.  Given the result in Aim 2 that patients with psychotherapy had better persistency in 
the first two months of their antipsychotic treatment, it is possible that the higher 
antipsychotic costs came from the better adherence among patients receiving psychotherapy. 
The larger effect observed in the IV models may be explained by potential 
confounding by indication (i.e. disease severity).  As described in Figure 5.2 below, without 
adjusting for disease severity, which is an unobservable confounder in our naïve model, our 
results could be biased towards the null.  In contrast, the IV model should adjust for this 
potential confounding, and therefore, the result from our IV analysis should not suffer from 
the downward bias.  This may explain the larger effect we observed in the IV model than the 
original model.  Lastly, we found that psychotherapy users were more likely to switch 
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medications in Aim 2.  The higher costs of antipsychotics may also be attributable to the 
higher rate of antipsychotic switching or treatment modifications in the psychotherapy users.       
 
Figure 5.2. Confounding by Disease Severity 
 
 
5.1.3.5  Treatment Costs – Total Costs 
 Unlike previous studies,
105, 106
 this study did not find the use of psychotherapy to 
decrease total treatment costs.  Instead, both our naïve and IV models showed that patients 
with psychotherapy had higher total treatment costs compared to patients without 
psychotherapy.  The different findings could come from the fact that the previous two studies 
are both trials, and patients in these trials are required to attend treatment sessions regularly; 
while in this current study, we evaluate the real world phenomenon where patients often do 
not or cannot attend treatment sessions regularly.  In addition, in the trials, the study samples 
were more homogeneous, and the intervention often focused on one particular issue, which 
could make the effect of psychotherapy more appealling.  Because both trials focused on 
patients with some cumbersome problems (ex. acute symptoms, stressful relationships with 
family members), given the regression to the mean phenomenon, it might be easier to find 
the intervention effective.  In contrast, our study did not select patients by disease severity or 
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other clinical factors and thus included average patients, which may make it harder to find a 
significant effect of psychotherapy.  Finally, although each study included slightly different 
mental-health services to calculate treatment costs, the major cause of different findings may 
come from the different ways to estimate costs.  The two previous studies used information 
from interview and external references as their major sources for cost estimation, while our 
study gathered cost information directly from administrative claims records.  As a result, our 
cost estimates should be more accurate than the two previous trials.   
The original hypothesis assumes that the use of psychotherapy will increase patients’ 
outpatient and medication costs, but this increase will be compensated by the decrease in 
patients’ inpatient costs.  In contrast to the original hypothesis, findings from the current 
study do not show the use of psychotherapy reduces any components (inpatient, outpatient, 
and antipsychotic costs) of the total treatment cost.  Since the expected inpatient, outpatient, 
and antipsychotic costs are all higher, it is not surprising to find higher total treatment costs 
for patients receiving psychotherapy. Therefore, from a payer’s perspective (especially 
Medicaid), the use of adjunctive psychotherapy will increase the cost of treatment for 
patients with schizophrenia.           
    
5.1.4 Implication 
Overall, we found low prevalence of adjunctive psychotherapy use among patients 
with schizophrenia.  Most patients initiated their psychotherapy during the first three to six 
months of the beginning of antipsychotic treatment and received psychotherapy only for a 
short period of time.  Individual therapy was the most prevalent type of psychotherapy being 
used, with family therapy as the least prevalent type.  Given that more evidence has support 
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the efficacy of family therapy than the other two types of psychotherapy,
45, 73
 and family 
therapy has been recommended in both the acute phase through the stable phase,
16, 18-20
 
clinicians should consider incorporating family therapy in the early treatment stage and 
encourage patients to consistently attend treatment sessions.   
As addressed in Chapter 2, common reasons for not referring patients to 
psychotherapy include physicians or patients’ lack of knowledge about the effectiveness of 
psychotherapy.  To improve the use of psychotherapy, in addition to further study the 
effectiveness of psychotherapy, evidence related to psychotherapy should also be 
disseminated to clinicians and patients through treatment guidelines or patient education.  
Patients may refuse to participate in psychotherapy because they do not know what 
psychotherapy is or do not think it is helpful, and patients with different races/ethnicities may 
have different perceptions about schizophrenia and its treatment.  For these reasons, we may 
encourage patients to participate in psychotherapy by improving patient and their relatives’ 
understanding about psychotherapy and emphasize the benefits that psychotherapy could 
bring.   
In addition, patients may be reluctant to use psychotherapy because it requires extra 
time or efforts to participate in a treatment session.  This may also explain the exceptionally 
low rate of family therapy since family therapy requires both patients and their family 
members’ participation.  To increase the utilization of psychotherapy, we suggest moving 
psychotherapy from clinics to home-based or community-based environment to increase the 
accessibility and convenience of psychosocial treatment.   
Our findings also suggested that the use of adjunctive psychotherapy improved 
patients’ medication persistency for a short period of time, but we did not find the use of 
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psychotherapy helped to reduce treatment costs.  The short effect of psychotherapy may 
come from the fact that most patients only had five to six psychotherapy visits during the 18-
month follow-up period, and the overall prevalence of psychotherapy use was low.  As 
discussed in Chapter 2, the effect of psychotherapy may not be significant or clinically 
meaningful until a patient received a minimum number of psychosocial treatments (at least 
ten sessions or six months of treatment in the case of family therapy).
57, 148
  Therefore, as 
revealed by the study findings, the underuse of psychotherapy may not help to improve 
patients’ treatment outcomes but simply increase the treatment costs.   
Although we did not find a significant protective effect of psychotherapy use on most 
of our outcomes in this study, the effect of psychotherapy on other clinical outcomes should 
not be overlooked.  For example, evidence has shown that psychotherapy can help to reduce 
the stress in patients’ families, improve their cognitive function, and reduce the severity of 
symptoms, which are all valuable outcomes that cannot be assessed in a claim database.
43, 57, 
69
  In addition, because we were unable to measure remission rates or disease severity using a 
claims dataset, in this study, psychotherapy was considered to be effective if it helps to 
reduce hospitalizations or treatment costs.  Given that pharmacotherapy and psychotherapy 
often have different treatment effects and goals, it is hard to find a common outcome that can 
be used to compare the effect between these two types of therapy fairly.  The outcomes we 
chose in the present study may be more suitable for pharmacotherapy evaluation rather than 
psychotherapy effectiveness evaluation.  In addition, the use of adjunctive psychotherapy can 
serve as a channel for patients to provide feedback on their medication treatment, which 
allows clinicians to better evaluate patients’ conditions and change patients’ treatment plans.  
Therefore, when treating patients with schizophrenia, it is important for clinicians to consider 
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both physical and functional recovery and provide both pharmacotherapy as well as 
psychotherapy to patients.   
Given that our cost analysis was conducted from a payer’s perspective, even though 
we found the use of psychotherapy increased the treatment costs for schizophrenia paid 
directly by Medicaid, psychotherapy may be cost-effective from the societal perspective.  As 
mentioned before, schizophrenia accounts for about 20% of Social Security disability days 
and 20% to 30% of homelessness,
9
 and most patients are unemployed.
1, 2
  If adjunctive 
psychotherapy can help patients achieve better cognitive and functional recovery, it may help 
to reduce some of the societal costs (e.g. homeless, unemployment, care givers’ time and 
efforts).  As a result, when considering both direct and indirect costs associated with 
schizophrenia, the use of adjunctive psychotherapy may actually help to reduce the disease 
burden on society.   
  In addition, evidence has shown that the use of psychotherapy has declined over 
time.
58, 59
  Concordant with that trend, this study found a low use rate of psychotherapy.  As 
discussed above, the under use of psychotherapy may be caused by several reasons such as 
lack of clear evidence to support the effectiveness of psychotherapy, physicians’ or patients’ 
lack of knowledge about psychotherapy, or the extra time and efforts required by 
psychotherapy.  However, another component that could largely influence the use of 
psychotherapy is insurance coverage.  In addition to financial disincentives and the move 
toward managed care,
58-60
 many plans may only cover certain types of psychosocial 
treatments or have limited psychotherapy coverage, which restricts patients’ access to 
psychotherapy.  For example, in Table 3.5, we can see that both Kansas and North Carolina 
have limited the number of mental-health ambulatory visits, and both Illinois and North 
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Carolina did not cover psychologist services.  Therefore, Medicaid policy makers should 
consider providing more generous coverage which allows patients to have sufficient 
psychotherapy visits and be benefit from psychosocial treatment.   
Another way to improve the use of psychotherapy is to encourage professionals other 
than psychiatrists, such as nurses, psychologists, and social workers, to provide 
psychotherapy.  Allowing these professionals to provide psychotherapy under psychiatrists’ 
supervision may not only help to reduce psychiatrists’ burden, but also provide some 
flexibility of psychotherapy since these professional psychotherapy providers may be more 
flexible to provide psychotherapy as home-based or community-based interventions.  Instead 
of directly providing psychotherapy to patients, a psychiatrist can supervise the treatment 
plan.  With less time and efforts from psychiatrists, involving other professionals to provide 
psychotherapy may also help to reduce the costs of psychotherapy.  
Finally, our study did not find psychotherapy helps to reduce hospitalizations or 
reduce treatment costs but it may have limited effect on adherence improvement.  These 
results may suggest psychotherapy is ineffective.  Therefore, clinicians may still need to 
carefully monitor the treatment outcomes even when a patient is receiving adjunctive 
psychotherapy.  
In summary, this study found that psychotherapy is underutilized among patients with 
schizophrenia.  Although we did not find a significant benefit of using psychotherapy in 
respect to hospitalization and treatment costs, our results suggested that psychotherapy may 
help to improve patients’ medication persistency.  Since psychotherapy has been shown to be 
beneficial for patients and recommended by treatment guidelines,
16-21
 clinicians and policy 
 147 
 
makers should increase the availability of psychotherapy for patients with schizophrenia to 
help them reach the best treatment outcomes.  
 
5.2 Study Limitations 
There are several limitations in this study.  First, this study is conducted on Medicaid 
claims data.  Therefore, the results may not be generalizable to privately insured or uninsured 
populations.   Second, even though we adjust for several demographic and clinical factors, 
there could still be un-measureable variables that could affect our outcomes of interest, such 
as income and disease severity.  Since our study population contains only Medicaid 
beneficiaries, patients in our study should have similar incomes.  Without being able to 
measure disease severity, our results can be biased.  In general, omitting disease severity will 
bias our results toward the null for outcomes such as adherence and hospitalization/inpatient 
costs, while the results may be biased away from the null for outcomes like outpatient or 
antipsychotic costs.  To solve the unobservable confounding issue, we applied IV methods, 
and the results from the IV models should not be biased from the un-measurable confounders.  
In addition, because we are unable to capture patients’ actual medication taking 
behaviors using pharmacy claims, it is assumed that patients take all of their medications 
once they filled a prescription.  In the survival analysis, a 15 or 30 day gap may not be able to 
best capture patients’ medication-taking behaviors.  An exploratory analysis conducted by 
Valenstein et al. showed that among those with poor adherence, 13% of them did not have a 
contiguous gap longer than one month, which indicates that they may take fewer medications 
than prescribed or have several short gaps over time.
81
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Due to small sample sizes, we are unable to differentiate the type of psychotherapy or 
detail the components of a psychotherapy visit from administrative claims.  Given that 
different types of psychotherapy often apply different modalities and have different 
orientations, our results could bias toward the null if certain types of psychotherapy are less 
effective than others in respect to the outcomes in this study.  Additionally, both the use of 
psychotherapy and the outcomes of interest (adherence, hospitalizations, and treatment costs) 
are assessed at the same period of time, which makes the temporality between the treatment 
assigned and outcomes less clear.  Nevertheless, this temporality issue should also be 
eliminated with IV estimations.   
As aforementioned, another limitation in this study is the short washout period.  With 
only a three-month washout period, some patients identified in this study can be actually 
prevalent users who had a history of antipsychotic use three months ago.
150
  Assuming 
prevalent antipsychotic users were less likely to receive psychotherapy because their 
condition has been stabilized.  This ―pseudo-new users‖ phenomenon could bias our results 
up or down depending on the association between the confounder (i.e. pseudo-new users) and 
psychotherapy use as well as the association between the confounder and the outcomes.  
Generally, this should bias our results toward the null.  Finally, using a claims data set, we 
are unable to assess the effect of psychotherapy on patients’ perceptions (ex. changes in 
insights or self-efficacy), behaviors, or symptom severity (ex. the positive and negative 
syndrome score), which are also important treatment outcomes.  
Finally, our results may be confounded by selection effect.  Given the descriptive 
results that patients using psychotherapy were more likely to have other mental comorbidities, 
patients with psychotherapy may be sicker than patients without psychotherapy. The 
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imbalance of disease severity between the two groups could bias our results.  If the true 
effect of psychotherapy is positive or null, the adverse selection situation (i.e. sicker patients 
were more likely to use psychotherapy) in this study can bias our results toward negative.  
(e.g. psychotherapy use results in poor adherence).   
 
5.3 Future Research 
 This study expands the existing literature by evaluating the effectiveness of 
adjunctive psychotherapy among Medicaid patients with schizophrenia.  It improves our 
epidemiological knowledge of psychotherapy use as well as the effect of psychotherapy use 
on patients’ clinical and economic outcomes.  However, with only limited evidence about the 
effectiveness of psychotherapy, many questions are still waiting to be answered.  Since there 
are no clear guidelines about how psychotherapy should be incorporated in a treatment 
course.  One important step will be to clarify the effect of different types of psychosocial 
interventions and standardize them into a psychotherapy treatment course which can be 
applied clinically.  In addition, it will also be important to identify outcomes that are 
clinically assessable and meaningful for clinicians to evaluate the effectiveness of 
psychotherapy.  Given the cross-sectional design of the current study, a future study should 
employ a longitudinal design with a longer wash-out period to further clarify the causal 
relationship between the use of psychotherapy and treatment outcomes.  With limited sample 
sizes, we were unable to examine the effectiveness by different types of psychotherapy.  A 
future study can advance our knowledge by comparing the effectiveness across different 
types of psychotherapy.  Finally, even though our study showed that psychotherapy may 
have limited effect on patients’ adherence, hospitalization rates, and treatment costs, future 
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research should consider examining the effect of psychotherapy on other types of outcomes, 
such as patients’ insight/perception, symptom improvement, or functional status, to provide a 
more comprehensive picture of the effectiveness of psychotherapy.   
 
5.4 Conclusion  
In conclusion, the rate of psychotherapy use was found to be low in this study.  
Although the use of adjunctive psychotherapy was associated with higher treatment costs, it 
also seemed to improve patients’ medication persistency for a short period of time.  To 
maximize the treatment effect, it takes not only pharmacotherapy to reduce the symptoms, 
but also psychosocial treatment to improve patients’ adherence and functional recovery.  
 Our study showed that psychotherapy was underutilized, and states with more 
restrictive policies seemed to have lower utilization rates of psychotherapy. To allow patients 
receiving adequate psychosocial treatment to benefit from this treatment, we suggest policy 
makers in Medicaid consider reducing restrictions of psychotherapy to improve access to 
these services.  Although we did not find significant benefits of psychotherapy use regarding 
inpatient admission reduction or cost saving, we found psychotherapy may help to improve 
patients’ medication persistency especially when patients attend the treatment sessions 
regularly.  Clinicians may consider providing psychotherapy to help patients better adhere to 
their treatment regimens.  Psychotherapy may also be used to improve patients and their 
family members’ understanding about the disease and treatment, or serve as a channel for 
patients and providers to better communicate the treatment effect.   
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APPENDIX 
Appendix 1. Differential Diagnosis of Psychotic Disorders 
 
Source: American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-
TR.Washington, DC: American Psychiatric Association; 2000.  
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Appendix 2. ICD-10 Diagnostic Criteria for Schizophrenia 
Diagnostic symptom groups: 
(a) thought echo, thought insertion or withdrawal, and thought broadcasting; 
(b) delusions of control, influences, or passivity, clearly referred to body or limb movements 
or specific thoughts, actions, or sensations; delusional perception; 
(c) hallucinatory voices giving a running commentary on the patient’s behavior, or discussing 
the patient among themselves, or other types of hallucinatory voices coming from some 
part of the body; 
(d) persistent delusions of other kinds that are culturally inappropriate and completely 
impossible, such as religious or political identity, or superhuman powers and abilities (e.g. 
being able to control the weather, or being in communication with aliens from another 
world); 
(e) persistent hallucinations in any modality, when accompanied either by fleeting or half-
formed delusions without clear affective content, or by persistent over-valued ideas, or 
when occurring every day for weeks or months end; 
(f) breaks or interpolations in the train of thought, resulting in incoherence or irrelevant 
speech, or neologisms; 
(g) catatonic behavior, such as excitement, posturing, or waxy flexibility, negativism, mutism, 
and stupor; 
(h) ―negative‖ systems such as marked apathy, paucity of speech, and blunting or incongruity 
of emotional responses, usually resulting in social withdrawal and lowering of social 
performance; it must be clear that these are not due to depression or to narcoleptic 
medication; 
(i) A significant and consistent change in the overall quality of some aspects of personal 
behaviour, manifest as loss of interest, aimlessness, idleness, a self-absorbed attitude, and 
social withdrawal. 
Diagnostic guidelines: 
 A minimum of one very clear symptom (and usually two or more if less clear-cut) belonging to 
any one of the groups listed as (a) to (d) above, or symptoms from at least two of the groups 
referred to as (e) to (h); 
 Symptoms have been clearly present for most of the time during a period of 1 month or more. 
 Symptoms (i) in the above list applies only to the diagnosis of Simple Schizophrenia, and a 
duration of at least one year is required. 
 The diagnosis of schizophrenia should not be made in the presence of extensive depressive or 
manic symptoms unless it is clear that schizophrenic symptoms antedated the affective 
disturbance, and schizophrenia should not be diagnosed in the presence of overt brain disease or 
during states of drug intoxication or withdrawal. 
 If both schizophrenic and affective symptoms develop together and are evenly balanced, the 
diagnosis of schizoaffective disorder should be made, even if the schizophrenic symptoms by 
themselves would have justified the diagnosis of schizophrenia. 
 
 
Source: World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical 
descriptions and diagnostic guidelines Geneva: World Health Organization; 1992. 
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Appendix 3. DSM-IV Diagnostic Criteria for Schizophrenia 
A.  Characteristic symptoms: Two (or more) of the following, each present for a significant 
portion of time during a 1-month period (or less if successfully treated): 
     1. delusions 
     2. hallucinations 
     3. disorganized speech (e.g., frequent derailment or incoherence) 
     4. grossly disorganized or catatonic behavior 
     5. negative symptoms, i.e., affective flattening, alogia, or avolition 
Note: Only once Criteria A symptom is required if delusions are bizarre or hallucinations consist 
of a voice keeping up a running commentary on the person’s behavior or thoughts, or two or more 
voices conversing with each other. 
B.  Social/occupational dysfunction: For a significant portion of the time since the onset of the 
disturbance, one or more major areas of functioning such as work, interpersonal relations, or self-
care are markedly below the level achieved prior to the onset (or when the onset is in childhood 
or adolescence, failure to achieve expected level of interpersonal, academic, or occupational 
achievement). 
C.  Duration: Continuous signs of the disturbance persist for at least 6 months. This 6-months 
period must include at least 1month of symptoms (or less if successfully treated) that meet 
Criteria A (i.e., active-phase symptoms) and may include periods of prodromal or residual 
symptoms. 
During these prodromal or residual periods, the signs of the disturbance may be manifested 
by only negative symptoms or two or more symptoms listed in Criteria A present in an 
attenuated form (e.g., odd beliefs, unusual perceptual experiences). 
D.  Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder and Mood Disorder 
With Psychotic Features have been ruled out because either (1) on Major Depressive, manic, 
or Mixed Episodes have occurred concurrently with the active-phase symptoms; or (2) if 
mood episodes have occurred during active-phase symptoms, their total duration has been 
brief relative to the duration of the active and residual periods. 
E.  Substance/general medical condition exclusion: The disturbance is not due to the direct 
Physical effect of a substance (e.g., a drug of abuse, a medication) or a general medical 
condition. 
F.  Relationship to a Pervasive Developmental Disorder: If there is a history of Autistic Disorder 
or another Pervasive Development Disorder, the additional diagnosis of Schizophrenia is made 
only if prominent delusions or hallucinations are also present for at least a month (or less if 
successfully treated). 
Source: American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR 
Washington, DC: American Psychiatric Association; 2000. 
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Appendix 4. UNC IRB Approval 
 
 
Subject:  IRB Notice 
Sender:  IRB <irb_no_reply@mailserv.grad.unc.edu> 
Recipient:  cc_wang@unc.edu <cc_wang@unc.edu> 
Copy:  jffarley@email.unc.edu <jffarley@email.unc.edu> 
Date:  24.08.2010 16:19 
To: Chi-Chuan Wang  
School of Pharmacy  
CB: 7573 
 
From: Biomedical IRB 
 
Date: 8/24/2010  
 
RE: Determination that Research or Research-Like Activity does not require IRB Approval  
Study #: 10-1463 
 
Study Title: The Effect of Adjunctive Psychotherapy on Health Related Outcomes among Patients 
with Schizophrenia 
 
This submission was reviewed by the above-referenced IRB. The IRB has determined that this 
submission does not constitute human subjects research as defined under federal regulations [45 CFR 
46.102 (d or f) and 21 CFR 56.102(c)(e)(l)] and does not require IRB approval.  
 
Study Description:  
 
Purpose: To document the patterns of adjunctive psychotherapy and to investigate the role of 
psychotherapy on anti-psychotic adherence, hospitalization, and treatment costs. Participants: 
Medicaid beneficiaries with schizophrenia in Illinois, Kansas, Minnesota, North Carolina, and 
Vermont (year 2001-2003). Procedures: The study will be conducted using a de-identified Medicaid 
claims datasets. A retrospective study design and statistical analyses will be performed to evaluate the 
effect of adjunctive psychotherapy on patients' outcomes.  
 
If your study protocol changes in such a way that this determination will no longer apply, you should 
contact the above IRB before making the changes.  
 
CC: 
Joel Farley, School Of Pharmacy  
 
IRB Informational Message—please do not use email REPLY to this address  
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Appendix 5. Patient Characteristics by Type of Adjunctive Psychotherapy  
 
Individual Therapy 
 
Family Therapy 
 
Group Therapy 
 
N= 555 
 
N= 16 
 
N= 83 
  %   %   % 
Baseline Characteristics  
     
Age, Mean(SD) 39.54(10.95) 
 
31.88(11.45) 
 
40.70(11.04) 
Age Group 
     
18-35 36.40 
 
56.25 
 
31.33 
36-50 45.41 
 
43.75 
 
50.60 
>50 18.20 
 
0.00 
 
18.07 
Gender 
     
Male 53.87 
 
68.75 
 
59.04 
Female 46.13 
 
31.25 
 
40.96 
Race 
     
White 44.32 
 
43.75 
 
36.14 
Black 47.93 
 
37.50 
 
55.42 
Other 7.75 
 
18.75 
 
8.43 
State 
     
IL 34.95 
 
31.25 
 
36.14 
KS 9.37 
 
12.50 
 
8.43 
MN 11.35 
 
25.00 
 
6.02 
NC 44.32 
 
31.25 
 
49.40 
MSA 
     
Yes 70.99 
 
68.75 
 
74.70 
No 29.01 
 
31.25 
 
25.30 
Charlson Score, Mean(SD) 0.19(0.56) 
 
0.06(0.25) 
 
0.16(0.71) 
Mental Comorbidities 
     
Depression 20.72 
 
12.50 
 
26.51 
Substance Abuse 7.57 
 
6.25 
 
16.87 
Anxiety 6.85 
 
6.25 
 
7.23 
Other Psychoses 8.69 
 
18.75 
 
8.43 
Type of Initial Treatment 
     
  Atypical 89.01 
 
81.25 
 
86.75 
  Typical 10.99 
 
18.75 
 
13.25 
Characteristics Measured During Follow Up 
Adherence 
     
Yes 30.45 
 
50.00 
 
25.30 
No 69.55 
 
50.00 
 
74.70 
Medication Switch – 30-day Window 28.29 
 
31.25 
 
33.73 
Medication Switch – 15-day Window 21.80 
 
12.50 
 
28.92 
Medication Augmentation 38.92 
 
50.00 
 
49.40 
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Treatment modification- switching 
in 15 days or augmentation 
41.62 
 
50.00 
 
51.81 
Treatment modification- switching 
in 30 days or augmentation 
43.42 
 
56.25 
 
53.01 
SD: Standard Devisation; IL: Illinois, KS: Kansas, MN: Minnesota, NC: North Carolina; MSA: Metorpolitan 
Statistical Area; PDC: Proportion of Days Covered 
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Appendix 6. Aim 2 Sensitivity Analysis- Medication Switching
†
  
(N= 3,536; Nuser= 606, Nnon-user= 2,930) 
 
Within a 30-day window  Within a 15-day window  
  OR 95% CI OR 95% CI 
Psychotherapy Use      1.47** (1.22-1.77)      1.49** (1.23-1.81) 
Age Group 
    18-35 Reference - Reference - 
36-50 0.91 (0.77-1.08) 0.95 (0.79-1.12) 
>50      0.74** (0.59-0.93)   0.75* (0.59-0.95) 
Gender 
    Male Reference - Reference - 
Female 0.94 (0.81-1.10) 1.03 (0.88-1.20) 
Race 
    White Reference - Reference - 
Black 1.02 (0.87-1.20) 1.03 (0.87-1.22) 
Other 1.17 (0.86-1.59) 1.13 (0.82-1.55) 
State 
    IL Reference - Reference - 
KS 1.03 (0.77-1.38) 1.04 (0.77-1.42) 
MN   0.76* (0.58-0.99) 0.84 (0.63-1.10) 
NC 1.02 (0.86-1.21) 1.07 (0.90-1.28) 
MSA 
    Yes Reference - Reference - 
No 0.97 (0.81-1.17) 0.97 (0.80-1.16) 
Charlson Score 0.95 (0.84-1.08) 0.96 (0.84-1.10) 
Mental Comorbidities 
    Depression 1.01 (0.81-1.27) 0.99 (0.79-1.24) 
Substance Abuse 1.04 (0.79-1.36) 1.04 (0.79-1.37) 
Anxiety   1.42* (1.02-1.98) 1.37 (0.98-1.92) 
Other Psychoses 1.12 (0.87-1.43) 1.13 (0.87-1.46) 
Type of Initial Treatment 
    Atypical Reference - Reference - 
     Typical 0.88 (0.71-1.09) 0.93 (0.75-1.17) 
OR: Odds Ratio; CI: Confidence Interval; SD: Standard Devisation; IL: Illinois, KS: Kansas, MN: Minnesota,  
NC: North Carolina; MSA: Metorpolitan Statistical Area; PDC: Proportion of Days Covered 
† In additional to the original switchers, the switching group here included patients who filled another 
antipsychotic before the end of the previous supply and never went back to the previous drug (only switch 
once)     
* p<0.05   
** p<0.01  
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Appendix 7. Aim 2 Sensitivity Analysis- Medication Modification
†
 
 
Within a 30-day window Within a 15-day window 
  OR 95% CI OR 95% CI 
Psychotherapy Use      1.49** (1.25-1.79)      1.50** (1.25-1.79) 
Age Group 
    18-35 Reference - Reference - 
36-50 0.85 (0.72-1.00) 0.87 (0.74-1.02) 
>50      0.67** (0.54-0.84)      0.69** (0.56-0.87) 
Gender 
    Male Reference - Reference - 
Female 0.98 (0.84-1.13) 0.99 (0.86-1.15) 
Race 
    White Reference - Reference - 
Black 0.97 (0.83-1.13) 0.98 (0.84-1.15) 
Other 1.15 (0.86-1.55) 1.08 (0.80-1.46) 
State 
    IL Reference - Reference - 
KS 1.07 (0.81-1.42) 1.08 (0.81-1.44) 
MN 0.87 (0.68-1.12) 0.95 (0.74-1.22) 
NC 1.07 (0.91-1.26) 1.10 (0.93-1.30) 
MSA 
    Yes Reference - Reference - 
No 1.03 (0.87-1.23) 1.05 (0.88-1.24) 
Charlson Score 0.91 (0.80-1.03) 0.91 (0.80-1.04) 
Mental Comorbidities 
    Depression 0.95 (0.76-1.17) 0.93 (0.75-1.15) 
Substance Abuse 1.01 (0.78-1.31) 1.00 (0.77-1.30) 
Anxiety 1.33 (0.97-1.84) 1.24 (0.89-1.72) 
Other Psychoses 1.15 (0.91-1.46) 1.15 (0.91-1.47) 
Type of Initial Treatment 
    Atypical Reference - Reference - 
     Typical 0.86 (0.70-1.06) 0.88 (0.71-1.09) 
OR: Odds Ratio; CI: Confidence Interval; SD: Standard Devisation; IL: Illinois, KS: Kansas, MN: Minnesota,  
NC: North Carolina; MSA: Metorpolitan Statistical Area; PDC: Proportion of Days Covered 
† The dependent variable was treatment modification with a 30-day or 15-day switching window  
* p<0.05   
** p<0.01  
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Appendix 8. Specification Test Results for IVs 
   Psychotherapy 
Use for the 
previous 
patient 
Psychotherapy 
Use for a MDD 
patient seen 
by the same 
provider 
Two IVs Jointly 
Test of 
Strength† 
Z-statistic  
(p-value) 
 14.84 
(p< 0.001) 
7.69 
(p< 0.001) 
N/A 
Chi-square 
statistic 
(p-value) 
 220.24 
p< 0.001 
59.15 
(p< 0.001) 
218.96 
p<0.001 
Exclusion 
Restriction 
Hausman 
Test‡ 
 
Survival 
Analysis 
Chi-square= 
0.89, p= 1.00 
Negative  
chi-square 
N/A 
Medication 
Switching* 
Negative  
chi-square 
Negative  
chi-square 
N/A 
Hospitalizations 
Part 1 Model 
Chi-square= 
2.47, p= 1.00 
Negative  
chi-square 
N/A 
Hospitalizations 
Part 2 Model 
Chi-square= 
1.30, p= 1.00 
Chi-square= 
1.72, p= 1.00 
N/A 
Inpatient Cost 
Part 1 Model 
Chi-square= 
2.54, p= 1.00 
Negative  
chi-square 
N/A 
Inpatient Cost 
Part 2 Model 
Negative  
chi-square 
Negative  
chi-square 
N/A 
Outpatient 
Costs 
Chi-square= 
0.84, p= 1.00 
Chi-square= 
0.82, p= 1.00 
N/A 
Antipsychotic 
Costs 
Chi-square= 
1.37, p= 1.00 
Chi-square= 
17.77, p= 0.47 
N/A 
Total Costs Negative  
chi-square 
Negative  
chi-square 
N/A 
LR Test+ 
 
Survival 
Analysis 
N/A N/A LR Chi-square= 
1.09, p= 0.30 
Medication 
Switching 
N/A N/A LR Chi-square= 
3.54, p= 0.06 
Hospitalizations 
Part 1 Model 
N/A N/A LR Chi-square= 
19.94, p< 0.01 
Hospitalizations 
Part 2 Model 
N/A N/A LR Chi-square= 
7.38, p= 0.02 
Inpatient Cost 
Part 1 Model 
N/A N/A LR Chi-square= 
19.87, p< 0.01 
Inpatient Cost 
Part 2 Model 
N/A N/A LR Chi-square= 
-0.19, p=1.00 
Outpatient 
Costs 
N/A N/A LR Chi-square= 
53.85, p< 0.01 
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Antipsychotic 
Costs 
N/A N/A LR Chi-square= 
1.87, p= 0.17 
Total Costs N/A N/A LR Chi-square= 
9.84, p< 0.01 
Test of 
Endogeneity 
Hausman 
Test§ 
Survival 
Analysis 
Negative 
Chi-square 
- - 
Medication 
Switching 
- - Negative 
Chi-square 
Hospitalizations 
Part 1 Model 
Negative 
Chi-square 
- - 
Hospitalizations 
Part 2 Model 
- - Chi-square= 
2.19, p=1.00 
Inpatient Cost 
Part 1 Model 
Negative 
Chi-square 
- - 
Inpatient Cost 
Part 2 Model 
- - Negative 
Chi-square 
Outpatient 
Costs 
- - Negative 
Chi-square 
Antipsychotic 
Costs 
- - Negative 
Chi-square 
Total Costs   Negative 
Chi-square 
Alternative 
Test for 
Endogeneity¶ 
Survival 
Analysis 
p= 0.13 - - 
Medication 
Switching 
- - p= 0.40 
Hospitalizations 
Part 1 Model 
p= 0.95 - - 
Hospitalizations 
Part 2 Model 
p= 0.01 - - 
Inpatient Cost 
Part 1 Model 
p= 0.93 - - 
Inpatient Cost 
Part 2 Model 
- - p= 0.11 
Outpatient 
Costs 
p= 0.04 - - 
Antipsychotic 
Costs 
- - p= 0.20 
Total Costs p= 0.03 - - 
LR Test: Likelihood Ratio Test; N/A: Not Applicable 
† H0: IV is not associated with psychotherapy use  
‡ H0: Assume the model including one IV is valid and will be consistent while the model including both IVs will 
be efficient 
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+ H0: Both IVs are valid and jointly uncorrelated with the second-stage model residuals 
§ H0: Assume the model without IVs is consistent while the model including IVs is efficient 
¶ H0: The use of psychotherapy is exogeneous and thus IVs do not have any explanatory power 
* Both IVs were included in the medication switching model based on the results from Chow tests 
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